{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Study URL</th>\n",
       "      <th>Study Status</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Collaborators</th>\n",
       "      <th>Phases</th>\n",
       "      <th>Study Design</th>\n",
       "      <th>Locations</th>\n",
       "      <th>country</th>\n",
       "      <th>summary_embedding</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05284071</td>\n",
       "      <td>Actiste® Diabetes Management as a Service (ADM...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05284071</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>The overall aim of the clinical investigation ...</td>\n",
       "      <td>['Diabetes type1', 'Diabetes type2']</td>\n",
       "      <td>DEVICE: Device: Actiste 1.0 and the Companion ...</td>\n",
       "      <td>['Northern Care Alliance NHS Foundation Trust']</td>\n",
       "      <td>['Brighter AB']</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>Salford Royal Hospital Northern Care Alliance ...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>[-2.583105    1.2393227  -0.38946435 -1.110179...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05029271</td>\n",
       "      <td>InPen User Experience</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05029271</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of this study is to evaluate the u...</td>\n",
       "      <td>['Diabetes Type 1']</td>\n",
       "      <td>DEVICE: InPen with Guardian 4 System</td>\n",
       "      <td>['Medtronic Diabetes']</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>NU-Hospital Group, Uddevalla, Sweden|Frolunda ...</td>\n",
       "      <td>Sweden</td>\n",
       "      <td>[-1.7408602   1.8224145  -0.6962592  -0.999329...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03976271</td>\n",
       "      <td>Consequences of Hypoglycaemia on Cardiovascula...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT03976271</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>People with Type 1 diabetes (T1DM), type 2 dia...</td>\n",
       "      <td>['Hypoglycemia', 'Inflammatory Response', 'Dia...</td>\n",
       "      <td>PROCEDURE: hyperinsulinemic normoglycaemic-hyp...</td>\n",
       "      <td>['Radboud University Medical Center']</td>\n",
       "      <td>['Rigshospitalet, Denmark']</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NON_RANDOMIZED|Intervention Model:...</td>\n",
       "      <td>Nordsjællands University Hospital, Hillerød, N...</td>\n",
       "      <td>['Netherlands', 'Denmark']</td>\n",
       "      <td>[ 0.23211886  1.287894   -1.7387999  -0.946216...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05560971</td>\n",
       "      <td>Monounsaturated Fatty Acid Supplementation for...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05560971</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of this study is to understand and...</td>\n",
       "      <td>['PreDiabetes', 'Insulin Resistance', 'Overwei...</td>\n",
       "      <td>DIETARY_SUPPLEMENT: Palmitoleic acid|OTHER: Pl...</td>\n",
       "      <td>[\"Brigham and Women's Hospital\"]</td>\n",
       "      <td>['Tersus Life Sciences LLC']</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>Brigham and Women's Hospital, Boston, Massachu...</td>\n",
       "      <td>United States</td>\n",
       "      <td>[ 2.5645995  -1.1341355  -1.7363315  -1.982987...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00462371</td>\n",
       "      <td>Comparison Between Insulin Pump Treatment and ...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT00462371</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>Comparison between insulin pump treatment and ...</td>\n",
       "      <td>['Diabetes Mellitus, Type 1', 'Child']</td>\n",
       "      <td>DEVICE: Insulin pump (CSII)</td>\n",
       "      <td>['Erasmus Medical Center']</td>\n",
       "      <td>['Ministry of Health']</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: CRO...</td>\n",
       "      <td>ErasmusMC/Sophia´s children´s Hospital, Rotter...</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>[ 0.6968588   1.3090037  -0.7710721  -1.648869...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    NCT Number                                        Study Title  \\\n",
       "0  NCT05284071  Actiste® Diabetes Management as a Service (ADM...   \n",
       "1  NCT05029271                              InPen User Experience   \n",
       "2  NCT03976271  Consequences of Hypoglycaemia on Cardiovascula...   \n",
       "3  NCT05560971  Monounsaturated Fatty Acid Supplementation for...   \n",
       "4  NCT00462371  Comparison Between Insulin Pump Treatment and ...   \n",
       "\n",
       "                                      Study URL Study Status  \\\n",
       "0  https://clinicaltrials.gov/study/NCT05284071    COMPLETED   \n",
       "1  https://clinicaltrials.gov/study/NCT05029271   RECRUITING   \n",
       "2  https://clinicaltrials.gov/study/NCT03976271    COMPLETED   \n",
       "3  https://clinicaltrials.gov/study/NCT05560971   RECRUITING   \n",
       "4  https://clinicaltrials.gov/study/NCT00462371    COMPLETED   \n",
       "\n",
       "                                       Brief Summary  \\\n",
       "0  The overall aim of the clinical investigation ...   \n",
       "1  The purpose of this study is to evaluate the u...   \n",
       "2  People with Type 1 diabetes (T1DM), type 2 dia...   \n",
       "3  The purpose of this study is to understand and...   \n",
       "4  Comparison between insulin pump treatment and ...   \n",
       "\n",
       "                                          Conditions  \\\n",
       "0               ['Diabetes type1', 'Diabetes type2']   \n",
       "1                                ['Diabetes Type 1']   \n",
       "2  ['Hypoglycemia', 'Inflammatory Response', 'Dia...   \n",
       "3  ['PreDiabetes', 'Insulin Resistance', 'Overwei...   \n",
       "4             ['Diabetes Mellitus, Type 1', 'Child']   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0  DEVICE: Device: Actiste 1.0 and the Companion ...   \n",
       "1               DEVICE: InPen with Guardian 4 System   \n",
       "2  PROCEDURE: hyperinsulinemic normoglycaemic-hyp...   \n",
       "3  DIETARY_SUPPLEMENT: Palmitoleic acid|OTHER: Pl...   \n",
       "4                        DEVICE: Insulin pump (CSII)   \n",
       "\n",
       "                                           Sponsor  \\\n",
       "0  ['Northern Care Alliance NHS Foundation Trust']   \n",
       "1                           ['Medtronic Diabetes']   \n",
       "2            ['Radboud University Medical Center']   \n",
       "3                 [\"Brigham and Women's Hospital\"]   \n",
       "4                       ['Erasmus Medical Center']   \n",
       "\n",
       "                  Collaborators  Phases  \\\n",
       "0               ['Brighter AB']     NaN   \n",
       "1                            []     NaN   \n",
       "2   ['Rigshospitalet, Denmark']     NaN   \n",
       "3  ['Tersus Life Sciences LLC']     NaN   \n",
       "4        ['Ministry of Health']  PHASE4   \n",
       "\n",
       "                                        Study Design  \\\n",
       "0  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "1  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "2  Allocation: NON_RANDOMIZED|Intervention Model:...   \n",
       "3  Allocation: RANDOMIZED|Intervention Model: PAR...   \n",
       "4  Allocation: RANDOMIZED|Intervention Model: CRO...   \n",
       "\n",
       "                                           Locations  \\\n",
       "0  Salford Royal Hospital Northern Care Alliance ...   \n",
       "1  NU-Hospital Group, Uddevalla, Sweden|Frolunda ...   \n",
       "2  Nordsjællands University Hospital, Hillerød, N...   \n",
       "3  Brigham and Women's Hospital, Boston, Massachu...   \n",
       "4  ErasmusMC/Sophia´s children´s Hospital, Rotter...   \n",
       "\n",
       "                      country  \\\n",
       "0              United Kingdom   \n",
       "1                      Sweden   \n",
       "2  ['Netherlands', 'Denmark']   \n",
       "3               United States   \n",
       "4                 Netherlands   \n",
       "\n",
       "                                   summary_embedding  \n",
       "0  [-2.583105    1.2393227  -0.38946435 -1.110179...  \n",
       "1  [-1.7408602   1.8224145  -0.6962592  -0.999329...  \n",
       "2  [ 0.23211886  1.287894   -1.7387999  -0.946216...  \n",
       "3  [ 2.5645995  -1.1341355  -1.7363315  -1.982987...  \n",
       "4  [ 0.6968588   1.3090037  -0.7710721  -1.648869...  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import csv\n",
    "import os\n",
    "\n",
    "def mergeaff(x):\n",
    "    if pd.notna(x['Sponsor']):\n",
    "        if pd.notna(x['Collaborators']):\n",
    "            # print(x['Collaborators'])\n",
    "            return x['Sponsor']+'|'+x['Collaborators']\n",
    "        else:\n",
    "            return x['Sponsor']\n",
    "    else:\n",
    "        if pd.notna(x['Collaborators']):\n",
    "            return x['Collaborators']\n",
    "        else:\n",
    "            return np.nan\n",
    "\n",
    "def mergecond(x):\n",
    "    cond = ''\n",
    "    for i, affiliation in enumerate(df['affiliations']):\n",
    "        if x in affiliation:\n",
    "            if pd.notna(df.iloc[i]['Conditions']):\n",
    "                cond += df.iloc[i]['Conditions']+'|'\n",
    "            else: continue\n",
    "    if cond == '':\n",
    "        return np.nan\n",
    "    elif cond.endswith('|'):\n",
    "        return cond[:-1]\n",
    "    else: return cond\n",
    "\n",
    "def mergesen(x):\n",
    "    cond = ''\n",
    "    for i, affiliation in enumerate(df['affiliations']):\n",
    "        if x in affiliation:\n",
    "            if pd.notna(df.iloc[i]['sentences']):\n",
    "                cond += df.iloc[i]['sentences']+'|'\n",
    "            else: continue\n",
    "    if cond == '':\n",
    "        return np.nan\n",
    "    elif cond.endswith('|'):\n",
    "        return cond[:-1]\n",
    "    else: return cond\n",
    "\n",
    "\n",
    "# 2. 키워드 기반 매핑\n",
    "mapping_dict = {\n",
    "    #type1\n",
    "    \"type 1 diabetes mellitus\": \"type 1 diabetes mellitus\",\n",
    "    \"diabetes mellitus type 1\": \"type 1 diabetes mellitus\",\n",
    "    \"diabetes mellitus, type 1\": \"type 1 diabetes mellitus\",\n",
    "    \"type 1 diabetes mellitus\": \"type 1 diabetes mellitus\",\n",
    "    \"type1 diabetes mellitus\": \"type 1 diabetes mellitus\",\n",
    "    \"t1dm\": \"type 1 diabetes mellitus\",\n",
    "    \"t1d\": \"type 1 diabetes\",\n",
    "    \"diabetes, type 1\": \"type 1 diabetes\",\n",
    "    \"type 1 diabetes (t1d)\": \"type 1 diabetes\",\n",
    "    \"type 1 diabetes\": \"type 1 diabetes\", \n",
    "    \"type1 diabetes\": \"type 1 diabetes\",\n",
    "    \"type1diabetes\": \"type 1 diabetes\",\n",
    "    \n",
    "    \n",
    "    # type2\n",
    "    \"type 2 diabetes mellitus\": \"type 2 diabetes mellitus\",\n",
    "    \"diabetes mellitus, type 2\": \"type 2 diabetes mellitus\",\n",
    "    \"type2 diabetes mellitus\": \"type 2 diabetes mellitus\",\n",
    "    \"type 2 diabetes mellitus (t2dm)\": \"type 2 diabetes mellitus\",\n",
    "    \"diabetes mellitus type 2\": \"type 2 diabetes mellitus\",\n",
    "    \"t2dm\":\"type 2 diabetes mellitus\",\n",
    "    \"t2d\": \"type 2 diabetes\",\n",
    "    \"diabetes, type 2\": \"type 2 diabetes\",\n",
    "    \"type 2 diabetes (t2d)\": \"type 2 diabetes\",\n",
    "    \"type 2 diabetes\": \"type 2 diabetes\", \n",
    "    \"type2 diabetes\": \"type 2 diabetes\",\n",
    "    \"type2diabetes\": \"type 2 diabetes\",\n",
    "\n",
    "    # prediabetes\n",
    "    \"pre-diabetes\": \"prediabetes\",\n",
    "\n",
    "    # 추가적인 매핑이 필요한 경우 여기에 추가\n",
    "\n",
    "}\n",
    "\n",
    "filepath = 'Diabetes-clinical-studies.csv'\n",
    "if os.path.isfile(filepath):\n",
    "    df = pd.read_csv(filepath)\n",
    "\n",
    "else:\n",
    "    df = pd.read_csv('Diabetes-clinical-studies.csv',delimiter=',')\n",
    "    df.drop(['Acronym','Study Type'],axis=1,inplace=True)\n",
    "    df = df[df['Study Status'].isin(['COMPLETED','ACTIVE_NOT_RECRUITING','AVAILABLE','RECRUITING','NOT_YET_RECRUITING'])]\n",
    "\n",
    "    # Sponsor, Collaborators 구분\n",
    "\n",
    "    def extract_country(locations):\n",
    "        if pd.notna(locations):\n",
    "            countries = [y.split(',')[-1].strip() for y in locations.split('|')]\n",
    "            return '|'.join(countries)\n",
    "        else:\n",
    "            return locations\n",
    "\n",
    "    df['country'] = df['Locations'].apply(extract_country)\n",
    "    df['affiliations'] = df.apply(lambda x: mergeaff(x),axis=1)\n",
    "\n",
    "    # 질병 기반 diabetes? \n",
    "    ## 17410 - Study Title, Brief Summary에 Diabetes 포함\n",
    "    ## 13880 - study status 제거하고난 뒤\n",
    "    diab = df[(df['Study Title'].str.contains('diabetes|Diabetes')==True) | (df['Brief Summary'].str.contains('diabetes|Diabetes')==True)]\n",
    "    diab.reset_index(drop=True,inplace=True)\n",
    "    diab.to_csv(filepath,index=False)\n",
    "    print(diab.shape)\n",
    "    df = diab\n",
    "display(df.head(5))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Salford Royal Hospital Northern Care Alliance NHS Foundation Trust, Salford, Greater Manchester, M6 6HD, United Kingdom'"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['Locations'][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Study URL</th>\n",
       "      <th>Study Status</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Collaborators</th>\n",
       "      <th>Phases</th>\n",
       "      <th>Study Design</th>\n",
       "      <th>Locations</th>\n",
       "      <th>country</th>\n",
       "      <th>summary_embedding</th>\n",
       "      <th>normalized_conditions</th>\n",
       "      <th>sentences</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05284071</td>\n",
       "      <td>Actiste® Diabetes Management as a Service (ADM...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05284071</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>The overall aim of the clinical investigation ...</td>\n",
       "      <td>['Diabetes type1', 'Diabetes type2']</td>\n",
       "      <td>DEVICE: Device: Actiste 1.0 and the Companion ...</td>\n",
       "      <td>['Northern Care Alliance NHS Foundation Trust']</td>\n",
       "      <td>['Brighter AB']</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>Salford Royal Hospital Northern Care Alliance ...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>[-2.583105    1.2393227  -0.38946435 -1.110179...</td>\n",
       "      <td>['Diabetes type1', 'Diabetes type2']</td>\n",
       "      <td>['Diabetes type1', 'Diabetes type2'] The overa...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05029271</td>\n",
       "      <td>InPen User Experience</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05029271</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of this study is to evaluate the u...</td>\n",
       "      <td>['Diabetes Type 1']</td>\n",
       "      <td>DEVICE: InPen with Guardian 4 System</td>\n",
       "      <td>['Medtronic Diabetes']</td>\n",
       "      <td>[]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>NU-Hospital Group, Uddevalla, Sweden|Frolunda ...</td>\n",
       "      <td>Sweden</td>\n",
       "      <td>[-1.7408602   1.8224145  -0.6962592  -0.999329...</td>\n",
       "      <td>['Diabetes Type 1']</td>\n",
       "      <td>['Diabetes Type 1'] The purpose of this study ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    NCT Number                                        Study Title  \\\n",
       "0  NCT05284071  Actiste® Diabetes Management as a Service (ADM...   \n",
       "1  NCT05029271                              InPen User Experience   \n",
       "\n",
       "                                      Study URL Study Status  \\\n",
       "0  https://clinicaltrials.gov/study/NCT05284071    COMPLETED   \n",
       "1  https://clinicaltrials.gov/study/NCT05029271   RECRUITING   \n",
       "\n",
       "                                       Brief Summary  \\\n",
       "0  The overall aim of the clinical investigation ...   \n",
       "1  The purpose of this study is to evaluate the u...   \n",
       "\n",
       "                             Conditions  \\\n",
       "0  ['Diabetes type1', 'Diabetes type2']   \n",
       "1                   ['Diabetes Type 1']   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0  DEVICE: Device: Actiste 1.0 and the Companion ...   \n",
       "1               DEVICE: InPen with Guardian 4 System   \n",
       "\n",
       "                                           Sponsor    Collaborators Phases  \\\n",
       "0  ['Northern Care Alliance NHS Foundation Trust']  ['Brighter AB']    NaN   \n",
       "1                           ['Medtronic Diabetes']               []    NaN   \n",
       "\n",
       "                                        Study Design  \\\n",
       "0  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "1  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "\n",
       "                                           Locations         country  \\\n",
       "0  Salford Royal Hospital Northern Care Alliance ...  United Kingdom   \n",
       "1  NU-Hospital Group, Uddevalla, Sweden|Frolunda ...          Sweden   \n",
       "\n",
       "                                   summary_embedding  \\\n",
       "0  [-2.583105    1.2393227  -0.38946435 -1.110179...   \n",
       "1  [-1.7408602   1.8224145  -0.6962592  -0.999329...   \n",
       "\n",
       "                  normalized_conditions  \\\n",
       "0  ['Diabetes type1', 'Diabetes type2']   \n",
       "1                   ['Diabetes Type 1']   \n",
       "\n",
       "                                           sentences  \n",
       "0  ['Diabetes type1', 'Diabetes type2'] The overa...  \n",
       "1  ['Diabetes Type 1'] The purpose of this study ...  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# sponsor, collaborators 없는거 삭제\n",
    "# df[(df['Sponsor'].isnull()==True)&(df['Collaborators'].isnull()==True)]\n",
    "\n",
    "filepath = 'Diabetes-sentences.csv'\n",
    "if os.path.isfile(filepath):\n",
    "    df = pd.read_csv(filepath)\n",
    "else:\n",
    "    def makesen(row):\n",
    "        return row['normalized_conditions'] + ' ' + row['Brief Summary']\n",
    "\n",
    "    df['normalized_conditions'] = df['Conditions'].replace(mapping_dict)\n",
    "    df['sentences'] = df.apply(lambda x: makesen(x),axis=1)\n",
    "    df.to_csv('Diabetes-sentences.csv',index=False)\n",
    "display(df.head(2))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "### affiliation 오타 체크\n",
    "check = []\n",
    "for aff in df['affiliations']:\n",
    "    if '|' in aff:\n",
    "        check.extend(aff.split('|'))\n",
    "    else:\n",
    "        check.append(aff)\n",
    "        \n",
    "from collections import Counter\n",
    "# 각 항목의 출현 횟수 계산\n",
    "count = Counter(check)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# 연구 기관(affiliation) 노드\n",
    "affiliations = set()\n",
    "\n",
    "# 적응증 노드\n",
    "conditions = set()\n",
    "\n",
    "for aff in df['affiliations']:\n",
    "    if '|' in aff:\n",
    "        for affiliation in aff.split('|'):\n",
    "            affiliations.add(affiliation)\n",
    "    else:\n",
    "        affiliations.add(aff)\n",
    "\n",
    "\n",
    "for condition in df['normalized_conditions']:\n",
    "    if '|' in condition:\n",
    "        for cond in condition.split('|'):\n",
    "            conditions.add(cond)\n",
    "    else:\n",
    "        conditions.add(condition)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'count' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[6], line 8\u001b[0m\n\u001b[1;32m      3\u001b[0m \u001b[38;5;66;03m# if os.path.isfile(filepath):\u001b[39;00m\n\u001b[1;32m      4\u001b[0m \u001b[38;5;66;03m#     countdf = pd.read_csv(filepath)\u001b[39;00m\n\u001b[1;32m      5\u001b[0m \n\u001b[1;32m      6\u001b[0m \u001b[38;5;66;03m# else:\u001b[39;00m\n\u001b[1;32m      7\u001b[0m countdf \u001b[38;5;241m=\u001b[39m pd\u001b[38;5;241m.\u001b[39mDataFrame()\n\u001b[0;32m----> 8\u001b[0m countdf[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124maff\u001b[39m\u001b[38;5;124m'\u001b[39m] \u001b[38;5;241m=\u001b[39m [item[\u001b[38;5;241m0\u001b[39m] \u001b[38;5;28;01mfor\u001b[39;00m item \u001b[38;5;129;01min\u001b[39;00m \u001b[43mcount\u001b[49m\u001b[38;5;241m.\u001b[39mmost_common()]\n\u001b[1;32m      9\u001b[0m countdf[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mcnt\u001b[39m\u001b[38;5;124m'\u001b[39m] \u001b[38;5;241m=\u001b[39m [item[\u001b[38;5;241m1\u001b[39m] \u001b[38;5;28;01mfor\u001b[39;00m item \u001b[38;5;129;01min\u001b[39;00m count\u001b[38;5;241m.\u001b[39mmost_common()]\n\u001b[1;32m     11\u001b[0m countdf[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mcondition\u001b[39m\u001b[38;5;124m'\u001b[39m] \u001b[38;5;241m=\u001b[39m countdf[\u001b[38;5;124m'\u001b[39m\u001b[38;5;124maff\u001b[39m\u001b[38;5;124m'\u001b[39m]\u001b[38;5;241m.\u001b[39mapply(\u001b[38;5;28;01mlambda\u001b[39;00m x:mergecond(x))\n",
      "\u001b[0;31mNameError\u001b[0m: name 'count' is not defined"
     ]
    }
   ],
   "source": [
    "filepath = '../Diabetes/affiliation_cnt.csv'\n",
    "\n",
    "# if os.path.isfile(filepath):\n",
    "#     countdf = pd.read_csv(filepath)\n",
    "\n",
    "# else:\n",
    "countdf = pd.DataFrame()\n",
    "countdf['aff'] = [item[0] for item in count.most_common()]\n",
    "countdf['cnt'] = [item[1] for item in count.most_common()]\n",
    "\n",
    "countdf['condition'] = countdf['aff'].apply(lambda x:mergecond(x))\n",
    "countdf['sentences'] = countdf['aff'].apply(lambda x:mergesen(x))\n",
    "\n",
    "import pandas as pd\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.cluster import KMeans\n",
    "\n",
    "# 1. 텍스트 정규화\n",
    "countdf['normalized_conditions'] = countdf['condition'].str.lower().str.strip()\n",
    "# 2. 키워드 기반 매핑\n",
    "countdf['normalized_conditions'] = countdf['normalized_conditions'].replace(mapping_dict)\n",
    "\n",
    "# 3. 비슷한 단어 기반의 클러스터링\n",
    "vectorizer = TfidfVectorizer(stop_words='english')\n",
    "X = vectorizer.fit_transform(countdf['normalized_conditions'])\n",
    "\n",
    "# KMeans 클러스터링\n",
    "num_clusters = 5  # 이 값을 조정하여 원하는 클러스터의 개수를 설정\n",
    "km = KMeans(n_clusters=num_clusters)\n",
    "km.fit(X)\n",
    "clusters = km.labels_.tolist()\n",
    "\n",
    "countdf['cluster'] = clusters\n",
    "\n",
    "# 결과를 확인\n",
    "countdf.head()\n",
    "\n",
    "# 각 normalized conditions 비슷한것들끼리 cluster\n",
    "normcond = []\n",
    "for i in countdf['normalized_conditions']:\n",
    "    if '|' in i:\n",
    "        normcond.extend(i.split('|'))\n",
    "    else:\n",
    "        normcond.append(i)\n",
    "\n",
    "with open('../Diabetes/normcond.txt','w') as f:\n",
    "    f.write('\\n'.join(list(set(normcond))))\n",
    "    \n",
    "countdf.to_csv('../Diabetes/affiliation_cnt.csv',index=False)\n",
    "display(countdf.head(2))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(6209, 6)"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "countdf.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes. Insulin Aspart (NovoLog®) is an ideal insulin to use in an intensive insulin regimen using continuous subcutaneous insulin injection (CSII) therapy in the pediatric and adolescent age population. This trial compares the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered by CSII in children and adolescents with type 1 diabetes.|Diabetes|Cardiovascular Disease A concise diabetes self-management education (DSME) program on the \"ABCs of Diabetes\" will be placed in an urban public library to assess the feasibility of using this community setting for the delivery of health care education in an urban African American population. Impact on knowledge of, prescriptions for, and control of blood sugar (A1C), blood pressure (BP) and LDL cholesterol (LDL-C)before and after participation in the program will be assessed. We will also examine the frequency of emergency department (ED) visits and hospitalizations for uncontrolled diabetes at 6 months post-DSME intervention.|Obesity This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes.\\n\\nThis study will look at how much weight participants lose, and if participants can go from having blood sugar that is higher than normal (prediabetes) to having normal blood sugar.\\n\\nSemaglutide is compared to a \"dummy\" medicine. The \"dummy\" medicine looks like semaglutide but has no effect on the body.\\n\\nIn addition to taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight.\\n\\nParticipants will either get semaglutide or \"dummy\" medicine - which treatment they get is decided by chance. Participants are 2 times as likely to get semaglutide as \"dummy\" medicine.\\n\\nParticipants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm.\\n\\nThe study will last for about 19 months. Participants have to take the study medicine every week for the first 12 months. The last 7 months participants will not take any medication.\\n\\nParticipants will have 14 clinic visits and 1 phone call with the study staff. At 9 of the clinic visits Participants will have blood samples taken. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoRapid® (insulin aspart) and Levemir® (insulin detemir) after switch from human insulins for treatment of type 1 diabetes under normal clinical practice conditions in Romania.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe.\\n\\nA 32-week efficacy and safety comparison of insulin detemir and insulin semilente MC in children between 6 and 21 years with type 1 diabetes.|Type 2 Diabetes Introduction: Changes in lifestyle are responsible for an important part of the type 2 diabetes epidemic of the last decennia. Current guidelines for physical activity focus mainly on high energy expenditure advising 30 minutes per day moderate to vigorous physical activity (most often physical exercise). Recent studies suggest that sitting has negative metabolic effects independent of the time spent exercising (Duvivier et al. PLOS ONE 2013).\\n\\nLow intensity physical activity (LIPA) -such as walking and standing- has been suggested to be an alternative to decrease the hyperglycaemic effect of sitting. Compared to exercise, LIPA might be a more feasible strategy. But, it remains to be determined whether reducing sitting time by replacing it by LIPA, results in lower 24 hour blood glucose levels and less blood glucose fluctuations (glycaemic variability) in type 2 diabetes patients and whether these effects are independent of the increase in energy expenditure\\n\\nMethods: The study population will involve 19 people with type 2 diabetes (BMI: 25-35 kg/m2) who perform no, or only little, exercise and who are treated with diet only or with oral blood glucose lowering medication. They will perform three regimes of each four days: 1) a sitting regime, 2) an exercise regime and a 3) sit less regime. Daily energy expenditure of the exercise regime will be identical to that of the sit less regime. Sitting, walking and standing will be objectively measured by a 24 hour physical activity monitor. The energy spent during exercise will be standardised and quantified by using a bicycle ergometer; energy intake will be standardised as well. During each regime blood glucose will be measured with a 24 hour continuous glucose sensor.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare NNC0123-0000-0338 (insulin-338) in a tablet formulation and insulin glargine in combination with metformin with or without DPP-4 inhibitor in subjects with type 2 diabetes currently treated with oral antidiabetic therapy|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess and compare the effect on blood sugar control of insulin detemir and insulin aspart or insulin detemir alone administered by a insulin pen PDS290 (FlexTouch®) versus a Novo Nordisk marketed insulin pen (FlexPen®) in subjects with type 1 or type 2 diabetes mellitus. Furthermore, the subject\\'s preference of the devices will be investigated by the use of questionnaires.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of the study is to observe the safety of insulin detemir (Levemir®) in patients with type 1 and type 2 diabetes patients.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and North America. This trial aims for comparison of the effect on the glycemic control in subjects with type 2 diabetes of basal insulin analogue with one oral anti-diabetic drug (OAD) versus oral anti-diabetic drug alone.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe.\\n\\nThe aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia episodes under normal clinical practice for patients with type 1 or type 2 diabetes.|Healthy Volunteers|Type 2 Diabetes In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested. Besides semaglutide, the current version of the tablet contains 300 mg SNAC and 3 helping agents, while the new version of the tablet contains 300 mg SNAC and only one helping agent. Both are for the treatment of diabetes. Currently, semaglutide is only prescribed as injections for the treatment of diabetes in some countries. Semaglutide cannot yet be prescribed as a tablet. The aim of this study is to find out if the dosage strength of the current formulation of semaglutide can be reduced in the new tablet formulation. For this purpose, it will be measured how much semaglutide is taken up in the body from the two (2) different tablet formulations each with three (3) different dosage strengths. Participants will get semaglutide in the current tablet formulation and in a new formulation - in which order they receive the two different formulations is decided by chance. Participants will get one tablet per day over 4 weeks in each of the 3 treatment periods (i.e. treatment for a total of 12 weeks). The tablets should be taken in the morning together with half a glass of water (120 mL), after an overnight fast of at least 6 hours (no food or drinks). Furthermore, water is not allowed from 2 hours before dosing. After dosing participants must wait 30 minutes before they may eat or drink. At home, they must take their breakfast 30-45 minutes after dosing.|Diabetes Mellitus, Type 1 The purpose of the proposed study is to compare insulin Degludec \\\\[TRESIBA® (insulin degludec injection)\\\\] with insulin Glargine U100 \\\\[Lantus® (insulin glargine injection)\\\\] to determine the basal insulin of choice for adults with type 1 diabetes (T1D) who fly non-stop across multiple time zones. With the introduction of Degludec as basal insulin for T1D and the opportunity to vary time of injection between 8 and 40 hours, the use of Degludec as a basal insulin may make it easier for both people living with T1D and diabetologists to plan long-haul travel compared to the use of existing basal insulins when crossing multiple time zones.The study hypothesis is that once daily Degludec as the basal insulin will provide better glycemic control for people with type 1 diabetes on multiple daily injections who are traveling non-stop across multiple time zones than once daily Glargine U100.|Diabetes|Diabetes Mellitus, Type 2 This trial was conducted in Japan. The aim of this trial was to evaluate the safety and efficacy of once daily administration of liraglutide in combination with an oral anti-diabetic drug (OAD) in Japanese subjects with type 2 diabetes who are insufficiently controlled on OAD monotherapy. All subjects will continue their pre-trial OAD (either glinide, metformin, alpha-glucosidase inhibitor or thiazolidinedione) during the trial at unchanged type and dose.|Type 2 Diabetes Background: Preclinical blood pressure (BP) data from studies of hypoglycemic effects of liraglutide treatment (the LEAD program), revealed a significant antihypertensive potential. The time course and the mechanism behind this effect are unknown.\\n\\nObjectives: To evaluate the time course of the antihypertensive effect of liraglutide treatment in patients with type 2 diabetes\\n\\nDesign: Open-label study with intervention and subsequent washout period\\n\\nPatient Population: 35 hypertensive (SBP ≥130 mm Hg and DBP ≥80 mmHg) patients with type 2 diabetes.\\n\\nIntervention: All patients will be treated with liraglutide 0.6 mg once daily for 7 days and will then be titrated to 1.2 mg once daily for 14 days and then titrated to 1.8 mg once daily for 4 weeks. This is followed by a washout period of 3 weeks without liraglutide treatment.\\n\\nEndpoints: 24-hour blood pressure, natriuresis, extra cellular volume (ECV|Type 2 Diabetes Treated With Insulin The trial is an open-label randomized controlled trial. Patients with T2D on insulin therapy will be randomized to a telemonitoring group (intervention) and a usual care group (control). The telemonitoring group will use various devices at home. Hospital staff will monitor their data for a period of three months.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of semaglutide once-weekly versus exenatide ER (extended release) 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate steady state pharmacokinetics of biphasic insulin aspart 30 and biphasic insulin aspart 70 in subjects with type 1 diabetes.|Diabetes Mellitus, Type 2 The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes (T2DM) patients across five selected countries in Europe. Participants will be asked to give information about their health. Participants will continue their normal way of life and will not get any medication other than what has been prescribed to them by their doctor. Participants\\' participation will be one day/one visit at study doctor. The study will last for about 3 months in total.|Healthy Volunteers|Type 2 Diabetes People with type 2 diabetes have too much sugar in their blood and need treatment to control their sugar level. The 3 study compounds in this study are similar to an approved antidiabetic medicine that helps to lower blood sugar levels in people with type 2 diabetes. This approved antidiabetic medicine is generally safe and well tolerated. The study compounds are expected to have the same antidiabetic effect as the approved medicine. The purpose of this study is to investigate how quickly and to what extent each of the 3 study compounds are broken down in the body (this is called pharmacokinetics). The dose of each study compound will be very low (this is called a microdose), and will be labelled with a small amount of carbon-14. This is radioactive, and it makes it possible to track the study compound in the blood. The 3 study compounds in this study have not been given to humans before. The study will be performed in up to 18 healthy male volunteers. The study will consist of 3 groups of 6 volunteers each. Each participant will receive only one dose of study medicine.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Asia, Europe and North America. The purpose is to confirm efficacy in terms of glycaemic control of treatment with mealtime faster-acting insulin aspart in combination with insulin degludec in adults with Type 1 Diabetes Mellitus.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Japan. The aim of this clinical trial is to investigate the effect of NN1250 (insulin degludec) in Japanese subjects with type 1 diabetes.|Diabetes Mellitus, Type 2 This study compares the effect on blood sugar levels of two medicines: insulin degludec and insulin glargine in people with type 2 diabetes. Participants will be treated with insulin degludec and insulin glargine during two different periods. Which treatment participants get first is decided by chance. Both medicines are approved for use in humans and available on the market. They can already be prescribed by participants\\' doctors. Participants will get pre-filled insulin pens to inject these insulins with. The study will last for about 41 weeks. Participants will visit the clinic 13 times and have 27 phone calls with the study doctor or study staff. At 12 of the clinic visits they will take blood samples. In order to evaluate the changes in participants\\' blood sugar level over time, participants will be asked to wear a small (35 millimetres (mm) x 5 mm) sensor on the back of participants\\' upper arm 3 times during the study. Each time participants must wear the sensor for 2 weeks. This sensor is called FreeStyle Libre Pro®. It has a very small tip which is 0.4 mm thick and is inserted 5 mm under participants\\' skin. Please note that participants will not be able to see the sensor readings while wearing it. The study doctor will show participants the readings when participants return to the clinic. Participants will be asked to fill in a diary in between visits. Participants will have contact with the study doctor or study staff each week. This is to adjust the dose of participants\\' study medicines and to ensure that participants are well. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Type 2 Diabetes Mellitus This study will examine two questions: 1. Whether insulin treatment of high blood sugar in patients with diabetes while they are in the emergency room will improve how quickly they recover from illness if they need to be hospitalized. 2. Whether immediately beginning long lasting insulin detemir in patients with diabetes when they are admitted to hospital from the emergency room will improve how quickly they recover from the illness which necessitated hospitalization.|Obesity This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a \"dummy\" medicine. In addition to taking the medicine, the child\\'s parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a \"dummy\" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults.\\n\\nThe child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).|Diabetes|Diabetes Mellitus, Type 1 The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime insulin aspart. The trial involves patients with Type 1 Diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of treatment intensification.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this non-interventional study is to investigate the safety and effectiveness of insulin degludec (Tresiba®) in a real world population with type 1 (T1DM) and 2 (T2DM) diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus before, during and after Ramadan.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of the study is to investigate the effectiveness of Xultophy® (insulin degludec/liraglutide) in an adult real-world population with type 2 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, and complications in diabetic subjects in Asia.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to compare the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart, IDegAsp) with NN1250 (insulin degludec, IDeg) and insulin aspart (IAsp) in subjects with type 1 diabetes mellitus.|Diabetes Mellitus, Type 2 This study compares insulin icodec to different daily insulins in people with type 2 diabetes.\\n\\nThe study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily. Participants will either get insulin icodec, that participants will have to inject once a week on the same day of the week, or a marketed insulin, that participants will have to inject once a day. Which treatment participants get is decided at random.\\n\\nThe insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach.\\n\\nParticipants will measure their blood sugar every day. Participants will get a study phone to record safety data in the electronic diary (eDiary). If participants get a daily insulin they will record their insulin doses in the eDiary. If Participants get weekly insulin icodec, participants study phone will also have the DoseGuide App. The DoseGuide App gives dose recommendations based on their blood sugar and previous doses. Participants will record their insulin doses in the DoseGuide App.\\n\\nThe study will last for about 1 year and 2 months. Participants will have 8 planned clinic visits with the study doctor. More visits will be planned to meet individual needs. At 6 clinic visits participants will have blood samples taken.\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different self-titration algorithms (dose individually adjusted) in combination with metformin.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and Asia. The aim of this trial is to compare basal bolus treatment with insulin aspart and insulin NPH to biphasic insulin aspart treatment on blood glucose control in type 2 diabetes.|Type 2 Diabetes High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the hospital complications. It is not known; however, what is the best insulin regimen in hospitalized patients. Recently, the use of basal/bolus insulin therapy with detemir (Levemir®) and rapid-acting insulin (lispro, aspart, glulisine) has been shown to facilitate outpatient glycemic control with lower rate of hypoglycemic (low blood sugar) events in patients with diabetes. In this study, we will determine the efficacy and safety of the combination of detemir and aspart insulin in the inpatient management of subjects with diabetes. We hypothesize that in patients with type 2 diabetes admitted to general medicine wards, treatment with insulin detemir once daily plus insulin aspart before meals will allow better glycemic control and lower rate of hypoglycemic events than treatment with twice a day NPH plus regular insulin before meals. Detemir is a long-acting insulin which is given subcutaneously (under the skin) once daily. Aspart is a rapid-acting insulin which is given subcutaneously several times a day and frequently before meals. Detemir and aspart insulins are approved for use in the treatment of patients with diabetes by the FDA.\\n\\nThis investigator-initiated research will be conducted at Grady Memorial Hospital, Atlanta and at Rush University Medical Center, Chicago, IL. Dr. Umpierrez designed the study and will serve as principal investigator. A total of 65 patients will be recruited at Grady and 65 patients at the Rush University Medical Center, Chicago, IL.|Type 2 Diabetes Treated With Insulin Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains a challenge.\\n\\nThis study examines the effects of Fiasp (a faster acting insulin) on blood sugars after meals compared to another type of insulin known as Novolog. The study will be performed in patients with type 2 diabetes admitted to the hospital, who are not in the intensive care unit, and who are being seen by the inpatient diabetes consult team. Eligible participants will be treated with Fiasp or Novolog injected multiple times a day before meals and at bedtime, in addition to a once daily injection of insulin glargine as basal insulin. Which type of meal time insulin (Fiasp vs Novolog) the subject gets is decided by chance, like the flip of a coin. Insulin doses will be started and titrated based on a protocol. All the subjects will wear a blinded continuous glucose monitoring (CGM)) sensor placed in their arm which they will wear for 72 hours during the study. The glucose values from the CGM, collected during the time it is worn, will be downloaded and compared to assess the response to the two different types of insulins - Fiasp and Novolog. The goal is to determine if Fiasp works as well as or better than Novolog in controlling blood sugars, particularly after meals, in the subjects of the study.|Diabetes Mellitus, Type 2 The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets (\"dummy\" medicine) - which treatment is decided by chance. Participants must take one tablet with water every morning on an empty stomach and not eat or drink anything for at least 30 minutes. The study will last for about 3.5-5 years. Participants will have up to 25 clinic visits and 1 phone call with the study doctor. Women cannot be in the study if pregnant, breast-feeding or if they plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1 This trial was conducted in Europe. The aim of this clinical trial was to look into the concentration of NN1250 (insulin degludec/insulin 454) in the blood after one injection of NN1250 in children, adolescents and adults with type 1 diabetes.|Diabetes Mellitus, Type 2 The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need to take one injection of semaglutide once a week, on the same day of every week. Participants will have a total of 11 clinic visits and the study will last for about 35 weeks (approximately 8 months).|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if a 31 gauge x 6 mm needle will provide comparable blood glucose control to the 29 gauge x 12.7 mm needle in obese subjects with diabetes.|Diabetes This trial is conducted in Asia. The aim of this Non-interventional study is to investigate the long-term safety and effectiveness of Ryzodeg® (insulin degludec/insulin aspart) in Japanese patients with diabetes mellitus requiring insulin therapy under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to document the glycaemic parameters, adverse events, including drug reactions, as well as hypoglycaemic episodes, in patients that switched from insulin glargine combined with oral antidiabetic drugs (OADs) to biphasic insulin aspart 30 (NovoMix® 30) combined with OADs, when applicable.|Type 2 Diabetes This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤ 7.5%) on MDI-based regimens (≤ 80 units of insulin per day), vs. further titration of insulin therapy in those continuing MDI. Weight loss, hypoglycemic episodes, and improvement in diabetes-treatment satisfaction will also be assessed between the two groups.|Diabetes Mellitus, Type 2 This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared. This is done to find the best way to change the dose of insulin 287. Participants will either get insulin 287 that they will have to inject once a week or insulin glargine that participants will have to inject once a day. Which treatment participants get is decided by chance. The study will last for about 5 months (23 weeks). Participants will have 14 clinic visits and 6 phone calls with the study doctor. At 3 of the clinic visits participants will be asked not to eat or drink anything (except for water) in the last 8 hours before the visit. During the study, the study doctor will ask participants to:\\n\\n* measure blood sugar every day with a blood sugar meter using a finger prick.\\n* write down different information in a diary daily and return this to the study doctor.\\n* wear a medical device (sensor) that measure blood sugar all the time for 18 weeks (about 4 months) during the study.\\n\\nWomen cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.|Diabetes Mellitus, Type 2|Stroke (CVA) or Transient Ischemic Attack A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication.\\n\\nGiven the available evidence supporting the neuroprotective effect of this drug class and stroke reduction with semaglutide, and our preliminary data showing that T2D had significantly reduced total number of distal arterial branches in the brain than non-T2D, we expect treatment with semaglutide will be associated with improved intracranial blood flow condition.|Diabetes|Diabetes Mellitus, Type 2 This clinical trial is conducted in Europe. The purpose of the trial is to investigate the influence on the pharmacokinetics (the rate at which the trial drug is eliminated from the body) of an oral contraceptive combination drug after multiple administration of semaglutide in female subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare different ratios of explorative formulations, not similar to the proposed commercial formulation, of IDegAsp (co-formulation of insulin degludec/insulin aspart and insulin aspart) with separately injected, simultaneous doses of insulin degludec (insulin 454), and insulin aspart, compared with biphasic insulin aspart 30 in male subjects with type 1 and type 2 diabetes mellitus.\\n\\nTrial part 1 is a five-period cross-over trial with incomplete block-design in subjects with type 1 diabetes where each subject will be randomised to five out of the ten possible treatments. Each treatment consists of an injection of the insulin product followed by a euglycemic clamp with a washout period of 7-15 days between treatments.\\n\\nTrial part 2 is a three-period cross-over trial with complete blockdesign in subjects with type 2 diabetes. Each treatment consists of an injection of the insulin product followed by a euglycaemic clamp with a washout period of 7-15 days between treatments.|Diabetes|Diabetes Mellitus, Type 2 The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).|Gestational Diabetes Mellitus|Type 2 Diabetes Mellitus|Metabolic Syndrome|Impaired Glucose Tolerance|Disorder of Glucose Regulation A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy. Systematic reviews of older studies conclude that 35-60% women with gestational diabetes will develop type 2 diabetes (DM2) at rates much greater than control groups who did not have glucose intolerance during pregnancy. Liraglutide may potentially delay disease progression in GDM considering the beta -(ß-)cell function improvement in DM2 and ß-cell mass shown to increase in animal models. This study will examine if the addition of liraglutide to metformin therapy is more effective than metformin alone in improving insulin sensitivity and normalizing insulin secretion in at-risk overweight/obese women with prior GDM.|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Hypoglycemia|Hypoglycemia Unawareness Hypoglycaemia or low blood glucose, and its fear are major barriers to achieving optimal glucose control. New technology, such as continuous glucose monitors (CGM), help to better identify hypoglycaemia and develop strategies to avoid it. These devices measure glucose in the skin, rather than in the blood, and provide information not only on how low glucose is, but also for how long. Recent studies showed that over half of episodes of low glucose with these systems are not recognised by people with diabetes, and even people without diabetes have sensor values that are below the current thresholds for hypoglycaemia \\\\[ low blood glucose\\\\] that we measure with traditional monitors.\\n\\nIn this study, the investigators will evaluate the impact of symptomatic as well as asymptomatic episodes of low sensor glucose on a variety of clinical, patient-related and health economic outcomes such as mood, quality of sleep and productivity. The investigators will test different levels and durations of low sensor glucose to identify the one that best matches episodes that are symptomatic to best define hypoglycaemia using these systems.\\n\\nThe investigators will also look at factors that influence this such as sleep or activity as well as diabetes management behaviours (such as insulin dosing, carb counting, etc). At the end of this study, the investigators will be able to provide a better definition of clinically relevant low sensor glucose readings that will help inform clinical as well as academic interpretation of CGM data.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study conducted in Europe. The aim of this study is to evaluated the use of insulin detemir (Levemir®) in insufficiently controlled patients with type 1 or type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 Diabetes The purpose of this study is to collect information about Fiasp® to evaluate how effective Fiasp® is in treating elevated blood sugar in patients with type 1 diabetes, compared with the participant\\'s previous insulin treatment. The study will also assess how satisfied the participants are with the treatment with Fiasp® and the impact of the treatment on quality of life. The study has also been set up to learn more about how effective Fiasp® is in controlling the glucose levels during the day and night. The duration of the study is expected to be approximately 2 years. The participation is expected to be approximately 6-8 months for each patient.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this study is to assess the efficacy of a pre-pregnancy life style intervention to reduce the risk of diabetes and prediabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoMix® 30 for treatment of type 1 and type 2 diabetes under normal clinical practice conditions in Romania.|Type 2 Diabetes The purpose of this study that when studies using our method of dosing adjustments driven by continuous glucose monitoring and because of the less variable glycemic effect of insulin detemir, insulin detemir treated subjects will spend a significantly greater time in the glucose target range than insulin glargine.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels, and to get side-effects information. Participants will get Rybelsus® as prescribed to them by the study doctor.\\n\\nThe study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The trial is designed to compare the effect on glycaemic control of liraglutide or glimepiride added to metformin in subjects with type 2 diabetes|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2 diabetes.|Type 2 Diabetes The results from the DECODE Study have shown that postprandial (1 - 2 hours after a meal) hyperglycemia (elevated blood sugar) is more common in elderly people with diabetes than younger people with diabetes and is the best predictor of the development of complications. The DECODE Study involved 6941 people who already had diabetes and 702 who did not have diabetes. Diabetes is diagnosed when the blood sugar 1st thing in the morning is over 7.0 mmol/L. The DECODE Study showed that people at risk for diabetes can have a normal blood sugar 1st thing in the morning but have a high blood sugar 2 hours after a meal and that these people are at risk for developing heart disease and other complications of diabetes. These people would not be identified as at risk if only a fasting blood sugar is done. Studies in younger people with diabetes have shown that after a meal, insulin levels are more like a person without diabetes and glucose (blood sugar) levels are lower with GlucoNorm than with Glyburide. There is no data available that demonstrates this in elderly people with type 2 diabetes.\\n\\nYou have been invited to participate in this study because you have type 2 diabetes controlled by diet and/or exercise or metformin only and are over 65 years of age.\\n\\nThe purpose of this study is to determine whether GlucoNorm has a greater effect than Glyburide on insulin levels and glucose (blood sugar) levels after a meal in elderly people with type 2 diabetes who control their diabetes with diet and exercise.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to compare two methods of injection in basal-bolus insulin regimen in children with type 1 diabetes with insulin detemir associated with insulin aspart given twice daily in either separate or mixed injections and to investigate if there is any clinical impact in choosing one regimen over another.|Diabetes|Diabetes Mellitus, Type 2 This trial was conducted in Asia, Europe and South America. The aim of this trial was to confirm efficacy of subject driven titration (individually adjusted) of biphasic insulin aspart 30 (BIAsp 30) twice daily in terms of glycaemic control assessed by change in glycosylated haemoglobin (HbA1c).|Non-alcoholic Steatohepatitis This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).\\n\\nNNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499. The 2 medicines may work better together than on their own.\\n\\nThe study will also look at a combination of semaglutide and another weight-loss medicine called NNC0174-0833, which may be another treatment option for NASH.\\n\\nEach week, participants will get 2 injections. These could be 2 of the 3 medicines OR 1 of the medicines and a placebo OR 2 placebo injections. Which treatment participants get is decided by chance. A placebo is a dummy medicine which looks like the real medicine but doesn\\'t contain any active medicine.\\n\\nThe study will last for about 19 months. Participants will have 14 clinic visits and 9 phone calls with the study doctor.\\n\\nParticipants will have 1 or 2 liver biopsies (tiny pieces of liver tissue) - one at the start (if participants have not had a biopsy recently) and one at the end of the study treatment.\\n\\nWomen: Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using NovoRapid® (insulin aspart) in children with type 1 and type 2 diabetes under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese subjects with type 2 diabetes inadequately controlled on metformin monotherapy. Eligible subjects will continue their metformin background treatment during the trial.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject\\'s ongoing OAD (oral anti-diabetic drug) treatment of either metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes. Two trial periods: A 26 week randomised, followed by a 52 week extension (14 + 38 weeks) where all subjects received liraglutide + OAD after previous randomisation to either liraglutide or exenatide, both combined with OAD treatment.|Diabetes|Diabetes Mellitus, Type 1 The trial was conducted in Germany, The Republic of Macedonia, Russian Federation, Serbia and South Africa. The aim of this trial was to make a safety comparison of insulin detemir produced by a new production method (NN729) with insulin detemir made by the previous production method (NN304). Subjects were treated with NN729 or NN304 for a period of 52 weeks at the same total daily dose and frequency of administration as their own pre-trial basal insulin . During the trial doses were individualised based on subject\\'s plasma glucose measurements.|Diabetes Mellitus, Type 2 This study is comparing the medicine RYBELSUS® to other medicines in people with type 2 diabetes who need extra treatment. All medicines used in this study are tablets which lower blood sugar in people with type 2 diabetes. The purpose of the study is to see how well RYBELSUS® is at lowering blood sugar compared to other tablets when used in addition to metformin. Participants doctor will give participants either RYBELSUS® or any other blood sugar lowering tablets - which treatment participants get is decided by chance. The doctor treating participants diabetes will give participants a prescription for the medicine and tell how to take it. The study will last for about 1 year. Participants will have 2 planned visits with their doctor which are part of the usual routine diabetes management: the first visit is when participants are included in the study, the second visit is a 1-year follow-up visit. In addition, the study personnel will contact participants up to 3 times during this period and to follow-up on information from participant doctors visits. Participant will be asked to respond 3 times to 4 questionnaires via their personal smartphone or tablet or paper if participant do not have access to one during the study. All clinic visits are part of the usual routine diabetes management and are covered by participants health insurance plan. The study team will collect information from these visits recorded in the medical chart. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Type 2 Diabetes Mellitus The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising IDegLira, metformin, and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe, Oceania and the United States of America (USA).\\n\\nThe aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like peptide-1 (GLP-1) receptor agonist and OAD therapy.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2|Healthy This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body), and pharmacodynamics (the effect of the investigated drug on the body) of multiple doses of a long-acting GLP-1 analogue (oral semaglutide) and a carrier in healthy male subjects and male subjects with type 2 diabetes (T2D).|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia, Europe and in the United States of America. The aim of this study is to examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin regimens.|Diabetes Mellitus, Type 2 The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to compare the pharmacokinetic profile of two different methods of insulin administration in children with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to evaluate the incidence of serious adverse drug reactions when initiating insulin therapy with NovoMix® 30 in subjects with type 2 diabetes mellitus under normal clinical practice conditions in Sweden.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Oceania and North America. The aim of this trial is to assess the long term safety and efficacy of biphasic insulin aspart 30 in subjects with type 2 diabetes who have completed the BIAsp-1234 trial.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using insulin detemir under normal clinical practice conditions in the Gulf countries|Type 2 Diabetes The objectives is to compare the changes in body composition (primary objective), diabetes parameters, energy expenditure and energy intake between Insulin detemir (Levemir® - Novolin® 4 pen) and insulin glargine (Lantus® - Solostar®) both in combination with Metformin and insulin secretagogues (SU) between baseline and after 6 months of insulin therapy in 80 type 2 diabetic patients failing on oral diabetic agents .|Diabetes Mellitus, Type 1 This study is looking at how five different formulations of faster aspart 200 U/mL reach and stay in the blood after injection. The purpose is to find a formulation that behaves similarly to the reference product called faster aspart 100 U/mL (marketed as Fiasp®). The participant will get all five formulations and the reference product. The order in which the participant gets them is decided by chance. The participant will get each medicine once during the study meaning that the participant will get a total of six injections with study medicine. The medicine will be injected under the skin in the stomach. The study will last for about 2 to 21 weeks depending on individual visit schedule. The participant will have nine clinic visits with the study doctor (including the one in which the participant give consent).|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 Fast-acting insulin aspart (faster aspart) will be tested to see how well it works and if it is safe. The study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine doctors can already prescribe). Participants will either get faster aspart or insulin aspart (NovoRapid®) - which treatment is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day: 3 injections 0-2 minutes before breakfast, lunch and dinner and 1 injection at the same time every day. All study medicines are provided in pens. A pen is a tool to inject insulin under the skin.The study will last for about 7 months (30 weeks). Participants will have 11 clinic visits and 17 phone contacts with the study doctor. At 8 clinic visits participants will have blood samples taken. At 3 clinic visits participants cannot eat or drink (water is allowed) 8 hours before the visits - at 2 of these visits participants will be asked to drink a liquid meal and to stay at the clinic for about 5 hours. Participants will fill in a diary the last 3 days before the visits/phone contacts. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.|Diabetes Mellitus, Type 1 This study will look at how insulin 287 works, if it is safe and the side effects in people who are Japanese with type 1 diabetes. The study will test how insulin goes through your blood, how long it stays there and how the blood sugar is lowered. Insulin 287 is a new medicine. Insulin glargine is already approved to treat diabetes. The study doctors can prescribe insulin glargine. The participants will get both of the insulins in a random order. The participants will get 8 weekly doses of insulin 287 and 14 daily doses of insulin glargine. There will also be a run-in period of 2 days to 7 weeks when the participants inject insulin glargine every day before they start insulin 287 period or insulin glargine period. All doses will be injected under the skin. During the run-in period, the participants adjust the insulin glargine dose and make their blood sugar levels stable. From the run-in period, the participants will take insulin aspart as bolus insulin. The study will last for about 16 - 28 weeks. The participants will have 24 visits with the study doctor. There will be 3 glucose clamps where the participants\\' blood sugar is tested over time. The participants cannot be in the study if the study doctor thinks that there are risks for their health.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate the exposure of NN5401 (insulin degludec/insulin aspart) in young adults and elderly subjects with type 1 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to compare oral anti-diabetic drug (OAD) combined with insulin vs. insulin alone in subjects with type 2 diabetes not adequately controlled on the current OAD therapy.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe, Africa and the United States of America (USA).\\n\\nThe aim of this trial is to compare the safety and efficacy of two different insulin treatments, the \"basic\" and the \"advanced\" treatment in type 2 diabetes.|Type 2 Diabetes Mellitus The main purpose of this study is to find the long-term effects of daily administration of 40 IU of intranasal insulin (INI) as compared to placebo (sterile saline) on cognition and memory in people with type 2 diabetes mellitus (DM), and non-diabetic controls over 24 weeks with a follow-up period for 24 weeks. Four groups will be tested: DM group treated with INI; DM group treated with placebo; control group treated with INI and the control group treated with placebo. The INI or placebo will be delivered into the nose. The investigators are interested to see whether INI can improve memory and cognition and blood flow in the brain in the type 2 DM group as compared to placebo and to the non-diabetic group over a long-term period.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2 diabetes (T2DM).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to compare repaglinide and metformin administered alone or in combination in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 The trial is conducted in Asia. The aim of the trial is to evaluate the effect of insulin detemir on blood glucose control in Taiwanese patients with type 2 diabetes failing on OAD with/without once-daily NPH Insulin treatment.|Diabetes Mellitus, Type 1 This study is looking at the safety of the new medicine, insulin NNC0471-0119, its concentrations in the blood and effect on blood sugar for the treatment of type 1 diabetes. Insulin NNC0471-0119 will be compared to faster aspart. The purpose of this study is to test how insulin NNC0471-0119 is tolerated by participants body, how it is transported in participants bloodstream, how long it stays there and how the blood sugar is lowered compared to faster aspart. Participants will get either the new insulin NNC0471-0119 or faster aspart-which treatment participants get is decided by chance. It is the first time insulin NNC0471-0119 is tested in people. Faster aspart is a globally used medication for treatment of diabetes mellitus. Participants will get one single injection in a fasting state which will take place at the study site. The medicine will be injected under the skin in the stomach. The study will last for about 13-53 days, depending on individual visit schedule. Participants will have four clinic visits with the study doctor, one of which will require an in-house visit period of 3 days. During the in-house visit, two intravenous cannulas will be inserted for sampling of blood and infusion of insulin. Participants cannot be in the study if the study doctor thinks that there are risks to their health. Women: Women cannot take part if they are of childbearing potential.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia and Europe. The aim of the trial is to compare the efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 (biphasic insulin aspart 30) in insulin naïve subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to evaluate glycaemic control in subjects with type 2 diabetes using once daily Levemir® as initiation of insulin therapy in Hungary.|Diabetes Mellitus, Type 2 This study looks into how the type 2 diabetes medicine, semaglutide, can prevent risk of heart disease complications and stroke. Participants will either get semaglutide or placebo (\"dummy\" medicine) - which treatment is decided by chance. Semaglutide is a new medicine to treat type 2 diabetes and can be prescribed by doctors in some countries. The study medicine will be in a pen, and must be injected with a needle in the stomach, thigh or upper arm once a week. The study will last for 57-63 weeks. Participants will have 10 clinic visits with the study doctor, 5 visits to the specialised clinic for imaging and at least 1 phone contact. Participants\\' health will be monitored carefully and blood samples will therefore be taken at the clinic visits. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate the efficacy on blood glucose control in type 2 diabetes.|Diabetes Mellitus, Type 2 ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of the trial is to investigate the effects of semaglutide on ß-cell function in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 This study looks at the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965), its concentration in the blood and its effect on the blood sugar for the treatment of diabetes. The study will test how insulin 965 is tolerated by the body, how it is taken up in the blood, how long it stays there and how the blood sugar is lowered. Participants will either get the new insulin 965 or the already marketed insulin glargine U100 (Lantus®) - which treatment is decided by chance. Participants will get six injections (one per day) of either insulin 965 or insulin glargine U100 under the skin of the left thigh. The study will last for about 5 weeks. Participants will have 6 clinic visits with the study doctor. Participants can only be in the study if the study doctor thinks that there are no risks for their health. Women can only take part in the study if they can\\'t have children.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe, North America and Asia. The aim of this observational study is to evaluate the safety and effectiveness while using Levemir® once daily in combination with oral antidiabetic drugs in type 2 diabetics during 24 weeks under normal clinical practice.\\n\\nData from the NN304-3573 study (NCT00740519) will be pooled with data from this study and reported together in the final study report for this study.|Type 2 Diabetes|Comparative Effectiveness of Glycemia-lowering Medications The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.|Type 1 Diabetes The objective of this in-clinic study is to test our closed-loop glucose control system in patients with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin glargine (IGlar), both as add-on to subject\\'s ongoing treatment with metformin + at least one OAD (oral anti-diabetic drug).\\n\\nThe main period is registered internally at Novo Nordisk as NN5401-3590 while the extension period is registered as NN5401-3726.|Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity This study in healthy men and women compares the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (sc, under the skin). Participants will receive 2 single doses of semaglutide 0.25 mg on 1 day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. A seven day dose escalation study in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe, and the United States of America (USA).\\n\\nThe aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp) with/without metformin and with/without pioglitazone in subjects with type 2 diabetes (main period) followed by investigating the long-term safety in terms of comparing NN1250 with insulin glargine plus insulin aspart with or without metformin and with or without pioglitazone in subjects with type 2 diabetes.\\n\\nAll oral anti-diabetic drug (OAD) treatment will be discontinued, if applicable, when trial participant enters the trial (NN1250-3582) with the exception of metformin and pioglitazone.\\n\\nSubjects who consent to participate in the extension trial (NN1250-3667) will continue to receive the treatment to which they were randomly allocated in the 52 week trial NN1250-3582.\\n\\nThe main period is registered internally at Novo Nordisk as NN1250-3582 while the extension period is registered as NN1250-3667.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in South America. This aim of this trial is to evaluate the comparative prandial blood glucose lowering profile in subjects with type 1 diabetes.|Diabetes Mellitus, Type 2 This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.\\n\\nThe study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to semaglutide.\\n\\nParticipants will either get IcoSema or semaglutide. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe semaglutide in many countries.\\n\\nParticipants will get IcoSema or semaglutide, which they must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach.\\n\\nThe study will last for about 1 year and 1 month. Participants will have 18 clinic visits, 34 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls.\\n\\nAt 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.|Type 2 Diabetes Mellitus Glucagon-like peptide 1 is known to improve sensitivity of the pancreatic beta-cell. Further it inhibit secretion from the pancreatic alpha-cell by mechanisms not fully understand. With this study we wish to elucidate the potential of GLP-1 to increase the sensitivity of the alpha-cell.\\n\\nType 2 diabetic patients and control subjects receive infusions of GLP-1 in increasing doses or saline, alpha- and beta-cell responses are measured in blood-samples. During the study plasma-glucose levels are clamped at fasting levels.\\n\\nWith this study we hope to elucidate the pathophysiology behind defect glucose tolerance in type 2 diabetes mellitus and further more the potential of GLP-1 in treatment of type 2 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this study is to evaluate the safety and efficacy of biphasic insulin aspart (NovoMix® 30) in hospitalised patients with type 2 diabetes with the aim of intensifying their treatment.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this clinical trial is to compare the blood glucose lowering effect of NN5401(insulin degludec/insulin aspart (IDegAsp)) with NN1250 (insulin degludec (IDeg)) and insulin aspart (IAsp) in subjects with type 1 diabetes where the trial participant will receive one single dose of each trial product in varying order.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of FIAsp (faster-acting insulin aspart) in subjects with type 1 diabetes.|Obesity|Diabetes Mellitus, Type 2 This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking \"dummy\" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or \"dummy\" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the \"dummy\" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. After receiving first dose, the dose of semaglutide will be gradually increased until reaching the target dose. The study will last for about 1.5 years.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor. Participants will be asked to complete some questionnaires about their diabetes treatment. Participants will complete these during their normally scheduled visits with the study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of the trial is to compare efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) + insulin aspart (IAsp) once daily (OD) versus basal bolus with insulin degludec (IDeg) OD + IAsp three times a day (TID) in controlling glycaemia by evaluating glycosylated haemoglobin (HbA1c). The trial is an extension to trial NN5401-3941 (NCT01680341).|Diabetes Mellitus, Type 2 This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK). The data for this study will be drawn from the Clinical Practice Research Datalink (CPRD) Register.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate the effectiveness of Tresiba® (insulin degludec) after switching basal insulin in a population with type 1 or type 2 diabetes mellitus.\\n\\nEU-TREAT (EUropean TREsiba AudiT)|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.|Type 2 Diabetes|Non-alcoholic Steatohepatitis (NASH)|Non-alcoholic Fatty Liver Disease (NAFLD) The aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm parallel group, interventional study is to assess for the first time the effects of either a combined therapy with the antihyperglycemic drugs semaglutide and empagliflozin or empagliflozin monotherapy compared to placebo as potential treatments for non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes.|Overweight|Obesity The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity, but it has been approved as a treatment for diabetes mellitus. Participants will get 1 of the 2 forms of semaglutide - which one is decided by chance. Participants will get the medicine as an injection under the skin of the belly using a pen-injector. The type of pen-injector is different for the two forms of semaglutide. The study staff will teach participants how to inject the medicine. Participants will take an injection once a week and will get a total of 21 injections of study medication. The study will last for about 27-30 weeks. Participants will have 25 study visits with the study doctor. For 2 of the visits, participants will stay in the clinic for 3 days and 2 nights. Participants may have to stop the study if the study doctor thinks that there are risks for their health. Women cannot take part if they are pregnant, breast-feeding or planning to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Asia and Oceania. The aim of this trial is to compare the efficacy and safety of human insulin produced by the current process and the NN729 process in type 1 diabetes.|Healthy Volunteers|Type 2 Diabetes In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested. One is the current formulation and the other one is a new formulation of semaglutide. Both will be administered as a tablet and are for the treatment of diabetes. Currently, semaglutide is only prescribed as injections for the treatment of diabetes in some countries. The aim of this study is to find out if the dosage strength of the current formulation of semaglutide can be reduced in the new tablet formulation. For this purpose, it will be measured how much semaglutide is taken up in the body from the two (2) different tablet formulations each with three (3) different dosage strengths. The tablet version of the study medicine is a new medicine that cannot yet be prescribed. Participants will either get semaglutide in the current tablet formulation previously tested in many large studies, or get the tablet that contains semaglutide in a new formulation - which treatment is decided by chance. Participants will get one tablet per day over 4 weeks in each of the 3 treatment periods (i.e. treatment in a total of 12 weeks). The tablets should be taken in the morning together with half a glass of water (120 mL), after an overnight fast of at least 6 hours (no food or drinks). Furthermore, water is not allowed from 2 hours before dosing. After dosing participants must wait 30 minutes before they may eat or drink. At home, participants must take their breakfast 30-45 minutes after dosing.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs) excluding SUs (sulfonylureas)/glinides in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Africa, Asia and Europe. The aim of this study is to investigate biphasic insulin aspart 30 (NovoMix® 30) alone or in combination with oral hypoglycaemic agent (OHA) for type 2 diabetes management in routine clinical practice.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the the dose-response of insulin detemir and insulin NPH in subjects with type 2 diabetes of various race and ethnicity.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the safety and tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the treatment of Filipino patients with Type 1 and Type 2 Diabetes Mellitus.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Thailand.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate compatibility and safety of FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®) with an external continuous subcutaneous insulin infusion (CSII) system in adult subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of the study is to evaluate long term safety and efficacy of Tresiba® (insulin degludec) in patients with diabetes mellitus in routine clinical practice in India.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in India. Perceptions and practices of physicians and subjects about diabetes management will also be evaluated.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. An observational study evaluating the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for treatment of Type 2 diabetes mellitus in Czech Republic.|Type 1 Diabetes The investigators hypothesize that non-optimally treated carbohydrate counting-naïve patients with type 1 diabetes can achieve better metabolic control by counting carbohydrates and that the metabolic control can be further improved with concurrent use of an integrated glucose meter and bolus calculator. The investigators want to test the hypothesis in this study.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe and the United States of America (USA).\\n\\nThe aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with insulin glargine in patients with type 2 diabetes inadequately controlled with insulin and oral anti-diabetic drugs (OADs). Subjects continued their ongoing treatment with OADs in the trial.|Diabetes Mellitus, Type 2 The study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and placebo (a dummy medicine). Researchers will test semaglutide to see how well it works compared to placebo. The study will also test if semaglutide is safe. Participants will either get semaglutide or placebo - which treatment is decided by chance. Participants will get 1 tablet a day to take with up to half a glass of water. Participants must take the tablet first thing in the morning on an empty stomach. After taking the tablet, participants must not eat or drink anything for at least 30 minutes. After the 30 minutes, participants can have their first meal of the day and take any other medicines they may need. The study will last for about 8 months (36 weeks). Participants will have 9 clinic visits and 2 phone calls with the study doctor. At all 9 of the clinic visits, participants will have blood samples taken. At 5 of the clinic visits, participants must arrive fasting. This means they cannot eat for 8 hours before the visit. It is fine to drink water up to 2 hours before the visit. This is for some of the blood samples that will be taken at the visit. Women cannot take part if pregnant, breastfeeding or planning to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.|Diabetes Mellitus, Type 1 This study is designed to investigate the movement of insulin NNC0363-0845 throughout the body and how it works for the treatment of type 1 diabetes mellitus.\\n\\nThe aim of the study is to improve clinical outcomes for patients with type 1 diabetes mellitus by better controlling the blood sugar levels.\\n\\nParticipants will get insulin NNC0363-0845 as well as insulin detemir (Levemir®). NNC0363-0845 is a new insulin molecule designed to provide blood sugar-dependent insulin action, while insulin detemir is commonly used and prescribed by doctors.\\n\\nParticipants will get subcutaneous (under your skin) injections of insulin NNC0363-0845 (study medicine) up to 6 times daily for 3 days, and of insulin detemir up to 6 times daily for another 3 days. Which medication participants receive first and which second, insulin NNC0363-0845 or insulin detemir, is decided by chance.\\n\\nThe study will last for about 6 weeks up to a maximum of 14 weeks. Participants will have 2 in-house visits (where participants will stay at the site for 4 nights) and 5 outpatient visits with the study doctor. Participants will have frequent contact with the study doctor during the study.\\n\\nDuring the in-house visits, two intravenous catheters (a thin tube inserted into a vein) will be inserted for blood sampling and infusions.\\n\\nInterested parties may not participate in the study if the study doctor believes it will affect their health negatively.\\n\\nWomen cannot take part if they are of childbearing potential.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 Diabetes Mellitus treated with insulin. All subjects should continue their pre-trial insulin therapy (basal, basal-bolus or premixed regimen including combinations of soluble insulins) throughout the trial. Subjects treated with metformin in addition to insulin treatment must continue their metformin treatment throughout the entire trial.|Type1 Diabetes Mellitus The purpose of this investigator-initiated trial is to compare the effect of a daily injection of insulin degludec vs. basal insulin delivery via Continuous Subcutaneous Insulin Infusion (CSII), both in combination with bolus insulin delivery via the patient\\'s usual insulin pump with insulin aspart, on glycemic variability, overall blood glucose control and incidence of hypoglycemia, all assessed by continuous glucose monitor (CGM), as well as patient satisfaction, in patients with type 1 diabetes currently using CSII.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Xultophy® works in patients like them with type 2 diabetes. Participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 18 months. Participants will be asked questions about their health and diabetes treatment as part of the normal study doctor\\'s appointment.|Diabetes Mellitus, Type 2 This study aims to estimate the number of patients with cardiovascular disease and risk factors in patients who had been diagnosed with type 2 diabetes mellitus. Simultaneously, this study also intends to obtain more information about the management of type 2 diabetes mellitus patients with established cardiovascular disease. This study is non-interventional, which means that will not require participant\\'s further related visits or procedures. The study will collect the participant\\'s clinical data from the current visit and, when applicable, within the last 3 years.|Diabetes Mellitus, Type 2 This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.\\n\\nThe study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. Participants will either get insulin icodec that participants will have to inject once a week on the same day of the week or insulin glargine that participants will have to inject once a day at the same time every day. Which treatment participants get is decided by chance.\\n\\nThe insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. The study will last for about 1 ½ years. Participants will have 37 clinic visits and 26 phone calls with the study doctor. At 11 clinic visits participant will have blood samples taken. At 8 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.\\n\\nParticipants will be asked to wear a sensor that measures the blood sugar all the time in 5 periods of about one month during the study (about 5 months in total). Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and North America. The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus liraglutide and metformin in subjects with type 2 diabetes. Subjects will continue their own pre-trial metformin treatment during the trial.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Indonesia.|Overweight|Obesity|Type 2 Diabetes Mellitus This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance.\\n\\nThe study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.|Metabolism and Nutrition Disorder|Obesity This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America.\\n\\nThe aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline.\\n\\nBased on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).|Diabetes|Diabetes Mellitus, Type 2 This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Vietnam.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this study is to assess the efficacy, safety and convenience of the use of Mixtard® 30 NovoLet® used alone or combined with oral hypoglycaemic agent (OHA) in the management of type 2 diabetes mellitus in an out-patient setting.|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 The purpose of this study is to collect historical data in real life conditions in a large group of people who have type 1 or type 2 diabetes and were treated with Tresiba® (insulin degludec) for at least 6 months. Data will be collected beginning 6 months before the participant started Tresiba® up to around 6 months after the participant started taking insulin degludec.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this study is to investigate Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in daily Practice.|Nephropathy|Hypoxia|Mitochondrial Alteration|Type 1 Diabetes|Autonomic Neuropathy, Diabetic Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes. The exact mechanisms of the beneficial effects of SGLT2 inhibition (SGLT2i) are still unknown. Kidney hypoxia has been demonstrated in diabetic kidney disease and SGLT2i is thought to relieve hypoxia in the kidneys. Mitochondrial dysfunction and autonomic dysfunction might also contribute to kidney hypoxia.\\n\\nObjective: The primary aim of the study is to assess the acute effects of SGLT2 inhibition on parameters reflecting oxygenation and oxygen consumption of the human kidney in persons with type 1 diabetes. Exploratory aims are to investigate acute changes in oxygen availability and oxygen access to the kidneys after SGLT2i. This include measures of peripheral blood oxygenation, mitochondrial function and autonomic function.\\n\\nMethods: Acute intervention study with oral dapagliflozin given in two doses each of 50 mg or matching placebo as intervention. Kidney oxygenation and perfusion parameters will be assessed by blood-oxygen-dependant level magnetic resonance imaging. Mitochondrial function will be assessed by extracellular flux analysis on lymphocytes. Autonomic function will be assessed by measuring baroreflex sensitivity.\\n\\nDesign: Randomized, double blinded, placebo-controlled, cross-over intervention study.\\n\\nStudy population: Fifteen healthy controls are recruited by advertisement and 15 patients with type 1 diabetes recruited from Steno Diabetes Center Copenhagen.\\n\\nEndpoints: Primary end-point: Renal cortical and medullary oxygenation (T2\\\\*). Exploratory end-points: Renal cortical and medullary perfusion, renal artery flow, renal oxygen consumption, peripheral capillary oxygen saturation (SpO2), arterial oxygen partial pressure (PaO2), arterial oxygen saturation (SaO2), lymphocyte mitochondrial function, baroreflex sensitivity.\\n\\nTimeframe: Inclusion of patients from January 2020. Last patient last visit January 2021. Data analysis completed spring 2021, presentation autumn 2021 and publications Winter 2021.|Diabetes Mellitus, Type 2 This study looks at how a person with type 2 diabetes can be treated with insulin icodec and a flash glucose monitor (a small sensor inserted under the skin to measure blood sugar all the time). The study will look at how well insulin icodec controls blood sugar when used in combination with a flash glucose monitor. Participants will get insulin icodec that they have to inject once a week on the same day of the week. The insulin will be injected with a needle in a skin fold in the thigh, upper arm, or stomach. The study will last for about 8 months. Participants will have to wear a flash glucose monitor throughout the study. This is a sensor that fits on arm. Participants will be asked to use a commercially available app called LibreView to allow team to view flash glucose monitor data. Participants will get a study phone to scan the flash glucose monitor 4 times daily and they will be able to see all of the flash glucose monitor data during the study. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.|Gestational Diabetes Mellitus It is well-known that women with previous gestational diabetes mellitus are in risk of developing type 2 diabetes later in life; approximately half of the women develop overt type 2 diabetes within the first 10 years after pregnancy. Knowing this, we want to examine the effect of the type 2 diabetes medicine, liraglutide (Victoza), in women with previous gestational diabetes with the aim of reducing the risk of developing type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this study is to evaluate efficacy and safety of insulin detemir (Levemir®) used as basal insulin on the glycaemic control, weight and incidence of hypoglycaemic events in insulin treated subjects with type 1 or type 2 diabetes treated with insulin NPH under normal clinical practice conditions in Slovakia.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (Soluble Insulin Analogue Combination \\\\[SIAC\\\\], insulin degludec/insulin aspart) formulations with each other and with biphasic insulin aspart 30, all in combination with metformin in insulin naive subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as add-on to current Oral Antidiabetic Drug treatment in reducing HbA1c in patients with Type 2 Diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa and Middle East. The objective of the study is to compare glycemic control of Biphasic insulin Aspart 30 twice daily with Biphasic insulin Aspart 30 twice daily plus Insulin Aspart, both insulin treatments with or without metformin, in subjects with type 2 diabetes, previously treated with Biphasic Human Insulin 30/70.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about the health and the diabetes treatment. Participants will complete these during the normally scheduled visits with the study doctor.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Japan. The aim of the trial is to evaluate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the trial drug on the body) properties of FIAsp (faster-acting insulin aspart) and the currently marketed insulin aspart (NovoRapid®) in Japanese subjects with type 1 diabetes.|Cystic Fibrosis Related Diabetes|Pancreatic Insufficiency The purpose of this study is to provide the necessary data and experience to design a larger, full scale clinical trial to determine if a certain medicine (repaglinide), which increases the amount of insulin secreted by the pancreas, can improve the nutritional status and pulmonary function of adolescents and young adults with cystic fibrosis and prediabetes by improving blood glucose control. The investigators are also trying to determine the relationship between systemic inflammatory factors and glucose impairment.|Diabetes|Diabetes Mellitus, Type 1 This study is conducted in the United States of America (USA). The aim of the study is to assess longitudinal variation of immune biomarkers in subjects at risk for development of type 1 diabetes (T1D).|Diabetes|Healthcare Professionals|Delivery Systems This trial is conducted in the United States of America (USA). The aim of this trial is to examine whether nurses prefer to use the NovoFine® Autocover Needle or the BD Safety Glide (TM) Syringe (only) in a hospital setting. The number of needle stick injuries will also be evaluated and whether these hospital nurses prefer the safety features of the NovoFine® Autocover Needle versus those of the BD Safety Glide (TM) Syringe. The identified hospital nurses will evaluate the two types of needles during standard administration of insulin to patients being treated for diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect and the safety profile of biphasic insulin aspart 30 compared to biphasic human insulin 30, both in combination with metformin in Chinese insulin-naive subjects with type 2 diabetes when failing on oral antidiabetic drug (OAD) therapy.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics (the effect of the investigated drug on the body) and pharmacokinetics (the exposure of the trial drug in the body) of insulin degludec (insulin 454), an explorative formulation, not similar to the proposed commercial formulation, with insulin glargine in subjects with type 1 and type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard®, Humulin® N (NPH insulins) as basal insulin as part of their ICT under normal clinical practice conditions in Hungary.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control and complications in diabetic subjects in Asia.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Europe and the United States of America (USA).\\n\\nThe aim of the trial is to compare the difference in change in glycosylated haemoglobin (HbA1c) between insulin degludec/insulin aspart (IDegAsp) and/or oral anti-diabetic drugs (OADs) and insulin degludec (IDeg) plus insulin aspart (IAsp)and/or OADs.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this study is investigate the potential of a supplementary insulin therapy regimen (SIT) as intensification for insufficiently controlled patients with type 2 diabetes in a normal diabetes care setting.|Diabetes Mellitus|Arterial Hypertension|Hypercholesterolemia Project: An analysis of Diabetes Control in Puerto Rico Hypothesis: This project seeks to determine the causes for: i) poor adherence to prescribed treatment by patients, ii) low compliance by providers with national guidelines iii) barriers impose by health insurance in control of diabetes mellitus iv) effectiveness of a disease management program for treatment adherence by patients.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in children and adolescents with type 1 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of the trial is to investigate the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes (T2DM).|Diabetes Type 2 The purpose of this study is to compare the effectiveness of two different kinds of diabetes medications, insulin detemir (Levemir) and exenatide (Byetta), in improving blood sugar levels with little or no weight gain in patients with type 2 diabetes who are not well controlled on two or more oral (by mouth) diabetes medications. Both medications are given by injection with a very small needle just below the surface of your skin (called subcutaneous injection). The medication that you inject will be in addition to your oral medications.|Diabetes|Diabetes Mellitus, Type 1 This study is conducted in Africa. The aim of this non-interventional study is to evaluate the current status of diabetes management, complications and psychosocial aspects for children with type 1 diabetes in Algeria.|Diabetes|Type 2 Diabetes Mellitus This trial is conducted in Asia. The aim of the trial is to compare efficacy and safety of thrice daily versus twice daily NovoMix® 30 (Biphasic insulin aspart 30) in subjects with type 2 diabetes inadequately controlled with basal insulin.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America. The aim of this trial is to explore how different fasting blood glucose targets affect glucose control in patients with type 2 diabetes, when patients are empowered to do dose adjustments themselves.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Africa, Asia, Europe, Oceania, and South America. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir compared to NPH insulin administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight, and insulin antibodies and side effects).|Diabetes Mellitus, Type 2 This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant\\'s blood sugar and participant\\'s body weight are controlled when they are taking the study medicine at different doses. Participants will either get semaglutide \\\\[2 milligrams (mg), 8 mg, or 16 mg\\\\] or semaglutide placebo (a dummy medicine). Participants will take the study medicine with an injection pen called NovoPen®4. The injection pen is a medical tool with a needle used to inject the study medicine under the skin. The study will last for about 52 weeks. Participants will have 13 clinic visits and 4 phone calls.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject\\'s ongoing treatment with metformin and/or dipeptyl peptidase 4 (DPP-4) inhibitors, in patients with type 2 diabetes being treated with oral anti-diabetic drugs (OADs) qualifying for intensified treatment.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of adverse events while using Levemir® under normal clinical practice conditions.|Type 2 Diabetes Mellitus|Health Behavior|Delivery of Health Care The Danish healthcare system is universal and free of charge for Danish citizens, as all healthcare services are financed by general taxes. However, socioeconomic differences exist in access to healthcare services, treatment, and consequences of type 2-diabetes (T2D).\\n\\nUsing a realistic evaluation approach, this study aimed to evaluate the implementation of a Danish peer support intervention, targeted on improving self-management and use of healthcare services among socially vulnerable people with type 2-diabetes (\"peers\"). The study focused on the mechanisms generating the intended outcomes. Further, how contextual factors in peers\\' everyday life facilitated or hindered the mechanisms to operate.\\n\\nThe study design is a multi-method case study (n=9). Data include qualitative semi-structured interviews with four key groups of informants (peer, peer supporter, project manager, and a diabetes nurse). Each type of informant per case was interviewed (n=25) to obtain different perspectives of how the peers\\' interacted, and benefited from the intervention. All interviews were completed immediately after the after the 6-month intervention.\\n\\nFurther, a quantitative survey was conducted among peers at baseline (N=9) and follow-up (N=9) to obtain information about how peers\\' individual contextual factors, such as their sociodemographic characteristics, co-morbidity, diabetes complications, social relations, and other life events influenced how they perceived and interacted in the intervention. Further, to measure improvements in their diabetes-self management (DSM) and use of healthcare services (outcomes). Questions from the Danish National Health Survey were used to measure DSM: (eating habits, physical activity,and medication intake). Use of healthcare services was measured by the number of times (during a 12-month period) the peers\\' attended diabetes controls at the GP; food therapist, and ophthalmologist or had other form of contacts with relevant health care services.\\n\\nAll data were collected between February 2018 and April 2020.\\n\\nHypothesis: 6-month individual face-to-face peer support provided by non-professional persons with T2D can improve self-management and use of healthcare services among socially vulnerable people with T2D if contextual factors such as peers\\' sociodemographic characteristics, health condition, and social relations facilitate their engagement in the intervention. Potential mechanisms that generate the expected outcomes might be: peers\\' motivation, trust, perceived beliefs and needs; and experience of being supported by the peer supporters.|Diabetes|Diabetes Mellitus, Type 2 This trial was conducted in Africa, Asia, Europe, North and South America. The aim of the trial was to compare efficacy and safety of insulin degludec and insulin glargine in insulin naïve subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes|Diabetes|Diabetes Mellitus, Type 1 This study is conducted in Africa. The aim of this study is to estimate the percentage of children and adolescents below or equal to 15 years in Tunisia with acceptably controlled diabetes mellitus type 1.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is evaluate the remission rate in newly diagnosed subjects with type 2 diabetes after short-term intensive treatment with insulin aspart and insulin NPH.|Diabetes Mellitus, Non-Insulin-Dependent|Hypertensive Disease The investigators are conducting this research to study the effect of Liraglutide on blood pressure. Several studies have shown increased cardiovascular complications and deaths in diabetics with hypertension. The importance of blood pressure control in diabetes has been shown in many clinical trials. No drug already approved for treating Type 2 Diabetes Mellitus is known to reduce blood pressure along with improving diabetes. However, prior research studies with liraglutide have suggested that treatment with liraglutide improves blood pressure. This effect is seen very quickly and even prior to any weight loss. The mechanism behind this effect is yet to be determined.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Tresiba® works in real world patients with Diabetes Mellitus, Type 2 (type 2 diabetes). Participants will get Tresiba® as prescribed by their doctor. The study will last for around 6 to 8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor\\'s appointment.|Diabetic Kidney Disease The purpose of the study is to determine the effect of Liraglutide on albuminuria in type 2 diabetes.|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin therapy under normal clinical practice conditions.\\n\\nA total of 4000 patients will be enrolled to investigate long term (3 years of treatment) safety of Tresiba® and additional 2000 patients will be enrolled to assess the safety in an early stage of the PMS more precisely. At the time of enrolment the patients will be randomly allocated to either 3 years or 6 months observation group.|Diabetes Mellitus, Type 2 The aim of this study is to assess the safety and effectiveness of Ozempic initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Ozempic as prescribed by study doctor. The study will last for about 26 weeks.|Type 2 Diabetes|Systolic Hypertension Purpose:\\n\\nThe purpose of this study is to further study the mechanism by which liraglutide, a relatively new anti-hyperglycemic medication, might lower blood pressure in patients with Type 2 diabetes and high blood pressure.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in the Middle East, Northern Africa and Europe. The aim of this study is to contribute to the design of a simple screening strategy for countries in scope, by exploring the association between risk factors and undiagnosed diabetes in a screening study.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effect on glycemic control of NNC 90-1170 (liraglutide) added to metformin compared to metformin given alone in subjects with type 2 diabetes previously treated with OHAs (oral hypoglycaemic agents).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate the impact of low blood sugar during the night on sleep in subjects with type 2 diabetes.|Diabetes Mellitus, Type 1 This study compares the new long-acting insulin 287 with the marketed insulin glargine for use in type 1 diabetes. The study will test how insulin is taken up in your blood, how long it stays there and how the blood sugar is lowered. The participant will get both of the insulins in a random order. Insulin 287 is a new medicine while insulin glargine is already approved for the treatment of diabetes and can be prescribed by a doctor. The participant will get 8 weekly doses of insulin 287 and 14 daily doses of insulin glargine. There will also be a run-in period of 2 days to 4 weeks with daily doses of insulin glargine before you start the insulin 287 period. All doses will be injected under the skin. The study will last for about 16 to 24 weeks. The participant will have 27 visits with the study doctor.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The intention of this health service research study is to obtain data from daily routine to evaluate the quality of life and the costs of the disease for patients with type 2 diabetes mellitus.|Diabetes Mellitus, Type 2 The purpose of this study is to investigate the glycaemic control and other clinical parameters in adult patients previously treated with basal insulin (with or without OADs) and switched to IDegLira in real-world clinical practice in Colombia.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in North America. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 in subjects with type 2 diabetes not achieving glycaemic targets on OADs (oral anti-diabetic drugs).|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the safety profile and clinical effectiveness of using various pre-mixes of Biphasic Insulin Aspart under routine clinical practice conditions in Israel in Type 2 Diabetes patients.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the pharmacodynamic (effect) and pharmacokinetic (exposure of drug) properties of NN1250 (insulin degludec, IDeg) in subjects with type 2 diabetes of different race and/or ethnicity.|Diabetes Mellitus, Type 2 This study looks at how the new medicine called NNC0480-0389 works in the body of Chinese men when it is given at different doses together with a fixed dose of semaglutide. Participants will get one injection of NNC0480-0389 and one injection of semaglutide - which dose of NNC0480-0389 participants get is decided by chance.\\n\\nNNC0480-0389 is a new medicine that has not been previously approved. It means that the medicine has not yet been approved by the health authorities.\\n\\nSemaglutide is a newly approved antidiabetic medicine that helps to lower blood sugar levels in people with type 2 diabetes.\\n\\nNNC0480-0389 is being developed to be given together with semaglutide. NNC0480-0389 targets a different part of the system that regulates sugar levels in the body than semaglutide. Therefore, it is expected that together NNC0480-0389 and semaglutide will more effectively lower sugar levels in the blood in people with type 2 diabetes.\\n\\nParticipants will get 2 injections of the study medicine (one of each). It will be injected with a needle into a skin fold on participants abdomen.\\n\\nThe study will last for a maximum of 72 days. Partcicipants will have 10 scheduled visits with the study doctor. For 1 of the visits participants will stay at the clinic for 6 days (5 nights). The study includes blood sampling.|Diabetes|Diabetes Mellitus, Type 2 This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec) with sitagliptin, as add-on to subject\\'s own current oral antidiabetic (OAD) treatment, in subjects with type 2 diabetes inadequately controlled with 1-2 OADs (metformin, sulphonylurea, glinides or pioglitazone).|Type 2 Diabetes Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and the GLP-1 receptor has been found in significant amounts in the lung, it could be hypothesized that the treatment with liraglutide (a GL-1 agonist) will improve this reduced pulmonary function|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the accrual of major adverse cardiovascular events (MACE) in this trial and the remaining research programme. The incidence of MACE will be monitored throughout the trial which will be terminated according to plan when pre-specified stopping criteria are met.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide in combination with sulphonylurea agent (SU) compared to SU monotherapy, as assessed by HbA1c after 24 weeks and 52 weeks in subjects with type 2 diabetes. Liraglutide will be compared to placebo, in combination with SU. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza®) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.|Diabetes Mellitus, Type 2 In this study, participants will receive semaglutide and NNC0480-0389 together at the same time. Semaglutide is a medicine that can already be prescribed, whereas NNC0480-0389 is a new potential medicine. Giving the medicines at the same time will be investigated once by using two separate syringes and once by using only one syringe containing both medicines (\"co-formulation\"). The co-formulation will be given together with an injection of placebo. Both medicines are tested for the treatment of type 2 diabetes. Giving the two complementary medicines at the same time is intended to lower blood sugar in people with type 2 diabetes. NNC0480-0389, in combination with semaglutide, is already being investigated in an ongoing human clinical study.\\n\\nThe aim of this study is to compare the amount of medicine (semaglutide and NNC0480-0389) in the blood: after participants received the medicines at the same time (0.5 mg semaglutide and 5 mg NNC0480-0389) using only one syringe (co-formulation)after participants received the medicines separately using two syringes.\\n\\nFor this purpose, the amount of semaglutide and NNC0480-0389 in the blood will be measured after participants received the medicines in co-formulation and after participants received the medicines using separate syringes. There will be two treatment periods: One period where participants receive the two medicines as two separate injections and another period where participants receive the two medicines in one injection (co-formulation), together with an injection of placebo. It will be randomly determined in which order participants will receive the 2 treatments (separate injections first or co-formulation first).\\n\\nFor both treatments the study medicines will be injected into a skin fold in the left and right stomach using a thin needle.Giving the medicines in the two treatment periods will take place at an interval of at least 8 weeks. The study can last for up to 19 weeks for each participant. This includes a screening period (up to 4 weeks), two treatment periods (5 weeks each) and a washout period (3 - 5 weeks). The washout period ensures that the given treatments and their effects have disappeared from the body. Participants will not receive any study medicines during this time. Participants will have 21 clinic visits. Some of the visits include overnight stays. Participants will have blood tests at every clinic visit.\\n\\nFor 4 visits (Visits 2, 11, 12 and 21; Day 1 and 36 of each period) participants must not have had any food or drink (water is allowed) for up to 8 hours before participantsr body weight is measured. Participants must be healthy and have a body mass index (BMI) between 20.0 and 29.9 kg/m2. If participants are a woman participants can only take part in this clinical study, if participants cannot get pregnant, for example, after menopause. A hormone test will be done to confirm this.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim is to compare changes in blood sugar and the number of periods where carbohydrate supplementation is needed to treat low blood sugar, during two different treatments with NN1250 (insulin degludec), a soluble insulin basal analogue (SIBA) in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart plus OAD compared to biphasic insulin aspart alone on blood glucose control in type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. This single arm trial aims to evaluate the blood glucose control with twice daily biphasic insulin aspart 30 in combination with metformin in Chinese subjects with type 2 diabetes inadequately controlled with once or twice daily basal insulin.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. This is a clinical trial investigating the effectiveness of using Biphasic Insulin Aspart 70/30 in two different treatment regiments for 6 months in subjects with type 2 diabetes, not well controlled on their current oral anti-diabetic drug therapy.|Diabetes Mellitus, Type 1 The iLet™ is a new insulin pump that is programmed to work with a Continuous Glucose Monitoring (CGM) device. This is to give participants insulin automatically. The CGM device is already available for sale. The iLet™ is not yet approved for use. Fast-acting insulin aspart is a type of insulin that doctors can already prescribe for use with insulin pens, but not for use in an insulin pump. This study is to test how safe fast acting insulin aspart is when used with different insulin delivery settings in the iLet™ in people with type 1 diabetes. Participants will get fast-acting insulin aspart as participants\\' insulin and use the iLet™ as participants\\' insulin pump with a CGM device. Participants\\' iLet™ will be set to 2 different insulin delivery settings for 7 days on each setting. The setting participants get first is decided by chance. The study will last for about 5 to 9 weeks. Participants will have 4 visits and 1 phone contact with the study or staff.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin analogue/intermediate-acting insulin or pre-mixed insulin/pre-mixed insulin analogue on a twice daily regimen to NN5401 (SIAC, insulin degludec/insulin aspart) on a twice daily regimen in subjects with type 2 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia and South Africa. The aim of this trial is to compare the efficacy and safety of repaglinide plus insulin NPH (insulin Neutral Protamine Hagedorn) with insulin NPH alone in subjects with type 2 diabetes inadequately controlled on repaglinide.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamics and pharmacokinetics of single doses of insulin detemir and insulin NPH in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects with Type 2 Diabetes Mellitus|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa and Asia. The aim of the trial is to compare patient-adjusted versus physician-adjusted titration of BIAsp 30 combined with metformin in type 2 diabetes patients uncontrolled on NPH insulin.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Asia. Further perceptions and practices of physicians and subjects about diabetes management in Asia will be evaluated.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare two different active treatment regimens of biphasic insulin aspart in subjects with type 2 diabetes.|Type 1 Diabetes The aim of this clinical study was to obtain type 1 diabetes data to identify models for glucose prediction and control and to construct a physiological pharmaco-kinetic/pharmaco-dynamic computer model of a type 1 diabetic person.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of the trial is to compare the effect on glycaemic control of biphasic insulin aspart 30 twice daily with two different dosage split regimens for Chinese subjects with type 2 diabetes who did not achieve the treatment target of a glycosylated haemoglobin A1c (HbA1c) below 7% in trial BIASP-3756 (NCT01123980).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe.\\n\\nThis is a clinical trial investigating the effectiveness and the safety of using biphasic insulin aspart 30 both for initiation and intensification of insulin treatment in type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The purpose of this study is to test whether Biphasic Insulin Aspart 70/30 twice a day with Metformin improves glycemic control vs. once daily Insulin Glargine with Metformin in subjects with Type 2 Diabetes who are inadequately controlled on basal insulin plus oral anti-diabetic therapy.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body)properties of FIAsp (faster-acting insulin aspart) in geriatric and younger adult subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in China. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of insulin detemir or NPH-insulin given once daily at bedtime as add-on to oral anti-diabetic drug(s).|Healthy Volunteers|Diabetes Mellitus, Type 1 This study is investigating the safety and tolerability of the new investigational product NNC0363-0845, its concentrations in the blood and its effect on the blood sugar for the treatment of diabetes. The study consists of 3 parts. The first part of the study is conducted in healthy people, while the second part involves people with type 1 diabetes (T1D). Part 3 of this trial involves also people with T1D.\\n\\nThe study will test how NNC0363-0845 is tolerated by the body, how it is taken up in the blood, how long it stays there and how much the blood sugar is lowered. Healthy volunteers will either get NNC0363-0845 or placebo - which treatment is decided by chance. Participants with type 1 diabetes will either get NNC0363-0845 or insulin degludec (Tresiba®), also decided by chance. It is the first time that NNC0363-0845 is tested in humans. Participants will get one dose of NNC0363-0845 or placebo or insulin degludec injected into their left thigh. Participation in the study will last for up to 6 weeks. There will be one Informed Consent visit and 6 clinic visits with the study doctor. Healthy volunteers will have blood sampling to measure blood sugar and the concentration of the investigational product in the blood. Participants with type 1 diabetes will have a clamp experiment where the blood sugar is measured and controlled for up to 42 hours.\\n\\nFor Part 3, the total duration of the trial for each individual is expected to be approximately 3-9 weeks.\\n\\nParticipants cannot be in the study if the study doctor thinks that there are risks for their health. Women can only take part in the study if they are of non-child bearing potential.|Metabolism and Nutrition Disorder|Obesity This trial is conducted in Africa, Asia, Europe and the United States of America (USA).\\n\\nThe aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with type 2 diabetes. Treatment will be added onto subject\\'s pre-trial background diabetes treatment of either diet and exercise only or single compound oral antidiabetic drug (OAD) treatment (metformin, sulphonylurea \\\\[SU\\\\] or glitazone) or combination OAD treatment (metformin, sulphonylurea or glitazone). The duration of the trial will be 56 weeks followed by a 12 week observational follow-up period.|Diabetes Mellitus, Type 2 In this study a known investigational medicinal product called semaglutide will be tested in four different tablet versions. In addition to semaglutide, the different tablet versions C, D, E and F contain different helping agents in different amounts. All tablet versions have a helping agent called SNAC. All tablet versions are tested for the treatment of type 2 diabetes. Recently the European Medicines Agency approved semaglutide in tablet form and currently, tablets in the doses 3 mg, 7 mg and 14 mg can be prescribed in some countries. The main aim of this study is to test oral semaglutide doses of 25 mg and 50 mg. These are higher dosages of oral semaglutide than can be prescribed today. With the 50 mg dose, we expect the amount of semaglutide in the blood to be higher than what has been tested before. Further aims of this study are to find an optimal version for the semaglutide tablets, and to examine the safety and tolerability of the different tablet versions. For this purpose, the amount of semaglutide in the blood will be measured after taking different semaglutide tablets, in different doses. The version of the tablet participants will receive (i.e. the treatment arm participants will be assigned to) is decided by chance.\\n\\nIn treatment periods 1 and 2 participants will receive one tablet daily over 2 weeks for each period. For treatment periods 3 to 5 participants will receive one tablet daily over 4 weeks for each period (participants may get 2 tablets per day in treatment period 5). This means that treatment will take 16 weeks in total. The tablets should be taken in the morning together with no more than half a glass of water (120 mL), after an overnight fast of at least 6 hours (no food or drinks). Water is also not allowed from 2 hours before dosing. After dosing participants must wait 30-35 minutes before they eat or drink. At home, participants must take their breakfast 30-45 minutes after dosing.\\n\\nNo oral medication (which are taken by mouth) can be taken from 2 hours before and until 30 minutes after each dosing with semaglutide. The study can last for up to 24 weeks for each participant. This includes a screening period (up to 3 weeks), a treatment period (16 weeks) and a follow-up visit (5 weeks after the last dosing). Participants will have 11 clinic visits with the study doctor. Some of the visits include overnight stays. Participants will have blood tests at every visit. Participants must be healthy and have a body mass index (BMI) between 21.0 and 29.9 kg/m\\\\^2 For women: Women cannot take part in this study if they are pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes Mellitus, Type 1 The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin analogues will improve post prandial glycaemic control in patients with type 1 diabetes|Diabetes Mellitus, Type 2 This study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and sitagliptin (a medicine doctors can already prescribe). Participants will either get oral semaglutide or sitagliptin - which treatment is decided by chance. Participants will get 2 tablets a day to take first thing in the morning on an empty stomach. Only 1 tablet has study medicine in it. The other tablet is a dummy medicine (placebo). After taking the semaglutide tablet, participants may not eat or drink anything for at least 30 minutes. After the 30 minutes, participants must take the sitagliptin tablet. Then participants can have their first meal of the day and take any other medicines they may need, including their metformin. The study will last for about 7 months (33 weeks). Participants will have 8 clinic visits and 1 phone call with the study doctor. At all 8 of the clinic visits, participants will have blood samples taken.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, North and South America, Asia and Europe. The purpose of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus insulin glargine once-daily on glycaemic control after 30 weeks of treatment in insulin-naïve subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor\\'s criteria, according to participant\\'s personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).|Diabetes Mellitus, Type 2 This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with type 2 diabetes (T2D). People taking part in the study will take the medicine together with their current diabetes medicine (sulphonylurea and/or metformin). Participants will get a dose of either 1.0 mg or 2.0 mg semaglutide once a week - which dose is decided by chance. Participants will inject semaglutide under the skin once a week. The study will last for about 49 weeks. Participants will have 9 clinic visits and 2 phone calls with the study doctor. At the visits participants will have blood taken and eye tests done. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period. Female participants who can get pregnant will be checked 11 times for pregnancy via urine tests.|Obesity This is a 52 week, single center, open-labeled, randomized controlled trial.\\n\\nA total of 150 subjects with obesity, who are free of types 1 and 2 diabetes, as well as contraindications to weight loss, will be randomly assigned to one of three treatment groups: 1) lifestyle counseling, as currently recommended by the Centers for Medicare and Medicaid Services (CMS) (i.e., CMS-Alone); 2) CMS lifestyle counseling plus liraglutide (i.e., CMS-Liraglutide); or 3) CMS-Liraglutide plus a portion-controlled diet (i.e., Multi-Component Intervention).\\n\\nSubjects in all three groups will have 14 brief (15 minute) lifestyle counseling visits the first 24 weeks, followed by monthly visits in weeks 25-52. This is the schedule and duration of counseling visits recommended by CMS. Counseling sessions will be delivered by a physician, nurse practitioner or registered dietitian (RD) working in consultation with the former providers.\\n\\nSubjects in all three groups also will have brief physician visits at weeks 1, 4, 8, 16, 24, 36, and 52 (total of 7 visits). These visits are needed for subjects in both liraglutide groups to monitor their response to the medication. These visits are included for subjects in CMS-Alone to match the intensity of medical care provided the two other groups.\\n\\nThe primary outcome is % reduction in initial body weight, as measured from randomization to week 52. Secondary outcomes include the proportion of participants who at week 52 lose \\\\>5%, \\\\>10%, and \\\\>15% of initial weight, as well as % reduction in weight at week 24 and the proportion of participants who meet the three categorical weight losses at this time. The secondary efficacy measures include changes (from randomization to week 52) in cardiovascular disease (CVD) risk factors, glycemic control, mood, quality of life, eating behavior, appetite, sleep, and satisfaction with weight loss.\\n\\nSafety endpoints will include physical examination, adverse events (AEs), standard laboratory tests, and mental health assessed by the Columbia Suicidality Severity Rating Scale (C-SSRS) and Patient Health Questionnaire (PHQ-9).\\n\\nStatistical Analysis. Using a sample size equation for longitudinal clustered samples, a randomization sample of 50 subjects in CMS-Alone, 50 in CMS-Liraglutide, and 50 in the Multi-Component Intervention provides \\\\>80% power to detect the two primary contrasts to be statistically significant. This estimate allows for 20% attrition during the 52-week trial, resulting in approximately 40 treatment completers per group. The ITT longitudinal statistical design will further improve power by allowing the inclusion of available data for non-completers and the adjustment of possible variance reducing baseline covariates.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this clinical trial is to investigate the blood glucose lowering effect of NN1250 (insulin degludec) in young and elderly subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1 The trial is conducted in Europe. This clinical pharmacology trial investigates the effect of exercise on the pharmacokinetics and pharmacodynamics of inhaled insulin in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with diabetes mellitus in routine clinical practice in India.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide, compared to sulfonylurea (SU treatment), as assessed by HbA1c after 24 and 52 weeks in subjects with type 2 diabetes. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart (BIAsp) 70 and/or BIAsp 50 with biphasic human insulin (BHI) 30 treatment.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate pharmacokinetics, pharmacodynamics and safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal clinical practice setting.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in the United States of America (USA). The aim of the trial is to evaluate continuous subcutaneous infusion of NN1218 formulations and NovoLog® in subjects with type 1 diabetes.|Type 1 Diabetes Mellitus The overall objective of the study is to assess whether complete avoidance of cow\\'s milk (CM) proteins, for at least the first 6 months of life, prevents type 1 diabetes (insulin-dependent diabetes mellitus, IDDM) in genetically susceptible children who have a mother, biological father or sibling affected by type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Japan. The aim of this clinical trial is to investigate the blood sugar lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in Japanese subjects with type 1 diabetes. Each subject will be randomised to one of the two possible treatment sequences (NN5401 followed by biphasic insulin aspart (BIAsp) 30 or biphasic insulin aspart 30 followed by NN5401).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and North America. The aim of the trial is to compare the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs. Due to change in glycaemic data collection process, this trial is amended to allow for a full 36 weeks (maintenance 2 period) of the use of the new process.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this trial is to assess the safety after multiple s.c. (subcutaneously) doses of liraglutide in Japanese subjects with type 2 diabetes.|Metabolism and Nutrition Disorder|Obesity This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide.\\n\\nTrial has the following trial periods: A 20-week randomised, double-blind, placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an open label orlistat comparator arm followed by an 84 week extension period.|Overweight and Obesity|Type 2 Diabetes The overall aim is to investigate effects of acute exercise on ad libitum energy intake and study whether this differs between morning and evening in individuals with overweight/obesity with or without type 2 diabetes (T2D). Furthermore, the aim is to examine the role of hedonic and homeostatic drivers of appetite control in obesity and T2D in the context of meal and exercise timing.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of biphasic insulin aspart 30 in subjects with type 1 or type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. An observational study evaluating glycaemic control in patients using Levemir® as initiation insulin therapy as the treatment of type 2 diabetes in Slovakia.|Diabetes Mellitus, Type 2 This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes.\\n\\nThe study is being conducted to see how well semaglutide, in combination with different doses of NNC0480-0389, work to lower blood sugar levels. Results from this study will be used to select the doses of the two medicines for other studies.\\n\\nParticipants will either get:\\n\\nSemaglutide (a medicine doctors can already prescribe for treatment of type 2 diabetes) in combination with NNC0480-0389 (a potential new medicine) or placebo (a \\'dummy\\' medicine that looks like the medicines but without any medicine).\\n\\nNNC0480-0389 alone, or semaglutide alone which treatment participant get is decided by chance.\\n\\nParticipant will need to take 2-3 injections once every week during the study. One injection will be with semaglutide or placebo and 1-2 injections will be with NNC0480-0389 or placebo.\\n\\nParticipant must inject the study medicines themself into the stomach, thigh, or upper arm.\\n\\nThe study will last for about 41weeks. Participant will have 20 clinic visits. Participant will have blood samples taken at all clinic visits. At 3 clinic visits, participant will also have an electrocardiogram (ECG). This is a test to check participants heart. Participant will have their eyes checked before or at the start of the study and at the end of the study.\\n\\nWomen can only take part in the study if they are not able to become pregnant|Diabetic Nephropathies|Diabetic Glomerulosclerosis This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (\\\\> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of observation. High through-put genomic analysis associated with genetic and biomarker testing will serve to identify key potential therapeutic targets for DKD by comparing patients with rapid and slow progression patterns. Each participating clinical site will search for, consent, harvest the biopsy sample, and enroll the participants as required for the TRIDENT protocol.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes mellitus|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy and safety of two different formulations of insulin degludec (IDeg) in subjects with type 2 diabetes.|Type 2 Diabetes The purpose of this study is to find out if treatment with degludec insulin when compared to glargine U100 insulin will result in similar blood sugar control in patients with diabetes who are admitted to the hospital and then transition to home after discharge from the hospital.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe and the United States of America (USA).\\n\\nThe aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart (IDeg/IAsp) in subjects with type 2 diabetes mellitus previously treated with insulin glargine.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This non-interventional study is conducted in Europe. The study is both retrospective and prospective.\\n\\nThe purpose of the study is to assess the frequency of hypoglycaemia (low blood glucose) in insulin-treated patients with type 1 and type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of repaglinide plus metformin as initial treatment compared to repaglinide alone in Chinese subjects with type 2 diabetes having an HbA1c (glycosylated haemoglobin A1c) over 8.5 % and who never have taken oral sugar-lowering drugs before. The associated unfavourable events including low blood sugar episodes between the two treatments are also compared.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to compare the single dose and steady state pharmacodynamics of biphasic insulin aspart 30 and biphasic insulin aspart 70 in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The objective of this observational study is to evaluate the number of serious side effects, when initiating NovoMix® treatment in patients with type 2 diabetes who previously used a human premix insulin under normal clinical practice|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of flexible versus fixed dosing and simple versus stepwise titration with OD insulin degludec in inadequately treated subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Oceania.\\n\\nThe aim of this trial is to compare the safety of using pulmonary inhaled human insulin to s.c. insulin aspart both combined with NPH insulin in subjects with type 1 diabetes.|Obesity This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants\\' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get placebo. Placebo is a \"dummy\" medicine that looks like the study medicine, but has no effect on the body.\\n\\nParticipants will either get semaglutide or \"dummy\" medicine - which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm.\\n\\nParticipants will also have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight.\\n\\nThe study will last for about a year (50 weeks). Participants will have 10 clinic visits and 8 phone calls. At 6 of the clinic visits participants will have blood samples taken. At 3 of the clinic visits participants cannot eat and drink (water is allowed) for 8 hours before the visit.\\n\\nParticipants cannot take part if participants have or have had diabetes. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic response (the effect of the investigated drug on the body) of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 (insulin degludec, IDeg) formulations in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to investigate the safety profile of liraglutide under normal conditions of use.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on participant\\'s blood sugar levels, body weight, how satisfied participant is with the treatment, and how participant takes his/her diabetes medicines. Participant will get Rybelsus® as prescribed by study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of the trial is to compare the efficacy and safety of liraglutide 1.8 mg/day to liraglutide 0.9 mg/day in Japanese subjects with type 2 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This observational study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in subjects with type 2 diabetes during Levemir® treatment.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to investigate the postprandial glucose metabolism after treatment with faster-acting insulin aspart in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of biphasic insulin aspart 30 once daily compared to insulin glargine once daily both in combination with metformin and glimepiride in Chinese and Japanese subjects with type 2 diabetes who have never received insulin before.\\n\\nThe trial is conducted as a phase 4 trial in China and phase 3 in Japan.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of major hypoglycaemic episodes and other adverse events, and to evaluate efficacy while using insulin under normal clinical practice conditions. The switch from OAD treatment to insulin therapy will be determined by physician.|Diabetes|Diabetes Mellitus, Type 2 This trial is globally conducted. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe and Asia. The aim of this observational study is to evaluate the effectiveness and the incidence of serious adverse reactions while using Levemir®, NovoMix® and/or NovoRapid® in subjects with type 2 diabetes that have not used insulin previously under normal clinical practice conditions.|Diabetes Mellitus, Type 2 The purpose of this study is to collect information on how Ryzodeg® works in real-world patients.\\n\\nParticipants will get Ryzodeg® as prescribed to by their doctor. The study will last for about 5-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor\\'s appointment|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this trial is to investigate the pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30 (NN-X14Mix30) and biphasic insulin aspart 50 (NN-X14Mix5050) in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems This study is conducted in Asia. The aim of of this study is to evaluate the safety of NovoPen® 3 and/or FlexPen® devices (if available on the market) measured by the number of adverse events and technical complaints in patients with type 1 and type 2 diabetes in routine clinical practice.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes.|Diabetes Mellitus|Cardiovascular Diseases There are currently only few data on the coronary artery calcium score in patient with diabetes in France, and the diagnostic and therapeutic attitudes towards a high coronary artery calcium score are not standardized and depend on clinical practices, which may vary from one center to another. The proposed multicenter prospective study would provide a better understanding of the epidemiological particularities of the coronary artery calcium score in French diabetics, refine the indications for better performance of the examination, and compare attitudes when this score is high.|Diabetes Mellitus Basal-bolus insulin therapy is recommended for patients with poorly controlled type 2 diabetes (T2D) and HbA1c \\\\>9%. However, basal-bolus insulin is labor intensive and associated with increased risk of hypoglycemia, glycemic variability, weight gain and poor compliance. Thus, there is a critical need for a simpler treatment regimen that could overcome these limitations. IDegLira, a fixed-ratio combination (FRC) therapy consisting of insulin degludec and liraglutide, is an attractive option for this population given its proven benefits on glycemic control, weight and compliance. This study aims to show that a simpler regimen using a novel FRC agent (IDegLira) can improve glycemic control, decrease hypoglycemia, reduce the burden of diabetes care, and improve satisfaction/adherence in patients with poorly controlled T2D with HbA1c between ≥ 9-12%. This open-label, treat-to- target, two-arm parallel, controlled trial will randomize participants with T2D and HbA1c ≥ 9%, treated with oral anti-diabetic agents and/or basal insulin therapy to lDegLira or basal-bolus insulin for 26 weeks.|Diabetes Mellitus, Type 2 The study compares 2 medicines for people with type 2 diabetes: insulin 287 (a new medicine) and insulin glargine (a medicine doctors can already prescribe). The study doctors will test insulin 287 to see how well it works compared to insulin glargine. The study will also test if insulin 287 is safe. The study participants will either get insulin 287 or insulin glargine (100 units/mL) - which treatment the participants get is decided by chance. The participants will need to inject their selves every day about the same time. Once a week the participant will need to take 1 extra injection on the same day of the week. The participants will have 16 clinic visits and 14 phone calls with the study doctor. During the study, the doctors will ask you to: 1) measure your blood sugar every day with a blood glucose meter using a finger prick, 2) write down different information in a paper diary daily and return this to your doctor, 3) wear a medical device to measure your blood sugar all the time for 2 weeks 5 times during the study.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how the medicine Victoza® (liraglutide) works in people with Type 2 diabetes in Iran. Patients will get Victoza® as prescribed to them by their study doctor. The study will last for about 5 to 8 months. Patients will be asked to complete some questionnaires about their health and diabetes treatment. Patients will complete these during their normally scheduled visits with study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Africa, Europe and Oceania. The aim of this trial is to investigate whether insulin detemir combined with insulin aspart compared to NPH insulin combined with insulin aspart could reduce the frequency of hypoglycaemic episodes whilst maintaining the same degree of glycaemic control subjects with type 1 diabetes.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Ryzodeg® works in real world participants. Participants will get Ryzodeg® as prescribed to them by the study doctor. The study will last for about 6 to 8 months. The participants will be asked questions about their health and their diabetes treatment as part of their normal study doctor\\'s appointment.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of this trial is to determine the dose-response relationship for body weight and five escalating doses of NNC 90-1170 (liraglutide) in subjects with type 2 diabetes previously treated with an oral hypoglycemic agent (OHA).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate the difference in frequency of episodes of hypoglycaemia during treatment with biphasic insulin aspart 30 compared to biphasic human insulin 30 in subjects with well controlled type 2 diabetes.|Diabetes Mellitus, Type 2|Peripheral Arterial Disease This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo (\"dummy\") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for injection. Participants must inject it once a week into the stomach area, thigh, or upper arm, at any time of the day. The study will last for about 59 weeks. Participants will have 8 clinic visits and 1 phone call with the study doctor. At some clinic visits, participants will have blood tests. At some visits participants will also do a treadmill test to measure how far they can walk. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) and the pharmacokinetic (exposure of the trial drug in the body) properties of insulin degludec/insulin aspart 15 in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in patients with type 2 diabetes during NovoMix® 30 treatment.|Cardiac Surgical Procedures|Hyperglycemia Patients with or without diabetes may have high blood sugar levels due to stress response of the body during heart surgery. This study is being done to determine if maintaining normal blood sugar levels during open-heart surgery by using intravenous insulin results in a lesser incidence of death, wound infections in the chest, disturbances of heart rhythm, kidney failure, stroke and prolonged time on the breathing machine (artificial ventilation) within 30 days after surgery.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to investigate the Safety, Tolerability,Pharmacokinetics (the exposure of the trial drug in the body) and Pharmacodynamics (the effect of the investigated drug on the body) of subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects with Type 1 Diabetes|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Japan. The aim of this trial is to investigate the efficacy of insulin detemir on blood glucose control in subjects with insulin requiring diabetes.|Diabetes|Diabetes Mellitus, Type 2 The purpose of this study is to collect information about the participant\\'s ability and willingness to pay for NovoMix 30 using a modern device, which is prescribed to the participant by the study doctor for Type 2 Diabetes Mellitus according to routine clinical practice. The study aims to obtain data that can guide prescribers\\' understanding of the ability and willingness to pay for NovoMix 30 FlexPen or Penfill among participants in the growing middle class in India and Egypt. The decision to prescribe NovoMix 30 FlexPen or Penfill has been made independent from this study.|Diabetes Mellitus, Type 2 This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart - which treatment the participant get is decided by chance. Insulin glargine is taken once a day and semaglutide once a week. Insulin aspart is taken three times per day before a meal. All three medicines come in pre-filled pens for injection under the skin. The study will last for about 71 weeks. If participant\\'s blood sugar gets under or over certain values participant will only participate in 14 weeks. The study doctor will inform the participant about this. The participant will have 15 clinic visits and 22 phone calls with the study doctor.|Healthy Participants In this study, a known medicine called \\'semaglutide\\' will be tested in a new tablet version. The medicine will be tested in healthy men to explore the effect of different water volumes and tablet-meal delays on blood levels of semaglutide after 10 days of oral administration. Semaglutide tablets, under the brand name Rybelsus, are approved in the EU and USA for the treatment of type 2 diabetes. Participants will get a daily treatment with dose 1 new oral semaglutide tablet for 5 days followed by another 5 days with a daily treatment of dose 2 new oral semaglutide tablet. Participants will get one tablet each day for 10 days. The tablet should be taken in the morning on an empty stomach with either 50 milliliter (mL) or 120mL water, after an overnight fast of at least 6 hours (no food or drinks). Water is not allowed from 2 hours before dosing. A predefined breakfast will be served either 30, 60 or 120 minutes after taking tablet, depending on the treatment received. Breakfast will need to be eaten within 30 minutes. Which treatment participants will get is decided by chance. The study will last for about 11 weeks. This will include a screening period (up to 28 days), a treatment period (10 days) and a follow-up visit (at least 5 weeks after the last dose). Participants should not take any prescription or non-prescription medicines or herbal products (including St John\\'s wort) within 14 days prior to the screening visit and until the follow-up visit, except for routine vitamins, medicines applied on the skin and occasional use of paracetamol (a mild pain killer). No oral medication can be taken from 2 hours before and, depending on the group participants are in, until 30, 60 or 120 minutes after each dosing with semaglutide.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Asia.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of repaglinide and Glurenorm® and Glucobay® given as the mono-therapy in Chinese subjects being treatment-naive type 2 diabetics.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about their health and diabetes treatment. Participants will complete these questionnaires during their normally scheduled visits with the study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide once weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes.|Non-alcoholic Steatohepatitis Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.\\n\\nParticipants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.\\n\\nParticipants will need to inject themselves with medicine under the skin. Participants will need to do this once a week.\\n\\nThe study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day.\\n\\nParticipants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the efficacy on blood glucose control while using NovoMix® 30 FlexPen® under normal clinical practice conditions in Korea. A clinical safety profile will be also evaluated.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about their health and diabetes treatment. Participants will complete these during their normally scheduled visits with their doctor.|Diabetes|Diabetes Mellitus, Type 1 The investigators are doing this study to see the effect of insulin degludec in pregnant women with type 1 diabetes, and if it is safe to use. In this study the medicine insulin degludec is compared to another medicine called insulin detemir. Participants will either get insulin degludec or insulin detemir and take it together with a medicine called insulin aspart - which treatment participants get is decided by chance. Participants will get pre-filled insulin pens. Participants will need to take blood sugar measurements several times a day. The study will last between 10 and 25 months depending on whether participants are already pregnant when they join the study. The number of visits and the tests ( for example blood and urine samples and ultrasound scans) the participants will have also depends on whether they are pregnant at study start.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 50 three times a day to biphasic insulin aspart 70 three times a day in non-obese and obese with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 The study is done to compare how faster aspart is taken up, broken down and removed from the body between different age groups (children \\\\[6-11 years\\\\], adolescents \\\\[12-17 years\\\\] and adults \\\\[18-64 years\\\\]) who have diabetes. The blood sugar (glucose) lowering effect of faster aspart will also be investigated after consuming a meal replacement drink. The effects of faster aspart will be compared to the effects of NovoRapid®.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the clinical performance of two formulations of insulin aspart (NovoLog®) in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of NovoRapid® (insulin aspart) as meal time insulin in subjects with type 2 diabetes treated on a basal-bolus regimen with Neutral Protamine Hagedorn (NPH) human insulin.|Diabetes|Diabetes Mellitus, Type 1 This trial was conducted in Europe, Middle East, North America and South America.\\n\\nThe aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart (NovoRapid®) versus human insulin (Actrapid®) in pregnancy.|Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 This study will look at how participants\\' daily life is affected by their heart failure. The study will also look at the change in participants\\' body weight.\\n\\nThis study will compare the effect of semaglutide (a new medicine) compared to \"dummy\" medicine on body weight and heart failure symptoms.\\n\\nParticipants will either get semaglutide or \"dummy\" medicine, which treatment participants get is decided by chance.\\n\\nParticipants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm.\\n\\nDuring the study participants will have talks with the study staff about healthy lifestyle and physical activity.\\n\\nThe study will last for about 59 weeks, that is a little more than 1 year. Participants will have 12 clinic visits with the study doctor.\\n\\n* At 6 of the visits participants will have blood samples taken.\\n* At 5 of the visits participants will be asked to fill in a questionnaire\\n* At 4 of the visits participants will have to do a 6-minute walking test\\n* At 3 of the visits participants will have a test to check the heart.\\n* participants will have their eyes checked before or at the start of the study and at the end of the study\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes Mellitus Type 2|Diastolic Dysfunction|Cardiac MRI|Myocardial Perfusion The purpose of this study is to determine whether liraglutide a GLP-1 analogue are effective in the treatment of diastolic dysfunction in type 2 diabetes patients analyzed by cardiac MRI. Secondary if the treatment has any effect on the perfusion of the heart on a cardiac-MRI.|Diabetes Mellitus Children and adolescents with type 1 diabetes mellitus are required to inject insulin daily. The injection technique should reliably deposit insulin into subcutaneous fat while minimizing inadvertent delivery into either the skin or the underlying muscle, both of which are associated with suboptimal outcomes. The use of shorter, thinner needles reduces the incidence of intramuscular delivery and is associated with reduced discomfort, but increases the risks of both shallow (intradermal) delivery and of loss of insulin through backflow to the skin surface.\\n\\nIn the current study, 240 subjects (children and adults) will receive multiple injections of small volumes of sterile air in the thigh and abdomen using 5 mm Novofine® needles, to simulate insulin injections performed at the two sites using various injection techniques (perpendicular or angled needle, with or without skin fold). Ultrasound visualisation of the injected air will allow determination of the incidence of intradermal or intramuscular delivery using the various delivery methods in the trial. In addition, adult subjects will receive injections of a liquid test medium in order to determine the incidence and extent of backflow. Qualitative data on perceived discomfort and information on body composition will also be collected. This investigation will form the basis for recommendations regarding preferred injection technique where 5 mm needles are used.|Diabetes Mellitus, Type 2|Chronic Kidney Disease We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.\\n\\nParticipants will either get semaglutide or placebo (a \\'dummy\\' medicine) - which treatment participants get is decided by chance.\\n\\nSemaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes.\\n\\nParticipants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week.\\n\\nThe study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations.\\n\\nStudy staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours.\\n\\nThe study includes magnetic resonance imaging (MRI) scans of participants\\' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is, under normal clinical practice conditions, to investigate the clinical safety and effectiveness in Chinese patients with type 2 diabetes who have never received anti-diabetic treatment before.|Metabolism and Nutrition Disorder|Obesity This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this trial is to compare biphasic insulin aspart 70 (NN2000-Mix70) in subjects with type 2 diabetes with that of biphasic insulin aspart 30 (NN-X14Mix30) in healthy volunteers.|Diabetes Mellitus, Type 2 The purpose of this study is to collect blood glucose values and activity data in patients with type 2 diabetes for approximately 12 weeks using electronic devices in a full virtual clinical setting. Virtual clinical setting means that all data are collected by use of participants\\' personal smartphone and study-related apps. In other words, everything will be handled without any visits to a hospital or doctor.\\n\\nFor collection of participants\\' blood glucose values participants will receive two different blood glucose monitors. One where participants cannot see the blood glucose values and one where participants can see the blood glucose values. Participants must wear them consecutively for 2 and 10 weeks, respectively. Further, participants will be asked to self-apply the monitors on their upper arm.\\n\\nFor collection of participants\\' activity data participants will receive an activity tracker, which participants will wear on the wrist throughout the study.\\n\\nWe will ask participants to keep an electronic diary of the timing of the meal- and medication intake through two shorter periods of the study.\\n\\nOn a voluntary basis, participants can choose to donate a saliva sample for the purpose of genetic research in diabetes patients.\\n\\nThe study does not include any study medication and participants will continue the current antidiabetic treatment as prescribed to participants by their own physician. If any questions about the treatment and/or health condition while participating in the trial, participants should consult your own physician If participants are in doubt about what the blood glucose values mean or whether participants should react to the blood glucose values, participants need to contact the research staff or their general practitioner.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.|Diabetes This study is conducted in Asia. The aim of the study is to evaluate safety and effectiveness in patients of all age groups excluding less than 12 month old infants with diabetes mellitus in routine clinical practice in Korea.|Diabetes Mellitus, Type 1|Healthy Volunteers This study is investigating the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965), its concentrations in the blood and its effect on blood sugar for the treatment of diabetes. This first part of the study is conducted in healthy people, while there is a second part involving people with type 1 diabetes. The study will test how insulin 965 is tolerated by the participants\\' body, how it is taken up in the participants\\' blood, how long it stays there and how blood sugar is lowered. Participants will either get the new insulin 965 or placebo (an injection that does not contain active medicine) - which treatment you get is decided by chance. It is the first time that insulin 965 is tested in humans. Participants will get one injection of either insulin 965 or placebo under the skin of the left thigh. The study will last for about 5 weeks. Participants will have 6 clinic visits with the study doctor. People cannot be in the study if the study doctor thinks that there are risks for their health.|Type 2 Diabetes The purpose of this experimental study is to investigate whether an acute lipid infusion added marine n-3 fatty acids produces effects on insulin sensitivity in subjects with type 2 diabetes, when compared with an acute lipid infusion without marine n-3 fatty acids. Furthermore other effects on intermediary metabolism are tested for.|Diabetes Mellitus, Type 2 This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot take part if they are pregnant, breast-feeding or planning to become pregnant during the study period. Women who can get pregnant will be checked for pregnancy via urine tests. Once daily semaglutide tablets (3 mg, 7 mg and 14 mg) are approved for the treatment of type 2 diabetes in the US, in the EU and in some other countries, under the brand name Rybelsus®.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and Japan. The aim of this clinical trial is to investigate the possible difference in the development of type 2 diabetes in a Japanese and a Caucasian population. Healthy subjects, subjects with impaired glucose tolerance, as well as subjects with type 2 diabetes will be included in the trial. The development of type 2 diabetes across the cohort will be investigated with regard to insulin sensitivity and B-cell capacity.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the safety and efficacy of modern insulins after switch from any other anti-diabetic treatment under normal clinical conditions in the Gulf countries.|Diabetes Mellitus, Type 2|Obesity This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this study is to investigate safety and efficacy in subjects with type 2 diabetes mellitus starting or switching to biphasic insulin aspart 30 (NovoMix® 30) treatment.|Healthy|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The purpose is to evaluate safety and tolerability of a range of single doses of subcutaneous insulin 338.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe.\\n\\nThe aim of this trial is to investigate the safety and efficacy of insulin detemir combined with oral anti-diabetic drugs (OADs) versus insulin NPH combined with oral anti-diabetic drugs (OADs) in Type 2 mellitus not well controlled on current therapy on blood glucose control.|Diabetes|Diabetes Mellitus, Type 1 This trial was conducted in Europe. The aim of this clinical trial was to evaluate the pharmacodynamic dose-response relationship of NN5401 (insulin degludec/insulin aspart) at three therapeutically relevant doses in subjects with type 1 diabetes.\\n\\nThe trial is designed as a four period, incomplete block cross-over trial where the trial participant will be randomised to a treatment sequence by which the subject will receive two matched dose levels of NN5401 and biphasic insulin aspart, respectively.|Diabetes|Diabetes Mellitus, Type 1 The purpose of this study is to:\\n\\nPart 1:\\n\\nTo investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia.\\n\\nPart 2:\\n\\nTo investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects counterregulatory hormones and cognitive performance during hypoglycemia.|Alzheimers Disease The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer\\'s disease. Semaglutide is a medicine that doctors can prescribe in some countries for the treatment of type 2 diabetes and excess body weight. This study will help us understand whether semaglutide can also be used for the treatment of Alzheimer\\'s disease. The study will last for about 77 weeks. In the first 12 weeks of treatment, participants will either get semaglutide (active medicine) or placebo (inactive dummy medicine). Which treatment participants get is decided by chance. In the following 52 weeks of treatment, all participants taking part in the study will get semaglutide. Participants must have a study partner, who is willing to take part in the study. Participants will get study medicine in a pen injector. The study partner will need to inject the study medicine into the skin of participant\\'s stomach, thigh or upper arm once every week.|Obesity|Overweight This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight.\\n\\nThis study will look at the change in participants body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets (\\'dummy\\' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation.\\n\\nSemaglutide tablets are new medicine being tested to treat overweight and obesity. Doctors in many countries can already prescribe semaglutide tablets at lower doses to treat type 2 diabetes.\\n\\nParticipants will get semaglutide or placebo tablets for 68 weeks and will need to take 1 tablet every morning\\n\\nIn addition to taking the medicine, participants will have talks with study staff about:\\n\\n* healthy food choices\\n* how to be more physically active\\n* what participants can do to lose weight The study will last for about 1½ year.Participants will have 14 clinic visits and 7 phone calls with the study doctor. Blood samples will be taken at 10 visits.\\n\\nParticipants will have a test to check their heart done at 3 visits. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. If participant is a woman and is able to become pregnant, participant will be checked for pregnancy via urine tests.|Type 2 Diabetes Mellitus Volunteers are being invited to take part in a research study about insulin therapy of diabetes. They are being invited to take part in this research study because they have diabetes and have an illness requiring hospitalization. If they volunteer to take part in this study, they will be one of about 120 people to do so. The investigators hope to answer the following research questions:\\n\\n* To show that insulin aspart protamine 70/30 mix taken twice daily is as good as insulin NPH/Reg 70/30 mix taken twice a day for treatment of diabetes after discharge from the hospital.\\n* To show how safe the two medicines are (insulin aspart 70/30 mix vs. insulin NPH/Reg 70/30 mix) and how well they work for the treatment of diabetes when transitioning from inpatient therapy to outpatient care.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) properties of FIAsp (faster-acting insulin aspart) in children, adolescents and adults with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in North America. The aim of this trial is asses the long term safety and efficacy of biphasic insulin aspart 30 in Canadian subjects with type 2 diabetes who had participated in the BIAsp-1237 trial.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of the study was to evaluate the safety and efficacy of biphasic insulin aspart 30 (NovoMix® 30) when switching to a modern premix insulin analogue treatment compared to previous insulin regimen in routine clinical practice in the Slovak Republic.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Xultophy® works in patients with type 2 diabetes. The participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26-34 weeks. The participants will be asked questions about their health and their diabetes treatment as part of their normal study doctor\\'s appointment.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Europe. This observational study is aimed to reflect the post-authorisation experience with insulin analogue (biphasic insulin aspart 30) when used under normal clinical practice conditions in Serbia.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination with two oral anti-diabetics compared to the two oral anti-diabetics alone for the control of blood glucose.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The purpose is to compare the safety of once-weekly dosing of semaglutide (0.5 and 1.0 mg) versus sitagliptin (100 mg) once daily, both as monotherapy during 30 weeks of treatment in Japanese subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes. Subjects treated with oral antidiabetic drug(s) (OAD(s)) should continue their current OAD treatment at the stable, prerandomisation dose level and dosing frequency.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe, and North and South America. The aim of this trial is to investigate if a dietary intervention has an effect on weight when initiating insulin treatment in subjects with type 2 diabetes currently treated with oral antidiabetic drugs (OADs).|Type 2 Diabetes Aim 1. Determine the impact of a daily, automated telephone intervention on HbA1c levels compared to standard care in older patients with type 2 diabetes.\\n\\nAim 2. Determine the impact of the automated telephone intervention compared to standard care on adherence to prescribed SMBG frequency in older patients with type 2 diabetes.\\n\\nAim 3. Determine the impact of the automated telephone intervention compared to standard care on self-reported diabetic control problems in older patients with type 2 diabetes.\\n\\nAim 4. Determine the impact of the automated telephone intervention compared to standard care on self-reported attitudes and health beliefs concerning diabetes in older patients with type 2 diabetes|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.|Type 2 Diabetes Mellitus|Insulin Resistance|Dyslipidemia Low birth weight (LBW), a marker of impaired fetal growth is an independent and strong risk factor for type 2 diabetes (T2D). A western lifestyle characterized by a surplus of calories, and/or a low physical activity level, associated with increased fat storage and altered lipid metabolism plays a central role in the pathogenesis of insulin resistance and T2D. Using state-of-the-art large-scale integrative physiology studies combined with basic studies of adipose and muscle tissue stem cell functions, the investigators aim to determine if LBW individuals exhibit decreased subcutaneous adipose tissue expandability, postprandial hyperlipidaemia and ectopic fat accumulation when exposed to 4 weeks of carbohydrate overfeeding. The investigators will subsequently examine if exercise training can revert and/or minimize the deleterious effects of carbohydrate overfeeding in a possibly birth weight differential manner.|Non-alcoholic Steatohepatitis Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver. NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used to treat type 2 diabetes and obesity. The study is being done to see how 2 medicines (NNC0194-0499 and semaglutide) are absorbed, transported, and eliminated from the body in a combination formulation. Participants will either get NNC0194-0499 and semaglutide in a combination formulation or the separate formulations. Which treatment participants get is decided by chance. The study will last for either 13 or 33 weeks. The duration is decided by chance.|Diabetes Complications|Osteoporosis The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function. Type 2 diabetes may cause multiple complications, and it is well known that patients with type 2 diabetes have a higher risk of fractures. If Liraglutide can be demonstrated to have a positive effect on bone, this may be one among other factors to consider before the decision about specific treatment of type 2 diabetes is made for the individual patient.|Healthy Volunteers Type 2 Diabetes This study looks at how the new medicine called NNC0480-0389 works in the body of Japanese men when it is given together with semaglutide. Participants will get NNC0480-0389 and semaglutide or 2 doses of placebo - which treatment participants get is decided by chance. NNC0480-0389 is a new medicine that has not been previously approved. It means that the medicine has not yet been approved by the health authorities. Semaglutide is a newly approved antidiabetic medicine that helps to lower blood sugar levels in patients with type 2 diabetes. NNC0480-0389 is being developed to be given together with semaglutide.NNC0480-0389 targets a different part of the system that regulates sugar levels in the body than semaglutide. Therefore, it is expected that together NNC0480-0389 and semaglutide will more effectively lower sugar levels in the blood. Participants will get 2 injections of the study medicine. It will be injected with a needle into a skin fold on participants\\' stomach. The study will last for a maximum of 72 days. Participants will have 10 scheduled visits with the study doctor. For 1 of the visits participants will stay at the clinic for 6 days (5 nights).The study includes blood sampling.|Diabetes Mellitus, Type 2 This is a non-interventional (observational), retrospective medical record review study collecting data reported in medical records of patients with T2D (Type 2 Diabetes ) who were treated with any basal-insulin or premix-insulin (plus/minus OAD (Oral Antidiabetic Drug)) for at least 26 weeks prior to switching to Ryzodeg® and treated for at least 26 weeks after switching to Ryzodeg® (plus/minus OAD).\\n\\nAll patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in South Korea.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Japan. The aim of the trial is to compare pharmacokinetics (at which rate the body eliminates the substance from the body) of insulin aspart with fast-acting insulin human following intravenous (IV) infusion or intramuscular (IM) injection in Japanese subjects with type 1 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe, Oceania, and the United States of America (USA).\\n\\nThe aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart in patients with type 1 diabetes (main period) followed by the extension period comparing the long-term safety of NN5401 plus insulin aspart with insulin detemir plus insulin aspart.\\n\\nThe main period is registered internally at Novo Nordisk as NN5401-3594 while the extension period is registered as NN5401-3645.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia.\\n\\nThe aim of this trial is to evaluate the blood glucose achieved with insulin detemir as add-on to current oral antidiabetic drug (OAD) treatment in subjects with type 2 diabetes.|T2D Studies of Greenland Inuit before the 1980s found a low prevalence of type 2 diabetes (T2D) compared to Western populations. However, recent population studies in Greenland found a notably high prevalence of diabetes (9%) and pre-diabetes (19%) in the adult population.\\n\\nIn many studies worldwide an increase in obesity, diabetes, and cardiovascular disease has been ascribed to social transition and in particular urbanization, but the Inuit in Greenland do not fit the pattern. Paradoxically, the highest prevalence of diabetes is seen in the least urbanized areas. Thus, while previously rare, T2D has become epidemic in Inuit. In a recent study by Moltke et al found that a variant in the TBC1D4 gene was strongly associated with insulin resistance in skeletal muscle, high postprandial blood glucose and a high risk of T2D.\\n\\nThe rapid increase in the prevalence of T2D and other metabolic traits and the well documented genetic susceptibility indicates that lifestyle components, particularly physical activity, and diet significantly modify the genetic effects on glucose homeostasis. Thus, changing dietary habits from a diet high in traditional foods, mostly consisting of marine mammals and fish (high in protein and unsaturated fats, and low in carbohydrate) to a westernized diet, with high contents of sugar and saturated fat may have increased the T2D incidence in Arctic Inuit.\\n\\nThe investigators will perform a 4-week cross-over intervention study of the traditional diet versus a western diet among homozygous carriers and WTs on 2-hour glucose after an oral glucose tolerance test (OGTT). In addition, the investigators will examine the effects on cardiometabolic abnormalities such as low-grade systemic inflammation and dyslipidemia. Furthermore, the investigators will characterize the metabolic phenotype of participants, as well as gut microbiota and brown adipose tissue markers to elucidate the molecular mechanisms underlying potential improvements of a traditional Inuit diet.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Healthy This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerance, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NN1952 as tablets in healthy volunteers and subjects with type 1 and type 2 diabetes.\\n\\nThe trial consists of two parts. In part 1, single escalating doses of NN1952, placebo or insulin aspart will be given to healthy volunteers. In part 2, subjects with type 1 or type 2 diabetes will receive single doses of NN1952 (with/without a meal), insulin aspart and placebo.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of insulin 287 in subjects with type 2 diabetes.|Cystic Fibrosis|Diabetes Mellitus To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize pulmonary function in cystic fibrosis (CF).|Healthy Volunteers Type 2 Diabetes The goal of this trial is to find out whether taking semaglutide tablets at different times before and after eating has a similar effect compared to the recommended dosing time. Participants with type 2 diabetes are recommended to take semaglutide on an empty stomach, and they should not eat, drink, or take any oral medicine for at least 30 minutes after that. The trial will look at how different dosing times of semaglutide before and after eating a meal changes how much semaglutide participants get into their blood. Participants will get one semaglutide tablet daily for a total of 10 days. For the first 5 days participants will receive semaglutide tablets of 3 mg and for the next 5 days, participants will receive semaglutide tablets of 7 mg. From here onwards, semaglutide tablets will be referred to as the \\'trial medicine\\', unless specifically mentioned. Participants will get the trial medicine (3 mg and 7 mg) under one of the 5 following dosing conditions. It will be decided by chance under which dosing condition participants will receive the trial medicine: A 2 hour fast before taking the trial medicine and 30 minutes fast after taking the trial medicine (Test arm A), A 4 hour fast before taking the trial medicine and 30 minutes fast after taking the trial medicine (Test arm B), A 6 hour fast before taking the trial medicine and 30 minutes fast after taking the trial medicine (Test arm C), A 2 hour fast before taking the trial medicine and an overnight fast (at least 6 hours fast) after taking the trial medicine (Test arm D), An overnight fast before taking the trial medicine and 30 minutes fast after taking the trial medicine (Reference arm E). Before each fasting period prior to receiving the trial medicine, participants will fast for 4 hours and then receive a standardised meal. The meal should be completed before the 2, 4 or 6 hours fasting is started. The trial will last for about 48 to 78 days (about 1.5 to 2.5 months). Participants will have 4 scheduled visits with the study doctor. At one of the visits, participants will be admitted to the trial unit and have to stay for 12 consecutive days. At all visits participants will meet with trial staff and will have blood tests along with other clinical checks and tests. Participants will be asked about their health, medical history, and habits. Women only: Women cannot take part if pregnant, breast-feeding, or planning to become pregnant during the trial period.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to compare the effect of exercise on blood glucose in subjects with type 1 diabetes, who are treated with either insulin degludec (IDeg) or insulin glargine (IGlar).|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe.\\n\\nThe aim of this observational study is to investigate the switch from metformin alone to metformin combined with repaglinide in type 2 diabetic patients not achieving adequate glycaemic control on maximal dose of metformin given alone and to analyse different epidemiological parameters.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes inadequately controlled with metformin alone.\\n\\nThe trial has been extended by 52 weeks. The extension will consist of two 26-week periods:\\n\\n1. Week 27-52 after randomisation\\n\\n   - All subjects will continue receiving sitagliptin or liraglutide at unchanged dose and dosing regimen.\\n2. Week 53-78 after randomisation\\n\\n   * Subjects receiving sitagliptin at the end of week 52 after randomisation will discontinue sitagliptin and will be randomised 1:1 to liraglutide 1.2 mg/day or liraglutide 1.8 mg/day. Liraglutide will be initiated at a dose of 0.6 mg/day, and increased to 1.2 mg/day or 1.8 mg/day in weekly intervals.\\n   * Subjects receiving liraglutide 1.2 mg/day or 1.8 mg/day at the end of week 52 after randomisation will continue the treatment at unchanged dose and dosing regimen. Trial completion is planned for June 2010.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This observational study is conducted in North America. The aim of this observational study is to evaluate the incidence of adverse events while using Levemir® under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems This trial is conducted in Europe. The aim of this trial is to compare two needle types when used with a disposable insulin injection pen in the everyday life setting of an insulin treated patient with diabetes.|Type 2 Diabetes To test the effect of Nexium and probiotics on insulin secretion and cardiovascular risk factors on type 2 diabetic patients.\\n\\nStudy Hypothesis:\\n\\n1. Nexium causes an increased gastrin secretion that increases the insulin secretion and thereby a reduction of HbA1c\\n2. Probiotics changes the gut flora and bloodpressure\\n3. Probiotics causes a change in inflammation and thrombosis.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this observational study is to evaluate the incidence of major hypoglycaemic episodes in patients with type 2 diabetes treated with NovoRapid® or Soluble Human Insulin under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Insulin glargine versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in combination with metformin in subjects with Type 2 Diabetes.|Diabetes|Diabetes Mellitus, Type 2 The study is conducted in Europe. The aim of this observational study is to assess glycaemic control while using liraglutide under normal clinical practice conditions in Belgium.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa. The aim of this clinical trial is to investigate the effect of 50 weeks of treatment with different intensified insulin administrations (all in combination with a fixed dose of metformin) on blood sugar control in subjects with type 2 diabetes inadequately controlled by oral anti-diabetic drugs (OADs).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare the efficacy of metformin and repaglinide used alone or combined administered as initial treatment in subjects with type 2 diabetes in which diet and exercise have failed.|Type 1 Diabetes Mellitus Each subject will be allocated to 2 periods of 3 months of once daily dosing with either liraglutide (1.2 mg) or placebo treatment (in random sequence) as add on to usual intensive insulin treatment. Wash-out period between treatments will be 1 month.\\n\\nThe trial can be divided into the following periods:\\n\\n* Screening\\n* Treatment period 1\\n* Washout period\\n* Treatment period 2\\n* Follow up Visit\\n\\nMixed Meal Tolerance Test (MMTT) enriched with paracetamol:\\n\\nAt the beginning and end of each period a MMTT (Fortimel complete) enriched with paracetamol will be performed to assess the remaining beta-cell function via obtained maximal plasma C-peptide levels as well as the gastric emptying.\\n\\nExperimental / Hypoglycaemic clamp :\\n\\nAt the end of each period (Visit 8, 15) a hypoglycaemic clamp will be performed. After the subject completed the MMTT on day 1, the subject will stay in the clinical unit to prepare for the hypoglycaemic clamp with an variable insulin infusion intravenously in order to obtain a steady state of a plasma glucose (PG) level of 5.5 mmol/L overnight until approximately 08:00. At 05:00 hours 10%-\\\\[6,6-2H2\\\\] glucose solution will be given i.v. as a primed (9.6mg/kg/min) for one minute and a constant (0.08 mg/kg/min) infusion until the last blood sampling of the plateau 4.0 mmol/L will be performed.\\n\\nAt 08:00 hours in the morning at day 2, insulin infusion will be increased to 1.5 mU/kg/min for each subject and the PG will be kept at a plateau of 5.5 mmol/L by a controlled variable intravenous infusion of glucose (10% glucose enriched with 4mg \\\\[6,6-2H2\\\\] glucose /ml) for one hour. Afterwards, PG is allowed to fall to a plateau of 3.5 mmol/L, then to a nadir of 2.5 mmol/L, then to a blood glucose of 4.0 mmol/L and finally back to a level of 5.5 mmol/L for safety reasons. Blood sampling for measurement of \\\\[6,6-2H2\\\\] glucose, glucagon, insulin, counterregulatory hormones, lactate, free fatty acids, glycerol, vital signs, hypoglycaemic symptoms questionnaire and hypoglycaemic awareness will be performed at each PG plateau.|Obesity|Insulin Resistance|Type 2-diabetes|Inflammation CD163 is a membrane bound receptor primary expressed in monocytes and macrophages. A soluble variant of CD163 (sCD163) is present in plasma and is elevated in pathological condition activating the monocyte-macrophage system. Recently sCD163 is associated with various inflammatory conditions, ex. adipose tissue inflammation and very recently to be a rather strong predictor of the development of type 2-diabetes. Only a subset of obese individuals develops insulin resistance, type 2-diabetes and related diseases. These healthy obese subjects are characterized of less adipose tissue inflammation and less insulin resistance as compared to unhealthy obese individuals. Consequently it would be of great importance to develop markers that could discriminate between healthy and unhealthy obese subjects. Aim: To investigate whether macrophage CD163 is involved in adipose tissue inflammation in obesity and thereby to the metabolic complications of metabolic syndrome. To investigate how sCD163 is regulated by metabolic factors such as obesity, fat distribution, weight loss and diet. Methods: Intervention study. 45 morbidly obese subject approved to gastric by-pass. Blood samples, MR-spectroscopy, DXA, weight control and fat biopsy are taken before and 12 month after surgery. Correlations studies: to investigate the influence of diet and weight loss on CD163 and sCD163. Perspective: To study the role of macrophages infiltration and activation for adipose tissue inflammation and to determine whether the macrophage marker, s-CD163, together with other markers will be able better to identify obese individuals who are at increased risk for developing complications such as diabetes|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or sulphonylurea or repaglinide.|Diabetes|Diabetes Mellitus, Type 2 The study is conducted in Asia. The aim of this observational study is to evaluate the weight change from baseline while using Levemir® in subjects with type 2 diabetes mellitus under normal clinical practice conditions in India.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate the quality of life and clinical outcomes in subjects using NovoMix® 30 (biphasic insulin aspart 30) for the treatment of diabetes mellitus under normal clinical practice conditions in India.|Diabetes|Diabetes Mellitus, Type 2|Delivery Systems This study is conducted in Asia. The aim of this observational study is to evaluate safety, efficacy and convenience in using NovoMix® 30 FlexPen® in type 2 diabetes under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin on blood glucose control in subjects with type 2 diabetes who are insulin naive and failing OAD therapy.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to compare cognitive function and associated brain activation patterns during an acute hypoglycaemic episode and during euglycaemia (normal blood glucose concentration). Additionally, the purpose is to assess cognitive function in the recovery phase after hypoglycaemia or euglycaemia, respectively, in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan. Depending on pre-trial oral anti-diabetic drugs (OADs), subjects continued at the same dose and dosing frequency.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26 weeks of treatment|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of biphasic insulin aspart 50 (BIAsp 50) twice daily versus biphasic human insulin 50 (BHI 50) twice daily, both in combination with metformin, in Chinese subjects with type 2 diabetes mellitus.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe.\\n\\nThe aim of this trial is to investigate the efficacy and safety of an intensified treatment regimen with preprandial insulin aspart and insulin detemir once or twice daily to a more convenient regimen with biphasic insulin aspart 30 twice daily on blood glucose control in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the long-term safety of insulin aspart in the management of type 1 diabetes. An extension to the ANA/DCD/065 trial|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment with oral antidiabetic drugs in patients with Type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia, Europe, Japan and North America. The aim of this observational study is to evaluate the safety and effectiveness while using NovoMix® 30 during 26 weeks under normal clinical practice, in the countries participating in the study. The primary outcome is the incidence of major hypoglycaemic events reported as serious adverse drugs reaction conditions on hypoglycaemic events.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.|Type 1 Diabetes To our knowledge, no trial has specifically studied the effect of liraglutide combined with a basal/bolus insulin regimen in type 1 diabetes in a cross-over, double-blind, unicentric model. Moreover, the potential impact of a glucagon-like peptide-1 agonist on measures of abdominal fat (assessed by CT scan), insulin sensitivity (assessed by the gold standard euglycemic-hyperinsulinemic clamp) and satiety sensations have not been evaluated in this population.\\n\\nHypothesis Overweight participants with type 1 diabetes on liraglutide/insulin treatment will present improved glucose control with decreased HbA1c, decreased fasting and mean weekly glucose concentrations and glycemic excursions as well as increased insulin sensitivity compared to participants on placebo/insulin treatment. Participants with liraglutide/insulin treatment will also present improved endothelial function, lower body weight, central adipose tissue assessed by CT scan and higher satiety sensations assessed by visual analogue scales.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Relatives to/Carers of Patients|Healthcare Professionals The study is conducted in Africa, Asia, Europe, Japan, North America and South America.\\n\\nThe multinational surveys will explore the experiences and unmet needs of people with diabetes, as well as those of family members of people with diabetes, and of healthcare professionals treating people with diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems This trial is conducted in Europe. The primary aim of this clinical trial is to locate and compare simulated insulin injections (injections of sterile atmospheric air) in normal weight and obese patients with diabetes mellitus. Injections are done with 6 mm and 12 mm needles with and without lifting of skin fold at different injection sites.|Healthy Volunteers Diabetes Mellitus, Type 2|Healthy Volunteers Overweight|Healthy Volunteers Obesity This study in healthy men and women looks at the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (s.c., under the skin). Participants will receive 2 single doses of semaglutide 0.25 mg on 1 day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.|Diabetes Mellitus, Type 2 The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atherosclerotic cardiovascular diseases.\\n\\nParticipants will be asked to give information about their health. Partipants will continue normal way of life and will not get any medication other than those prescribed to them by the doctor.\\n\\nThe study will last for about 6 months.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Africa, Europe, North and South America and Oceania. The aim of this trial is to compare the effect and safety on blood glucose control in pregnant women with type 1 diabetes of a modern insulin analogue (insulin detemir) and human insulin (NPH insulin) given as long-acting insulin in combination with a short-acting insulin (insulin aspart).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The trial aims to investigate if the blood glucose control of biphasic insulin aspart 50 is at least as effective as treatment with biphasic insulin aspart 30 both in combination with metformin.|Diabetes|Diabetes Mellitus, Type 1 This trial iss conducted in Europe. The aim of this clinical trial is to evaluate the hypoglycaemic response (the response to low blood sugar) to NN1250 (insulin degludec) in subjects with type 1 diabetes.\\n\\nThe trial is designed as a two-period, crossover trial where the trial participant is randomised to one of two treatment periods.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Asia, Europe, Japan and South America. The aim of the trial is to compare the efficacy, safety and tolerability of NN1250 (insulin degludec (\\\\[Deg\\\\]) with insulin detemir (IDet), both combined with insulin aspart.\\n\\nThe main period is registered internally at Novo Nordisk as NN1250-3585 while the extension period is registered as NN1250-3725.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to compare insulin degludec and insulin aspart (IDegAsp) co-formulations with separately injected, simultaneous doses of insulin degludec (insulin 454) and insulin aspart, compared with biphasic insulin aspart 30 (NovoMix® 30) in subjects with type 1 diabetes mellitus. Each subject will be randomised to four out of nine possible treatment arms. IDegAsp 40, IDegAsp 45, IDegAsp 55 and IDeg high concentration were explorative formulations, not similar to the proposed commercial formulation.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this trial was to investigate the safety and efficacy of NN2000-Mix30 produced by NN2000 process compared to that of NN-X14Mix30 produced by current process in Japanese subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this clinical trial is to compare the 24-hour pharmacodynamics/ pharmacokinetics of biphasic insulin aspart 30 (BiAsp 30) thrice daily treatment with that of a basal-bolus treatment with insulin glargine and insulin glulisine in type 2 diabetic subjects.\\n\\nPharmacodynamics is the glucose-lowering effect of the study medication over the entire observation phase from the time of administration and the efficacy period while the pharmacokinetics is the amount of the study insulin that can be determined in the blood.|Diabetes Mellitus, Type 2 This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.\\n\\nThe study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec.\\n\\nParticipants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe.\\n\\nParticipants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach.\\n\\nThe study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.\\n\\nNot applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.|Diabetes Mellitus, Type 1 Fiasp® is a meal-time insulin that has been available in Sweden since June 2017. This study will investigate the effectiveness of Fiasp® in treating Type 1 Diabetes Mellitus. The study will be based on blood sugar measurements that the participants have uploaded to the Diasend® database and on existing data in their electronic medical records. The study does not require any additional visits to the study doctor.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower participants blood sugar levels. Participants will get Rybelsus® as prescribed to them by their study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor. Participants will be asked to complete some questionnaires about their diabetes treatment. Participants will complete these during their normally scheduled visits with the study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe, South America, and the United States of America (USA).\\n\\nThe aim of the trial is to investigate efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months. The participants will be asked to complete some questionnaires about their health and their diabetes treatment. Participants will complete these during their normally scheduled visits with their study doctor.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed to them by their doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about their health and your diabetes treatment. Participants will complete these during their normally scheduled visits with their doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1 diabetes.|Diabetes Mellitus, Type 2 This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of switching from the insulin which the participants are already on to insulin 287 are also compared. This is done to find the best way to switch to insulin 287. The participants will either get insulin 287 that they will have to inject once a week or insulin glargine that they will have to inject once a day. Which treatment any participant gets is decided by chance. The study will last for about 5 months (23 weeks). The participants will have 14 clinic visits and 6 phone calls with the study doctor. At 3 of the clinic visits participants will be asked not to eat or drink anything (except for water) in the last 8 hours before the visit. During the study, the doctor will ask the participants to: 1) measure their blood sugar every day with a blood sugar meter using a finger prick; 2) write down different information in a diary daily and return this to their study doctor. 3) wear a medical device (sensor) that measures the participants blood sugar all the time for 18 weeks (about 4 months) during the study.|Pre Diabetes|Postpartum Disorder The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.|Diabetes Mellitus, Type 2 This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.\\n\\nThe study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily.\\n\\nParticipants will either get insulin icodec that participants will have to inject once a week on the same day of the week or insulin glargine that participants will have to inject once a day at the same time every day. Which treatment participants will get is decided by chance. Participants will also get a mealtime insulin.The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach.\\n\\nThe study will last for about 8 months. participants will have 17 clinic visits and 13 phone calls with the study doctor.At 8 clinic visits participants will have blood samples taken. At 4 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 3 periods for a total of 13 weeks (about 3 months) during the study.\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Japan. The aim for this trial is to investigate the pharmacodynamics and pharmacokinetics of insulin detemir and insulin NPH in Japanese subjects with type 1 diabetes mellitus.|Diabetes Mellitus The costs of diabetes care (in health care dollars \\\\& human suffering) in the United States are second only to mental illness. Randomized control trials \\\\& observational studies have shown that glycemic control is predictive of the onset \\\\& severity of complications from diabetes and costs of care. In addition, a significant percentage of costs associated with diabetes can be reduced or delayed by appropriate diagnosis, preventive strategies, \\\\& management. The Planned Care Model (advocated by the Institute for Healthcare Improvement) has shown success in demonstrating improved practice performance and patient outcomes during a limited pilot in our clinical practice. We are proposing to generalize the Planned Care Model, to assess the value of planned care for all people with diabetes. The Planned Care Model will be implemented at each practice site and will consist of a structured communication schema between the patient and the primary health care team, to improve care for people with diabetes. Traditional care will be defined as the traditional system of care for patients prior to their participation in the Planned Care Model. It is hypothesized that this Planned Care Model will improve compliance with appropriate care guidelines and improve short and long term health outcomes (metabolic, satisfaction, morbidity, mortality and healthcare utilization). In conjunction with this study, providers at each of the practice sites will be randomly assigned to a structured communication with specialty care, referred to as UNITED Planned Care (Use of Networks, Informatics, Telemedicine, and Education in Disease Management). This communication schema will only be possible once the assigned provider?s patient is participating in the Planned Care Model. The UNITED Planned Care model will include point-of-care evidence based messages and specialty advice determined by performance gaps and outcomes for the patient. UNITED Planned Care is hypothesized to have the greatest impact on short \\\\& long term health outcomes.|Diabetes Mellitus, Type 2|Primary Care This observational study intends to evaluate the use and adherence of different types of primary care practices to the diabetes criteria-protocol (diabetes score), developed by the Swiss Society of Endocrinology and Diabetology. This diabetes score comprises visits to the doctor, lifestyle consultations, clinical measures such as blood pressure, cholesterol or blood sugar, as well as measures concerning the prevention of secondary complications like kidney, eye or feet issues. The participating primary care practices need to treat 80% of their diabetes patients (their \"diabetes population\") in accordance to the score-criteria. In addition to the adherence to the eight score-criteria, the practices are required to also document statistically if their diabetes patients get the following medication: oral antidiabetics, insulin, blood pressure medication, statins and / flu vaccine. As this observational study is and before-and-after study, the primary care practices need to document for each of their diabetes patients the care they provided in the year before the introduction of the score-criteria and in the year following their introduction. Participating primary care practices ask their diabetes patients\\' consent to the documentation and anonymous transmittance of their data. Data evaluation is anonymous and on a population-based level (as opposed to individual-based). The hypothesis of the study is to prove that the implementation of evidence-based measures, such as a diabetes score can increase the treatment quality of diabetes patients in primary care practices and this increase is independent of the primary care practice structure in which it is applied.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensification.\\n\\nThis is an extension to trial NN9068-3952, NCT01952145 (DUAL™ V).|Diabetes Mellitus, Type 2 This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone.\\n\\nBefore a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective.\\n\\nParticipants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by chance.\\n\\nA dummy medicine (placebo) looks like the study medicine but does not contain any active medicine. The dummy medicine is in the study to see if the study medicine works as expected.\\n\\nParticipants will get 2 injections per week on the same day. Participants will take the study medicine with a pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show how.\\n\\nThe study will last for about 39 weeks. Participants will have 12 visits at the clinic and 5 phone calls with the study doctor.\\n\\nAt 6 of the clinic visits participants must not eat and drink for 8 hours before the visit (water is allowed).\\n\\nWomen who can become pregnant cannot take part in this study. Only women that are surgically sterilised or post-menopausal are allowed to participate in this study Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to compare pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (the exposure of the trial drug in the body) properties of insulin degludec and insulin glargine 300 U/mL at steady-state conditions in subjects with type 1 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to describe the diabetes management, control status and complication profile in a diabetic population of Philippines.|Type 2 Diabetes Mellitus|Cardiovascular Disease There are recent advances in therapies for the treatment of Type 2 Diabetes Mellitus (T2DM) which include the GLP1 analogues and the DPP IV inhibitors. Both of these therapies target the incretin system using different methods to elevate/maintain circulating levels of GLP1 to subsequently achieve improved blood sugar control. Interestingly, GLP1 analogues have been reported not only to improve blood sugar control but to additionally induce weight-loss and emerging experimental evidence has shown it may have beneficial effects on the heart\\'s structure and function. Due to the profile of this condition being a lot worse and younger patients having greater CVD risk, a therapy offering multiple positive effects, in particular the potential cardiometabolic effects, make this line of therapy attractive in this patient population.\\n\\nThe aim of this research is to investigate the cardiometabolic effects of Liraglutide (GLP1 analogue) compared to that of its clinically relevant comparator Sitagliptin (DPP IV inhibitor).|Diabetes Mellitus, Type 1 This feasibility study builds upon mental health and technology acceptance theoretical frameworks. It seeks to examine potentials of a mobile-based novel digital health solution based on emotional and behavioral change techniques, to provide emotional and self-management tailored support to caregivers of children with type I diabetes (T1D).\\n\\nThe digital health program, called Adhera® Caring, is designed to be used for approximately 3 months. The study will enroll 100 participants (20 in sub-study 1 and 80 in sub-study 2) who are caregivers of children with type 1 diabetes. There will be a nurse coaching the participants by providing support related to their emotional wellbeing via the mobile solution.|Overweight|Obesity|Diabetes Mellitus, Type 2 This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking \"dummy\" medicine. In addition to taking the medicine participants will have talks with study staff about healthy food choices, how to be more physically active and what else they can do to lose weight. Participants will either get semaglutide or \"dummy medicine\" - which treatment is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skinfold in the stomach, thigh or upper arm.• The study will last for about 1 year. Participants will have 11 clinic visits and 8 phone calls with the study doctor. Participants will have 3 clinic visits where they cannot eat and drink (water is allowed) for up to 8 hours before the visit and 1 clinic visit where they cannot eat and drink for up to 2 hours before the visit. (4 visits and 1 visit, respectively, if they have type 2 diabetes (T2D)). Participants will have 4 clinic visits where they will have blood samples taken. (5 visits if they have T2D). For China: Participants will have 9 clinic visits where they will have blood samples taken. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1 The trial is conducted in Europe and Middle East. The aim of the trial is to compare the use of Insulin Detemir once or twice daily combined with mealtime Insulin Aspart against that of NPH Insulin once or twice daily combined with mealtime Insulin Aspart. The trial involves children and adolescents with Type 1 Diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate the safety and efficacy of insulin aspart produced by current process compared to that of insulin aspart produced by NN2000 process in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 This study is comparing the effect of a long-acting insulin analogue (insulin 287) with insulin glargine (Lantus®) in subjects with type 2 diabetes. In addition, the study is looking at symptoms of low blood sugar, awareness of low blood sugar and the time and amount of glucose needed to recover from low blood sugar after injecting 2 and 3 times the basal dose of insulin 287 and glargine. The purpose of the study is to make a once-weekly injectable basal insulin treatment for people with type 2 diabetes. Participants will get insulin 287 as well as insulin glargine - which treatment any participant gets first is decided by chance. Insulin 287 is a new medicine; insulin glargine can already be prescribed. The study medicines will be in a pen, and must be injected with a needle in the thigh once per day (insulin glargine) or once per week (insulin 287). The study will last for minimum 3 months and up to approximately 6 months. Participants will have 21 clinic visits and at least 2 phone calls with the study doctor. The participants\\' health will be monitored carefully and blood samples will be taken at the clinic visits.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to gain practical experience with once daily Levemir® administration in type 2 diabetes patients who were previously treated with NPH insulins (e.g. Protaphane®) as basal insulin as part of their IIT under normal clinical practice conditions in Lithuania|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).|Diabetes Mellitus, Type 2 The purpose of this study is to collect information on how Xultophy® works with other oral anti diabetic medication in patients with type 2 diabetes.\\n\\nParticipants will get Xultophy® as prescribed by the study doctor. The study will last for about 26 weeks. Participants will be asked questions about health and diabetes treatment and lab tests as part of normal doctor\\'s appointment.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The purpose of this trial is to compare the pharmacokinetic properties (the exposure of the trial drug in the body) of different formulations of NN1218.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems This trial is conducted in Europe. The aim of this investigation is to explore the safety of a 4 mm needle compared to a 6 mm needle when injected in children and lean adults with diabetes.|Type 2 Diabetes|Atherosclerosis|Arteriosclerosis Type 2 Diabetes Mellitus patients (T2DM) have an increased mortality rate due to macrovascular disease. The primary objective of the study is to evaluate the effect of an 18-month treatment with metformin versus placebo in combination with one of three insulin analogue regimens following a treat-to-target principle. The primary outcome measure is change in wall thickness of the carotic arteries(CIMT)measured by ultrasound. A total of 900 patients with T2DM and HbA1c above 7.5% will be included.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia and North America. The aim of this trial is to compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily in insulin-naïve subjects with type 2 diabetes mellitus when using two different titration algorithms (dose individually adjusted) as add-on to subject\\'s ongoing treatment with metformin.|Diabetes Mellitus, Type 2 The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. This study is a prospective, open, uncontrolled, observational surveillance study with Levemir® FlexPen® conducted in Korea.\\n\\nThe aim of this observational study is to evaluate the short term and the long term safety and efficacy of Levemir® FlexPen®. The study is planned and conducted as per requirement from Korea Food and Drug Administration (KFDA).|Diabetes Mellitus, Type 1|Cardiovascular Diseases|Hypoglycemia|Patient Participation Cardiovascular (CV) diseases are the most frequent type 1 diabetes (T1D) complications. A recent epidemiological study showed that patients with T1D have a two-fold CV mortality risk, even in case of good glycemic control. In addition, it has been shown that patients with T1D with no traditional CV risk factors had about a 80% higher risk of cardiovascular event compared to non-diabetic individuals. This indicates that further modifiable risk factors in relation to CV mortality remain to be identified.\\n\\nOne of the candidates that could help to disentangle the factors associated with the increased CV mortality in T1D patients is glycemic variability which could contribute to diabetes complications. Indeed, severe hypoglycaemia, one of the most severe consequence of glycaemic variability, are associated with a higher mortality in patients with type 1 and type 2 diabetes.\\n\\nIn order to evaluate the relation between glycemic variability, insulin therapy modalities and CV risk as well as some other questions related to health determinants of T1D, we are building up a large observational, prospective, multi-centric cohort study of patients gathering 15,000 patients with T1D, age above 6 years old, to perform the following:\\n\\n* Collecting clinical information\\n* Evaluating Glycemic variability (assessed by the coefficient of variation of glucose (CV) calculated from automatically downloaded continuous glucose monitoring data (CGM)\\n* Biobanking including plasma, DNA, urine, saliva and hair.\\n* Collecting patients\\' reported outcomes through auto-questionnaires (online questionnaires).\\n* Doing an active follow-up for a period of 10 years with an intermediate visit every 3 years.\\n* Passive follow-up: link to national Health data system (Système National de Données de Santé, SNDS) in order to exhaustively collect health events as death, CV events and hospitalizations (including severe hypoglycemia).|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this study is to evaluate the safety and effectiveness of liraglutide in subjects with type 2 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control when using NovoMix® 50 up to 12 months after initiation subjects with type 2 diabetes currently on a therapy with human biphasic insulin. An additional objective is also to observe the different regimes of starting and maintaining the treatment with NovoMix® 50 during one year.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The purpose of this trial is to investigate the safety and the effect of biphasic insulin aspart 50 compared to biphasic human insulin 50 in patients with type 2 diabetes mellitus.|Diabetes Mellitus To compare application site reactions after superficial and deep subcutaneous and intradermal injections of insulin detemir and saline in patients with diabetes\\n\\n- The patient serves as his own control, n=100 patients with diabetes|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Japan. The aim of trial is to investigate the safety of insulin detemir and insulin NPH in children with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted Asia, Europe and North America. The aim of this study is to describe insulin therapy adherence and the burden of non-adherence on patient functioning, well-being and diabetes management.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin 100 mg once-daily on glycaemic control after 30 weeks of treatment. Subjects will remain on their stable pre-trial metformin.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to compare BIAsp 30 twice daily individually adjusted by the subject versus BIAsp 30 twice daily individually adjusted by the investigator both combined with oral antidiabetic drugs (OADs) in subjects with type 2 diabetes inadequately controlled with premixed human insulin. Subjects to continue their OAD background treatment: Metformin plus/minus alpha-glucosidase inhibitor.|Diabetes|Diabetes Mellitus, Type 1|Healthy This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of subcutaneous NNC0148-0000-0287 (insulin 287) in healthy subjects and in subjects with type 1 diabetes|Cystic Fibrosis|Diabetes Mellitus Is oral therapy with Repaglinide equivalent to insulin therapy with three daily injections with respect to blood glucose control, weight and pulmonary function over 2 years in patients with cystic fibrosis and secondary diabetes mellitus? That is the question examined in the phase III trial.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe.\\n\\nThe aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to current OAD (oral anti-diabetic drug) treatment in subjects with type 2 diabetes and to verify the safety of use (number and severity of episodes of hypoglycaemia, body weight and side effects).|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this non-interventional study is to evaluate the the current status of diabetes management, control, and complications in diabetic subjects with type 2 diabetes in Bangladesh.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH (Neutral Protamine Hagedorn) (both combined with insulin aspart at the main meals) in overweight and obese subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride monotherapy and to rosiglitazone as add-on therapy to glimepiride.|Diabetes Mellitus, Type 2 This study compares semaglutide in two different injection tools called \"PDS290\" and \"DV3372\". The study aims to show similar levels of semaglutide in the blood when using either of the two injection tools. The researchers also want to look at how well the injection tools work. Participants will either receive semaglutide using the PDS290 or the DV3372 injection tool. This is decided by chance, like flipping a coin. This is called randomisation. Semaglutide is an approved medicine (thus available on the market) for people with type 2 diabetes. Semaglutide will be injected subcutaneously (injection under the skin). Participants will get a total of 5 injections with semaglutide. The study will last for a maximum of 86 days. Participants will have 17 scheduled site visits with the study physician or study staff at the study centre. For one of the visits participants will stay at the research unit for 4 days and 3 nights. Participants cannot take part in this study if participants have any disorder that the doctor thinks is a health problem. Only healthy men and women are allowed to take part. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Tresiba® works in real world patients. Patients will get Tresiba® as prescribed to them by their study doctor. The study will last for about 6 to 8 months. Patients will be asked questions about their health and diabetes treatment as part of their normal study doctor\\'s appointment.|Metabolism and Nutrition Disorder|Obesity This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.|Diabetes Mellitus Type 2|Metabolic Syndrome|Cardiovascular Disease|Diastolic Dysfunction|Fatty Liver Among South Asians, in comparison to Western Europeans, there is an increased risk of type 2 diabetes mellitus (DM2) and DM2-related cardiovascular disease. The effect of Liraglutide (Victoza®) on cardiovascular function is therefore investigated in the DM2 patient group of South Asian descent specifically.\\n\\nLiraglutide is a new widely prescribed therapeutic agent for DM2 patients. It is a Glucagon Like Peptide - 1 homologue that improves glucose homeostasis and reduces blood pressure and body weight. The disadvantageous metabolic phenotype as seen in South Asians includes a relatively large total fat mass, with predominately visceral relative to subcutaneous adipose tissue and lower brown adipose tissue volume and activity, accompanied by increased lipid levels. The key elements in the mechanism of action of Liraglutide seem to correspond to the differences in metabolic profile between South Asians and Western Europeans. Diastolic dysfunction, an early finding of cardiovascular disease in DM2 and obesity and an independent predictor of mortality, has been shown to be associated with the amount of triglyceride accumulation in the heart and liver. The investigators hypothesize that Liraglutide has direct advantageous cardiovascular effects and reduces triglyceride accumulation in end-organs, specifically for DM2 patients of South Asian descent.|Diabetes|Diabetes Mellitus, Type 2 This trial was conducted in Europe and North America. The aim of this clinical trial was to compare NN1250 (insulin degludec (IDeg)), a soluble insulin basal analogue (SIBA), with insulin glargine (IGlar), as add-on to subject\\'s ongoing treatment with metformin and/or DPP-4 (dipeptyl peptidase 4) inhibitors, in patients with type 2 diabetes being treated with oral anti-diabetic drugs (OADs).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or maximum tolerated dose) in subjects with type 2 diabetes qualifying for treatment intensification.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin analogue or intermediate-acting insulin to insulin degludec (NN1250, SIBA) on a basal-bolus regimen in subjects with type 1 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2|Healthy This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 This study will be conducted to look at the effect of decreased kidney function when getting one dose of insulin 287 and to guide dosing recommendations in people who have altered kidney function. Insulin 287 works in the body for a long time (long-acting). It is taken once a day by injecting under the skin. The main target patient group for insulin 287 is people with type 2 diabetes. Participants will get just one injection. The study will last for up to 80 days. Participants will have 11 out-patient visits with the study doctor and one in-house visit of 3 days and 2 nights. Participants will have some assessments like several blood draws, electrocardiograms (ECGs), urine collections and capillary blood sugar tests. Participants cannot take part if they are hypersensitive to the study medicine, if they received any investigational product within 90 days before screening, or if they have certain diseases e.g. HIV or hepatitis or heart problems. Participants have to take photos if they experience any allergic reactions and send them to their study doctor. Participants\\' kidney function will be examined by a so called \"Iohexol test\".|Type 1 Diabetes|Puberty: >Tanner 2 Breast Development or Testis >4ml Type 1 Diabetes is the most common life-long disorder with onset in childhood. Patients need insulin injections, blood sugar monitoring several times each day, and adhere to a strict diet. Adequate control of blood glucose is essential to prevent long term kidney and eye complications that result in kidney failure and blindness. Adolescence is a time when diabetes is difficult to control, due in part to high growth hormone levels causing insulin resistance ( a state where the body does not respond as strongly to insulin). This study will test whether treatment with rosiglitazone (an oral medication used frequently in type 2 diabetes) will reduce the insulin resistance of adolescence and improve the control of type 1 diabetes during puberty.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about their health and diabetes treatment. Participants will complete these questionnaires during their normally scheduled visits with the study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. This a clinical trial to study the efficacy and safety of three times a day BIAsp-70 compared to two times a day BIAsp-30 in subjects with type 2 diabetes.|Gestational Diabetes|Diabetes The General hypothesis is that the IADPSG screening strategy for gestational diabetes (GDM) will lead to an important increase in the work load and the prevalence of GDM in Belgium but that this might not be cost effective concerning the prevention of adverse pregnancy outcomes. The risk to develop type 2 diabetes postpartum will probably be lower than for women diagnosed with the two-step screening strategy.\\n\\nIn this prospective multicentric cohort study, women will be universally screened for pregestational diabetes and GDM at the first prenatal visit during the first trimester by measuring the fasting plasma glucose. In the second trimester, women without diagnosis of diabetes or GDM in the first trimester, will be universally screened for GDM using the 50g glucose challenge test (GCT) and the 75g oral glucose tolerance test (OGTT) with the IADPSG criteria for GDM. Diagnosis of GDM will be based on the 75g OGTT.|Diabetes Mellitus|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Europe and Asia. The purpose of the study (Diabetes Pregnancy Registry) is to evaluate the safety of treatment with insulin detemir in pregnant women with diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate if the pharmacodynamic / pharmacokinetic properties of insulin aspart and human soluble insulin are different in elderly (65 years of age or older) with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe.\\n\\nThe aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir. You will be treated with either insulin detemir or NPH insulin once or twice daily as basal insulin. Additionally you will receive insulin aspart as bolus insulin|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The main objective of the study is to assess the safety of self-titration in type 2 diabetic patients on antidiabetic tablets who are receiving insulin for the first time. The study will also look at the blood glucose control, frequency of dose adjustment, clinic visits, and time spent training patients to self-titrate.\\n\\nThe objective of diabetes management is to achieve blood glucose levels as close as possible to normal in order to avoid late stage diabetic complications. Self-titration (where patients adjust insulin dosage themselves) offers the potential for better blood glucose control than titration only at clinic visits. In recent years treatment of type 2 diabetes in the United Kingdom has moved from hospitals to GP surgeries or local clinics. Patients with type 2 diabetes, in general, have not been trained in self-titration to the same degree as patients with type 1 diabetes. Less experience in self-titration could impact the level of blood glucose control and outcome for these patients.\\n\\nData from this study will be pooled with data from NN304-3714 (NCT00825643) and will be reported in the final study report for NN304-3714.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.|Diabetes|Diabetes Mellitus, Type 2 This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of the study is to gather information about hypoglycaemia (low blood glucose) among patients with Type 1 or Type 2 diabetes mellitus. The study is both retrospective and prospective.|Type 1 Diabetes Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases fasting, postprandial and the overall mean glucose concentrations.\\n\\nAim 1.1: To compare the mean fasting, the mean weekly glucose and the standard deviation of weekly blood glucose concentrations as recorded by continuous glucose monitoring prior to and following 6 weeks and 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily. In addition, the time spent at glucose concentrations \\\\>150 and 200mg/dl and \\\\<70 and \\\\<40 mg/dl will also be compared.\\n\\nAim 1.2: To compare the postprandial glucose concentrations following a test meal before and after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily. Glucose concentrations will be measured as areas under the curve for the data obtained from the meal challenge.\\n\\nAim 1.3: To compare HbA1c levels(glycated hemoglobin) before and after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily Hypothesis 2: Treatment with Liraglutide in patients with type 1 diabetes decreases postprandial glucagon concentrations and increases postprandial C-peptide concentrations.\\n\\nAim 2.1: To compare fasting and postprandial glucagon and C-peptide concentrations following a test meal before and after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily.\\n\\nHypothesis 3: Treatment with Liraglutide in patients with type 1 diabetes delays gastric emptying.\\n\\nAim 3.1: To compare the gastric emptying as measured by acetaminophen absorption before and after 12 weeks of treatment with 0.6, 1.2 and 1.8 mg of liraglutide daily.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on blood glucose control in insulin naive type 2 diabetes failing on secondary oral hypoglycaemic agent (OHA).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of NNC0123-0000-0338 (insulin 338) in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 This study is comparing the concentration of a single dose of insulin icodec when administered in the belly, upper arm and thigh on different occasions.\\n\\nParticipants will receive one injection of insulin icodec on three different occasions, each time injected at a different site, i.e. either on our belly, upper arm or thigh.\\n\\nThe study will last for about 34 weeks. Participants will have 23 visits with the study doctor. Informed Consent (V0) visit and screening visit (V1) will be performed on two different days. The informed consent visit may be performed via telephone to minimize personal contact with site staff during the coronavirus outbreak.\\n\\nWomen cannot take part if pregnant, breast- feeding or plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes mellitus inadequately controlled with basal or pre-mix/combination insulin therapy and oral anti-diabetic drugs.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.|Diabetes Mellitus, Type 2 Physical training can improve metabolic health in patients with insulin resistance and/or type 2 diabetes (T2D). The cellular and molecular changes underlying the improvements in metabolic health are multi-factorial and only partly understood, but most likely involve adaptation at a multi-organ level that includes improvements in skeletal muscle glucose uptake and adipose tissue insulin sensitivity.\\n\\nThe aim of this project is to study the transcriptional differences in skeletal muscle and adipose tissue at baseline and after a 3-month physical training program in obese patients with and without T2D and to use this information to identify novel therapeutic targets for improvement of glucose disposal and insulin sensitivity in patients with T2D.\\n\\nThus, the investigators aim to find answers to the question: What is the mechanism behind the effect of physical activity on insulin sensitivity in type 2 diabetes?|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, and complications in diabetic subjects in Asia.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of the trial is to confirm the efficacy of IDeg (insulin degludec) versus IGlar (insulin glargine) in controlling glycaemia. Subjects are to continue their pre-trial metformin treatment.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control, weight change and hypoglycaemic effects in patients with type 2 diabetes with Levemir® compared to Insulatard® under normal clinical practice conditions.|Diabetes Mellitus, Type 2 This study looks at how a new medicine insulin icodec helps in reducing blood sugar levels when given along with semaglutide in patients with type 2 diabetes. Participants will get the medicine insulin icodec once a week in the first part of the study (run-in period-26 weeks). Participants will only enter the second part of the study if the blood sugar levels have not reduced to normal. If blood sugar levels are normal after the first 26 weeks, participants will continue in a 5-week follow up period. In the second part of the study (intensification period-26 weeks), participants will get both insulin icodec and semaglutide once weekly after which they will continue in a 5-week follow up period. Participants will have to inject the study medicines once a week on the same day of the week in a skin fold in the thigh, upper arm or stomach. The study will last for about 13 months. Participants will get a blood glucose meter to check blood sugar levels. In addition, participants will be asked to enter blood sugar levels in the study phone. In addition, Participants will be asked to enter selected few blood sugar values (three times during the study) in a paper diary that will be provided to participants. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.|Diabetes Mellitus, Type 2 The trial is a phase IV clinical trial investigating the impact of Liraglutide on endothelial function and microvascular blood flow in 44 patients with type 2 diabetes mellitus aged 30-65 and HbA1c ranging from ≥ 5.5% ≤ 7.0%. The patients will be randomized into two study arms, one arm will be treated with Metformin monotherapy, the second arm will be treated with Metformin and Liraglutide at an increasing dose (0.6 mg/day to 1.8 mg/day.)|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with biphasic insulin aspart (BIAsp) 30 in patients with type 2 diabetes not optimally controlled on once or twice daily insulin with or without metformin.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is, to investigate the effect of upper gastrointestinal disease on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to compare the efficacy of postprandial plasma glucose of two treatment regimens in Chinese subjects.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 The purpose of this study is to collect information about safety and effectiveness of Ryzodeg® FlexTouch® in participants with diabetes mellitus requiring insulin therapy under routine clinical practice conditions with the aim of identifying or quantifying a safety hazard, early detection of unknown safety problems. Participants will attend the clinic/hospital/medical institution according to usual practice and receive medical care, as agreed with the study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to to investigate if there is a drug-drug interaction between liraglutide and paracetamol (Benuron®) and to investigate the effect of liraglutide on post prandial glucose.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of the trial is to assess the incidence rate and type of SADRs (serious adverse drug reactions).|Diabetes Mellitus, Type 1 The aim of this trial is to evaluate the efficacy and safety of insulin detemir using the 2400 nmol/mL formulation to optimise dosing in subjects with type 1 diabetes on a basal (once daily)-bolus regimen.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of repaglinide and metformin combination therapy in Chinese subjects with type 2 diabetes inadequately controlled with OAD (oral anti-diabetic drugs).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess the implications of switching from insulin glargine (IGlar) to insulin degludec (IDeg) in subjects with type 2 diabetes mellitus.|Prostatic Neoplasms|Exercise|Soccer Training|Androgen Deprivation Therapy Androgen Deprivation Therapy (ADT) is standard treatment for locally advanced or advanced Prostate Cancer (PC).\\n\\nThe musculoskeletal toxicity associated with ADT is well established, leading to a decrease in muscle mass, increased fat percentage, weight gain, sexual dysfunction and increased risk of depression, fatigue, diabetes, cardiovascular disease and reduced quality of life.\\n\\nNumerous studies have shown an association between physical activity, physical capacity and quality of life in cancer patients and recent epidemiological research suggest that regular, moderate-intensity physical activity may have a positive effect on survival in men with prostate cancer.\\n\\nWithin exercise physiology there is new evidence pointing to recreational soccer as a unique form of intermittent exercise that effectively stimulates aerobic and anaerobic energy delivery systems, leading to beneficial musculoskeletal, metabolic and cardiovascular adaptations of importance for health.\\n\\nIt is our overall hypothesis that 12 weeks of recreational soccer training 2-3 times per week will improve the health profile of PC patients receiving ADT treatment.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe, Oceania and South America.\\n\\nThis trial aims for a comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily all in combination with metformin and glimepiride in insulin naive subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe, North America and the United States of America.\\n\\nThe aim of this trial is to compare two different titration algorithms of insulin degludec/liraglutide.|Diabetes|Diabetes Mellitus, Type 1|Delivery Systems This study is conducted in Asia, Europe and North America. The aim of this observational study is to evaluate the safety of NovoPen Echo® by collecting safety information (incidence of technical complaints related to adverse reactions). Study duration: 12-18 weeks.|Diabetes|Gestational Diabetes This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.|Type 2 Diabetes|Chronic Inflammation|Intestinal Permeability This study plans to learn more about the effect of semaglutide once weekly on intestinal permeability in individuals with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i) monotherapy or in combination with either metformin or sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2 diabetes. Subjects will remain on their pre-trial medication.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Africa. The aim of this study is to assess the safety and efficacy of Levemir® treatment for insulin naive patients with type 2 diabetes under normal clinical practice conditions in Algeria.|Diabetes, Type I Prophylactic administration of metabolically active insulin can prevent or delay clinical onset of diabetes in a high risk group of nondiabetic siblings as defined by positivity for autoantibodies against IA-2 (IA-2-A).|Diabetes Mellitus, Type 2 This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.\\n\\nThe study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily.\\n\\nParticipants will get their study medicine in an injection pen. Participants will get a pen for weekly injection and one for daily injection. One will be icodec or degludec and the other will be dummy medicine. The treatment participants get is decided by chance. Participants and the study staff will not know which active medicine they get.\\n\\nThe insulin is injected with a needle in a skin fold in the thigh. The study could last for about 8 months. Participants will have 13 clinic visits and 17 phone calls with the study doctor. At 8 clinic visits participants will have blood samples taken. At 4 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 This this trial is conducted in Europe. The aim of this trial is to compare glycaemic control of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp) in patients previously treated with conventional Biphasic Human Insulin 30/70.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare the efficacy of repaglinide to glyburide and placebo on hepatic glucose metabolism in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This survey is conducted in South America. The aim of this survey is to investigate hypoglycaemia among Insulin-treated patients with diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate the effect of semaglutide on hypoglycaemic counter-regulation compared to placebo in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine. The study will also test if semaglutide is safe in children and teenagers. Participants will either get semaglutide or the dummy medicine - which one is decided by chance. Participants will take 1 tablet of the study medicine every morning on an empty stomach. They have to wait 30 minutes before they eat, drink or take any other medication by mouth. The study will last for about 1 year and 3 months (66 weeks). Participants will have 12 clinic visits and 8 phone calls with the study doctor. At all 12 clinic visits, participants will have blood samples taken. Participants will also be asked some questions.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Tresiba® works in patients with type 2 diabetes in China. The study will be based on data already recorded in participants\\' medical records and no new tests or procedures are required as part of the study. This study does not affect participants\\' current diabetes treatment. The study will look at data recorded in participants\\' medical records for approximately the last year. After signing the informed consent form, no further activities will be required from the participants.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to examine the effect of NNC 90-1170 on the hypoglycaemic counterregulation in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to test for bioequivalence between two formulations of insulin degludec/insulin aspart (IDegAsp) to see if the efficacy and safety obtained with formulation 1 can be assumed identical for formulation 2.|Diabetes|Diabetes Mellitus, Type 1 This trial was conducted in Europe. The aim of this clinical trial was to evaluate the effect on the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Levemir® (insulin detemir) administered once daily according to two titration algorithms after 20 weeks in subjects with type 2 diabetes inadequately controlled on metformin treatment with or without other anti-diabetic drugs (OADs).|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this research is to assess the impact of three basal (long-acting) insulin treatments on blood glucose levels in people with type 1 diabetes when performing physical exercise.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate if liraglutide adjunct to insulin treatment changes the glucagon response during hypoglycaemia in subjects with type 1 diabetes compared with conventional insulin treatment after 4 weeks\\' treatment with liraglutide or placebo.\\n\\nSubjects will initially be randomised to one of the three dose groups, and subsequently randomly allocated to one of two treatment sequences (liraglutide/placebo or placebo/liraglutide).|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of FIAsp (faster-acting insulin aspart) compared to insulin aspart, both in combination with insulin detemir in adults with type 1 diabetes. This trial consists of two periods: a 26 week treatment period followed by a 26 week additional treatment period.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia under normal clinical practice.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.|Type 2 Diabetes High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the hospital complications. Increasing evidence indicates that incretin-based agents are safe and effective for the hospital management of patients with type 2 diabetes (T2D).\\n\\nLiraglutide is a once-daily human glucagon-like peptide (GLP-1) analogue approved for the treatment of T2D. Liraglutide has been shown to lower blood glucose, stimulate endogenous insulin secretion, decrease plasma glucagon levels, inhibit gastric emptying, reduce food intake and body weight and improve ß-cell function when administered subcutaneously. Liraglutide increases insulin secretion in a glucose-dependent manner (i.e., only when plasma glucose levels are elevated), resulting in low-risk of hypoglycemia when used as monotherapy. When compared to insulin glargine therapy, the use of GLP-1 has resulted in comparable reduction in HbA1c level, lower rates of hypoglycemia and less weight gain. No prospective studies; however, have compared the efficacy and safety of liraglutide in the hospital setting or after hospital discharge.\\n\\nThe primary objective is to compare the safety and efficacy of liraglutide (Victoza®) versus glargine insulin in combination to oral anti-diabetic agents (OADs: metformin, sulfonylureas, nateglinide, repaglinide or pioglitazone) on glycemic control after 26 weeks of treatment in medicine patients with T2D after hospital discharge.|Healthy Participants A research study to investigate how quickly and to what extent different compositions of the study medicine ziltivekimab are absorbed, transported, and eliminated from the body. Ziltivekimab is not yet approved for market. The study medicine will be injected under the skin (this is called subcutaneous administration). Two different administration methods will be compared: a syringe and a pen-injector. A pen-injector is a device that is developed to make injections more easy and convenient. They are for example used by diabetes patients to inject insulin. It will also be investigated how safe ziltivekimab is and how well it is tolerated when it is used by healthy participants. Ziltivekimab has already been administered to patients with chronic kidney disease or rheumatoid arthritis. The current study will be the first study where ziltivekimab will be given to healthy participants.|Type 2 Diabetes Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). We propose a double-blind, randomized controlled study comparing the effect of liraglutide (a novel anti-diabetic drug with beta-cell protective potential) versus placebo, on the preservation of beta-cell function over one year in patients with T2DM. This study may demonstrate an important beta-cell protective capacity of liraglutide.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to evaluate the effect of Levemir® (insulin detemir) on glycaemic control, weight and incidence of hypoglycaemic events in insulin treated subjects with type 1 or type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment.\\n\\nThe trial medication will be add-on to the subject\\'s stable pre-trial OAD and/or insulin regimen.|Diabetes|Diabetes Mellitus, Type 1 This trial was conducted in Europe. The aim of this study was to investigate the total exposure of NN5401 (insulin degludec/insulin aspart) in children, adolescents and adult subjects with type 1 diabetes.|Diabetes Mellitus, Type 2 The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes patients across ten countries across the world. Participants will be asked to give information about their health. Participants will continue their normal way of life and will not get any medication other than prescribed to them by their doctor. Participants\\' participation will be one day/one visit at their doctor. The study will last for about 6 months in total.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic properties (the effect of the investigated drug on the body) of NN1218 in subjects with type 1 diabetes.|Overweight and Obesity Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight.\\n\\nThis study will look at the change in participants\\' body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets (\\'dummy\\' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation.\\n\\nSemaglutide tablets are new medicine being tested to treat overweight and obesity. Doctors in many countries can already prescribe semaglutide tablets at lower doses to treat type 2 diabetes.\\n\\nParticipants will get semaglutide or placebo tablets for 68 weeks and will need to take 1 tablet every morning.\\n\\nIn addition to taking the medicine, participants will have talks with study staff about:\\n\\n* healthy food choices\\n* how to be more physically active\\n* what participants can do to lose weight The study will last for about 1½ year. Participants will have 14 clinic visits and 7 phone calls with the study healthcare professional.\\n\\nBlood samples will be taken at 12 visits. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period. If participants are a woman and are able to become pregnant, participants will be checked for pregnancy via urine tests.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to compare the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®) given as a bolus on top of a basal continuous subcutaneous insulin infusion (CSII).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to evaluate efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD (thiazolidinedione) in subjects with type 2 diabetes.|Type 2 Diabetes Mellitus The HOME-trial is a prospective, randomized controlled trial. The purpose of this study is to investigate the effects of metformin HCL in patients with type 2 diabetes mellitus intensively treated with insulin on the quality of the metabolic control of diabetes, the daily dose of insulin, the lipid profile, the blood pressure, the incidence / progression of microvascular and macrovascular complications, and on the qualify of life (Diabetes Health Profile). Early results had been published in Diabetes Care, December 2002, pages 2133-2140.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetic (the rate at which the body eliminates the trial drug) and pharmacodynamic (the effect of the trial drug on the body) profiles of NN1218 in comparison with insulin aspart.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate Pharmacodynamics (the effect of the investigated drug on the body) , Pharmacokinetics (the exposure of the trial drug in the body), and Safety of NNC0143-0406 in Subjects with Type 1 Diabetes Mellitus|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled with SU (sulphonylurea) alone or in combination with metformin. All subjects will continue their pre-trial SU treatment with or without metformin treatment without changing the frequency or dose throughout the trial.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower participant\\'s blood sugar levels. Participants will get Rybelsus® as prescribed by the study doctor. The study will last for about 8-10 months. Participant will be asked to complete a questionnaire about how the participant will take Rybelsus® tablets. Participant will complete this questionnaire during the normally scheduled visit with the study doctor. Participant will be asked to complete some questionnaires about diabetes treatment. Participant will complete these questionnaires during normally scheduled visits with the study doctor.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood glucose lowering effect and the safety profile of repaglinide given alone compared to gliclazide given alone in Chinese subjects with type 2 diabetes who never have been treated with oral anti-diabetic drugs (OADs). This study also investigates the augment effect of repaglinide on the phases of insulin secretion as a subgroup study.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes mellitus.|Type 2 Diabetes The main purpose of this study is to explore experiences and understand the unmet needs of people with Type 2 Diabetes (T2D) among those who are being managed with basal insulin and those who are insulin naïve in order to understand perspectives for a once weekly insulin option; including any potential barriers to being managed with insulin therapy overall. Study participants will be recruited to complete a 15-minute self-administered online survey.|Diabetes|Diabetes Mellitus, Type 2 This trial was conducted in Russian Federation. This trial aimed for a comparison of the effect on glycemic control in subjects with type 2 diabetes of three different treatment regimens: biphasic insulin aspart 30 thrice daily, biphasic insulin aspart 30 twice daily in combination with metformin and treatment with oral anti-diabetic drugs.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The aim of this trial is to assess control of blood sugar, safety, and patient acceptance of insulin aspart compared to insulin lispro, both in insulin pumps, in standard clinical practice.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of faster-acting insulin aspart in subjects with Type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this study is to investigate a retrospective database assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide from primary care centers in Sweden.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with type 2 diabetes. Subjects continue their pre-trial treatment with metformin throughout the entire trial.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Africa, Asia, Europe and the United States of America (USA).\\n\\nThe aim of this trial is to investigate the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to observe the efficacy of Levemir® treatment in patients with type 2 diabetes in everyday clinical practice in Switzerland. Furthermore the time period between diagnosis of type 2 diabetes and insulin initiation is evaluated.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in subjects with type 2 diabetes in Malaysia.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2|Delivery Systems This trial is conducted in the United States of America (USA). This is an in-patient trial investigating stepwise dose increase in a period of up to 3-weeks followed by a 10-week out-patient maintenance period. A telephone contact visit is scheduled as a follow-up for the final clinic visit. A subject\\'s participation in this trial would be expected to be up to 16 weeks.|Type 2 Diabetes Mellitus|Obesity The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a high-dose insulin regimen (\\\\>1.8 units/kg/day) in patients with uncontrolled (HbA1c \\\\>7.5%) type 2 diabetes mellitus will improve blood sugar control.\\n\\nIt also evaluates the effect of liraglutide on liver and pancreatic fat content, explores the mechanism of blood sugar improvement by assessing weight and pancreatic hormone release, and assesses blood pressure, lipid profile, and liver function. Finally it will look at patient quality of life and safety.|Diabetes Mellitus, Type 2 Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called \"semaglutide\" for the treatment of type-2 diabetes (T2D). It is expected that the combination will further improve the blood sugar control compared to semaglutide therapy alone. The study will investigate the influence of the combination of semaglutide and NNC0480-0389 on the blood levels of a birth control pill (a combined oral contraceptive consisting of ethinylestradiol and levonorgestrel) and paracetamol. Participants will get semaglutide and NNC0480-0389 as injection under the skin of their belly using a pen-injector. The injections will be given once weekly for 14 weeks. Additionally, participants will at two occasions get paracetamol as soluble tablet in connection with a standardised breakfast meal. Further, participants will get the birth control pill in form of tablets in two periods of 8 days each. Participants will get the combination of semaglutide and NNC0480-0389 as well as paracetamol and the combined contraceptive in any case. The study participation will last up to about 24 weeks. Participants will have 25 visits at the study centre. For 4 of the visits participants will stay at the study centre; the remaining visits will be outpatient. Only healthy postmenopausal women can take part in this study.|Diabetes Mellitus, Type 2 This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and North America. The aim of this trial is to compare the efficacy and safety of adding liraglutide versus addition of insulin aspart with the largest meal to insulin degludec in subjects with type 2 diabetes.\\n\\nEligible subjects with an HbA1c equal to or above 7% at end of treatment in NN1250-3643 (NCT01193309) trial will be randomised to receive treatment intensification while subjects with an HbA1c below 7% at end of treatment in NN1250-3643 (NCT01193309) may continue to receive insulin degludec treatment. Subjects are to continue their pre-trial metformin treatment.|Diabetes|Type 2 Diabetes Mellitus This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of subcutaneously administered NNC0148-0287 (insulin 287) in subjects with type 2 diabetes|Healthy Volunteers|Diabetes Mellitus, Type 2 This study is investigating the safety and tolerability of the new medicine NNC0472-0147, its concentrations in the blood and its effect on blood sugar for the treatment of diabetes. Another goal of the study is to determine an effect of NNC0472-0147 on cholesterol. The first part of the study is conducted in healthy people, while the second part involves people with type 2 diabetes (T2DM). The study will test how NNC0472-0147 is tolerated by the body, how it is taken up in the blood, how long it stays there and how much blood sugar is lowered. In part 1, participants will either get the new medicine NNC0472-0147 or placebo (an injection that does not contain active medicine) - which treatment is decided by chance. In part 2, participants will either get the new medicine NNC0472-0147 or insulin glargine - which treatment is decided by chance. It is the first time that NNC0472-0147 is tested in humans. Participants will get once daily injections of either NNC0472-0147 or insulin glargine for a treatment period of fourteen days. The injections will be given under the skin (subcutaneously, s.c.) of the left thigh. Participants will be in the study for about 7 weeks. There will be 15 visits with the study doctor. People cannot be in the study if the study doctor thinks that there are risks for their health. Only women who cannot become pregnant are allowed to participate.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve subjects with type 2 diabetes mellitus inadequately controlled with oral anti diabetics.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this trial is to investigate the efficacy of insulin detemir on blood glucose control in type 2 diabetes when added to current OHA treatment.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This observational study is conducted in Africa. The aim of this observational study is to evaluate the efficacy and the incidence of serious adverse drug reactions while using insulin Levemir® under normal clinical practice conditions.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.\\n\\nParticipants will be asked to complete some questionnaires about their diabetes treatment. Participants will complete these during normally scheduled visits with the study doctor.|Diabetes Mellitus, Type 2 The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo (\\'dummy medicine\\'). This is known as participants\\' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this clinical trial is to compare the pharmacodynamics (i.e. the glucose-lowering effect of the study medication over the entire observation phase from the time of administration and the efficacy period) and the pharmacokinetics (i.e. amount of the study insulin that can be determined in the blood) of a treatment with biphasic insulin aspart 30 (BiAsp 30) administered once, twice or thrice daily and biphasic human insulin 30 administered once daily in type 2 diabetic subjects|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to collect efficacy and safety data of biphasic insulin aspart (NovoMix® 30) in type 2 diabetes under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to describe the conditions for the concomitant administration of a slow-acting insulin analogue with oral antidiabetics (OADs) in order to improve blood glucose control in type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial was conducted in Europe. The aim of this trial was to compare the pharmacodynamic (the effect of the investigated drug on the body) response of insulin degludec (insulin 454) with insulin glargine at steady-state conditions in subjects with type 1 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of biphasic insulin aspart (BIAsp) 50 (NN-X14Mix50) compared with biphasic human insulin (BHI) 50 in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in North America. The aim of this trial is to evaluate the safety of insulin detemir for the treatment of diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare FIAsp (faster-acting insulin aspart) to insulin aspart, both in combination with insulin glargine and metformin in adults with type 2 diabetes.|Diabetes Mellitus, Type 2 This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken with insulin aspart. Participants will either get IcoSema or insulin glargine taken with insulin aspart. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe insulin glargine and insulin aspart in many countries.\\n\\nParticipants will get IcoSema or insulin glargine together with insulin aspart. Participants must inject IcoSema once a week or inject insulin glargine once daily and insulin aspart 2-4 times a day. Participants will inject the medicines with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will be asked to wear a sensor that measures participants blood sugar level all the time during an 8 week period at the beginning of the study and a 4 week period at the end of the study.\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 This study will look at a new medicine, called IcoSema, for treatment of type 2 diabetes.\\n\\nIcoSema is a combination of a new insulin, called insulin icodec, and a GLP-1 receptor analogue, called semaglutide.\\n\\nInsulin icodec is a possible new medicine. That means that the medicine has not yet been approved by the authorities. Semaglutide is a medicine already approved by the authorities in the EU, USA, China and Japan.\\n\\nThe study will look at the way insulin icodec and semaglutide reach and stay in participants blood after injection when given together as IcoSema or alone as insulin icodec and semaglutide.\\n\\nParticipants will get each of the 3 medicines (IcoSema, insulin icodec and semaglutide) at 3 different timepoints:\\n\\nThe order in which participants get them is decided by chance. Participants will get the 3 medicines as an injection under the skin in the thigh. The injections will be done by study staff. The time between injections is 6 to 9 weeks.\\n\\nThe study will last for about 19 to 26 weeks. Participants will have 31 or 32 visits to the clinic. 3 of the visits will be in-house visits, meaning that participants will stay at the clinic for 5 or 6 days (4 or 5 nights).\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents|Diabetes Mellitus, Type 2 Novo Nordisk is developing a combination therapy with the study medicine NNC0480-0389 and an already approved medicine called \"semaglutide\" for the treatment of type-2 diabetes (T2D). It is expected that the combination will further improve the blood sugar control compared to semaglutide therapy alone.In this study the blood levels of NNC0480-0389 will be compared in people with various degrees of reduced kidney function to the blood levels in people with normal kidney function, after administration of one dose of 18 mg NNC0480-0389. Participants will only get the study medicine as two injections into a skinfold of participants belly (subcutaneous).\\n\\nThe study will last for about 65 days including a screening phase of up to 28 days prior to dosing.\\n\\nIf participants are eligible for the study, participants will have 11 visits to the study centre including one in-house stay of 5 days and 4 nights (Visit 2) and nine ambulatory visits (Visit 3 to Visit 11).\\n\\nParticipants\\' vital signs (heart rate, blood pressure, body temperature) will be measured, participants will have blood drawn, urine will be collected and electrocardiograms (ECGs) will be recorded.If participants are women and can get pregnant they cannot take part in the study. A hormone test will be done to check if participants may be post-menopausal.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this research is to assess the safety of continuous treatment with insulin detemir following participation in trial NN304-1689 (NCT00435019) on antibody development.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to investigate the incidence of serious adverse drug reactions when using NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) for treatment of type 2 diabetes mellitus under normal clinical practice conditions in Macedonia.|Diabetes Mellitus, Type 2 This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.\\n\\nThe study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily. Participants will either get insulin icodec that participants will have to inject once a week on the same day of the week or insulin degludec that participants will have to inject once a day at the same time every day. Which treatment participants get is decided by chance.\\n\\nThe insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach.\\n\\nThe study will last for about 8 months. Participants will have 17 clinic visits and 13 phone calls with the study doctor. At 8 clinic visits participants will have blood samples taken. At 4 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.\\n\\nParticipants will be asked to wear a sensor that measures their blood sugar all the time in 3 periods for a total of 13 weeks (about 3 months) during the study.\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes Mellitus, Type 2 The purpose of this study is to investigate glycaemic control and other clinical parameters in glucagon like peptide -1 (GLP-1) naive adult participants with type 2 diabetes (T2D) who initiated once weekly (OW) semaglutide in local clinical practice in North Macedonia. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians\\' discretion. The total duration of the study is planned to be approximately 30 weeks which is the period from OW semaglutide initiation to end of follow up.|Chronic Kidney Diseases|Albuminuria|Diabetic Kidney Disease|Diabetic Nephropathies|Diabetes type2|Molecular Sequence Variation|Kidney Biopsy a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.|Type 2 Diabetes Mellitus Liraglutide, a GLP-1-analogue has been shown to be an effective treatment option in patients on oral anti-diabetes therapy with beneficial effects on both glycaemic control and weight. However, to date there are no clinical trials of liraglutide added to insulin therapy, a population of patients generally having worse glycaemic control and weight gain. In clinical guidelines, use of multiple daily insulin injections (MDI) is usually the final therapeutic option for type 2 diabetic patients.\\n\\nThe primary study aim is to evaluate whether the addition of liraglutide, compared to placebo, reduces the HbA1c level for overweight and obese type 2 diabetes patients with inadequate glycaemic control treated with multiple daily insulin injections (MDI). MDI is defined as treatment with any basal insulin combined with separate meal time insulin injections before the main meals, i.e. an insulin regimen with premixed insulin is not considered as MDI.\\n\\nThe planned study duration is 24 weeks and includes 120 patients at 15 centers in Sweden.|Diabetes Mellitus Type 2|Metabolic Syndrome|Cardiovascular Disease|Diastolic Dysfunction|Fatty Liver The most important cause of mortality amongst DM2 patients is cardiovascular disease. An early finding of cardiovascular disease in DM2 and obesity is diastolic dysfunction. Diastolic dysfunction is an independent predictor of mortality and has been shown to improve in patients on a low calorie diet. The improvement of diastolic function was associated with a reduction in triglyceride accumulation in the heart and liver. A relatively new widely prescribed therapeutic agent for DM2 patients is Liraglutide (Victoza®). Liraglutide is a Glucagon Like Peptide - 1 homologue that improves glucose homeostasis and reduces blood pressure and body weight. Next to the induction of weight loss, which is potentially beneficial for cardiac function, GLP-1 therapy might have a direct advantageous effect on the cardiovascular system. However, the effect of Liraglutide on cardiovascular function has not been investigated yet. The investigators hypothesize that treatment of DM2 patients with Liraglutide is associated with improvement of cardiovascular function and a reduction of triglyceride accumulation in end-organs.|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study looks at how faster aspart reaches and stays in the blood after injection in Chinese people with type 1 diabetes or type 2 diabetes, compared to the reference product called NovoRapid®. Participants will get both faster aspart and NovoRapid®. The order in which Participants get them is decided by chance. Participants will get each study medicine once during the study meaning that they will get a total of 2 injections with study medicines. The medicine will be injected under the skin of the lower abdomen. The study will last for about 19-72 days. Participants will have 5 clinic visits with the study doctor (including the one in which participants give their consent). Participants will need to stay overnight for 2 of the 5 clinic visits. Participants will have blood samples taken during some of the clinic visits. During the visits where participants get the study medicines, samples of their blood will be taken several times for up to 12 hours after getting the study medicine.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The primary objective of this study is to evaluate the clinical safety profile during 26 weeks of NovoNorm® (repaglinide) and insulin analogue combination therapy in type 2 diabetes under normal clinical practice conditions in Korea while the secondary objective is to evaluate the safety and efficacy after 13 and 26 weeks of NovoNorm® and insulin analogue combination therapy in type 2 diabetes under normal clinical practice conditions in Korea.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) of insulin degludec (insulin 454), an explorative formulation, not similar to the proposed commercial formulation, under single-dose and steady-state conditions in male subjects with type 1 diabetes.|Type 1 Diabetes The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin analogues will improve post prandial glycaemic control in patients with type 1 diabetes.\\n\\nOBJECTIVE:\\n\\nThe objective is to describe pharmacodynamic (PD) and pharmacokinetic (PK) profiles of Insulin Aspart (IAsp), Biphasic Insulin Aspart (BIAsp) 30, 50 and 70 for a period of 12 hours following a standard test meal on four days respectively in subjects with type 1 diabetes.|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is to investigate the effects of Fiasp®, a mealtime insulin, in patients with diabetes mellitus. The purpose of this study is to collect information about Fiasp®, which is prescribed to the participants by their doctors. Participants will administer Fiasp® as prescribed by their doctors. The study will last for about 6 months.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia and Africa. This trial aims for a comparison of blood glucose control of biphasic human insulin 100 IU/mL and EX1000.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial investigate the the long-term safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 This study looks at different tablets with a new study medicine called semaglutide. It is to treat diabetes. The aim of the study is to find out how much study medicine from 4 different tablets is taken up in the body. Participants will either get semaglutide in the tablet currently being studied in large studies, or 1 of the 3 new tablets that also contains \\'semaglutide\\' - which treatment participants get is decided by chance. The tablet version of study medicine is a new medicine that cannot be prescribed. Semaglutide can be prescribed as injections for the treatment of diabetes in some countries. Participants will get 1 tablet per day for 10 days. The tablets should be taken in the morning by mouth together with half a glass of water. After dosing participants have to wait 30 minutes before participants may eat or drink. The study will last up to 70 days. Participants will have 17 clinic visits with the study doctor. Some of the visits are overnight stays. Participants will have blood tests at every visit.|Diabetes Mellitus, Type 2 The study will look at how insulin 287 and semaglutide work in the body, both when given alone or together. This study will look at the way insulin 287 and semaglutide reach and stay in participants\\' blood after injection when given alone or together. Participants will get 3 study medicines at 3 different time points: 1) a combination of semaglutide plus insulin 287, 2) insulin 287 alone and 3) semaglutide alone. The order in which participants get them is decided by chance. Participants will get all medicines as an injection under the skin in the thigh. The injections will be done by study staff. The time between injections is 6 to 9 weeks. The study will last for about 19 to 32 weeks in total.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe, and North America. The aim of this clinical trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes currently treated with metformin alone or with metformin combined with an oral anti-diabetic drug (OAD) qualifying for intensified treatment.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to determine diabetes control improvement, during the third month of follow-up after insulin intensification to at least 3 daily insulin injections, in assessing the proportion of uncontrolled fasting and postprandial glycaemia values recorded on a diary.|Type2 Diabetes|Nonalcoholic Steatohepatitis|Non-Alcoholic Fatty Liver Disease|Atherosclerosis|Dyslipidemias Further studies are needed to establish the optimal diet for treating T2D.\\n\\nThe investigators wishes to investigate whether a low carbohydrate diet, high in monounsaturated fats (LCD) will affect cardiovascular function, metabolism and the liver.\\n\\n135 participants with T2D, will be following either a LCD, or a regular diabetes diet (RDD) for 6 months. Measurements and investigations will be performed at baseline and after 6 months.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Asia.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type 2 diabetes mellitus in Korea.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems This study is conducted in Asia. The aim of this observational study is to evaluate subjects\\' treatment satisfaction and to evaluate subjects\\' preference of pen device and the incidence of clinical technical complains while using NovoPen® 4 under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics and pharmacokinetics after a single dose of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and insulin aspart in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Africa, Europe and the United States of America (USA).\\n\\nThe aim of the trial is to compare NN1250 (insulin degludec, soluble insulin basal analogue (SIBA)) plus insulin aspart with insulin glargine (IGlar) plus insulin aspart in patients with type 1 diabetes.\\n\\nThe main period is registered internally at Novo Nordisk as NN1250-3583 while the extension period is registered as NN1250-3644.|Diabetes|Diabetes Mellitus Type 2 This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections of NNC0090-2746 for 12 weeks, as an adjunct to metformin, in participants with T2D.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy of insulin decludec with insulin glargine on glycaemic control using continuous glucose monitoring in patients with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 The study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control in patients using a modern insulin: NovoRapid®, NovoMix® 30 or Levemir® for the treatment type 2 diabetes.\\n\\nFull acronym for this study: COMMIT - CLEAN SWITCH|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to evaluate safety and efficacy in children with type 1 diabetes.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Ryzodeg® works in real world patients and to see if Ryzodeg® can lower blood sugar levels. Participants will get Ryzodeg® as prescribed to them by their doctor. The study will last for about 6 to 9 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor\\'s appointment.|Type 2 Diabetes Mellitus|End-stage Renal Disease Incretin-based therapy for the treatment of patients with type 2 diabetes mellitus (T2D) is new and fundamentally different from the classical treatments with oral antidiabetic agents and insulin. The novel and original aspect of this investigator-initiated study is the focus on treatment with an incretin-based agent (the GLP-1 analogue liraglutide) in T2D patients with severely reduced kidney function. At present there is virtually no knowledge of the physiology and clinical implications of the role of incretin hormones and incretin-based therapy in this group of diabetic patients.The aim of the study is to establish an evidence-based rationale for introducing a GLP-1 analogue to the limited armamentarium of antidiabetic drugs for patients with type T2D and severe renal insufficiency. The overall hypothesis is that patients with T2D and severe renal insufficiency will tolerate and benefit from treatment with the GLP-1 analogue liraglutide, hereby improving glycaemic control and reducing risk factors of cardiovascular disease|Type1 Diabetes Mellitus The purpose of this study is to reduce the frequency of hypoglycemia and severe hypoglycemic events in subjects who use insulin pens to treat their Type 1 Diabetes Mellitus (T1DM). Hypoglycemia is the number one fear of many individuals and families with someone who has type 1 diabetes, and this fear often prevents optimal glycemic control. It is expected that this protocol will yield increased knowledge about using a decision support system to help control the glucose level.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to investigate the percentage of patients reaching the treatment target on blood glucose control after treatment with either human insulin or insulin analogues in type 2 diabetes subjects inadequately controlled with two or more oral antidiabetic drugs in China. Further the safety profiles will be evaluated.|Type 2 Diabetes|Cardiovascular Risk|Hemostasis|Inflammation|Endothelial Function The purpose of this study in patients with type 2 diabetes was to investigate the acute effect of postprandial blood glucose levels modified by two different insulin treatment regimens on coagulation activation, inflammation and endothelial cell function. The investigators hypothesized that the rapid-acting insulin analogue aspart has a beneficial postprandial effect on coagulation, endothelial dysfunction and inflammation compared with the intermediate-acting insulin NPH due to its ability to lower postprandial glycaemia.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to evaluate the safety profile of insulin aspart in subjects with type 1 diabetes having participated in trial ANA/DCD/035.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Healthy This study is conducted in the United States of America (USA). The aim of this study is to assess longitudinal variation of immune biomarkers in subjects with type 1 diabetes (T1D), type 2 diabetes (T2D) and healthy, non-diabetic subjects over a one year period.|Maturity-onset Diabetes of the Young The purpose of this study is to evaluate the treatment potential of GLP-1-analogues in patients with Maturity Onset Diabetes of the Young (MODY) compared to common treatment.|Healthy Volunteers|Overweight|Obesity|Diabetes Mellitus, Type 2 The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide. This will be investigated in healthy participants, participants with high bodyweight and participants with type 2 diabetes (T2D). NNC0480-0389 has not been given to humans before. It has been previously tested in the laboratory and on animals. NNC0480-0389 will be tested at various dose levels. Semaglutide is a new approved drug and is already available on the market for treatment of diabetes. It will also be investigated how quickly and to what extent NNC0480-0389 and semaglutide are taken up and eliminated from the body. This is called pharmacokinetics. The effect of NNC0480-0389 given together with semaglutide will also be investigated on body weight and glucose levels in the blood. This is called pharmacodynamics. The effects of NNC0480-0389 and/or semaglutide will be compared to the effects of a placebo. A placebo is a \"dummy\" medicine without any active medicine. Placebo looks like NNC0480-0389 and/or semaglutide. There are 4 possibilities for which treatment participants will get; participants will receive NNC0480-0389 and semaglutide or NNC0480-0389 and placebo or placebo with semaglutide, or placebo with placebo. Participants and the responsible doctor will not know which combination participants will be given. This is called a double-blinded study. However, this information can be looked up during the study if it is important for participants\\' health. The study medicines will be given as injections under the skin. Participants will be in the study for about 25 weeks.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics (the determination of the concentration of the administered medication in blood over time) and pharmacodynamics (the determination of the effect over time and the duration of action) of multiple doses of liraglutide in the pediatric population (children).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). This trial aims for a comparison of the safety and efficacy in subjects with type 2 diabetes using either self titration or physician guided titration according to the local standard of care.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). The study will compare A1C reduction achieved in patients receiving biphasic insulin aspart 70/30 once or twice daily to patients receiving exenatide twice daily. Patients enrolled in the study will be insulin naive patients who have not achieved glycemic control with metformin and sulfonylurea.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart (NovoMix®30) to that of biphasic human insulin (Mixtard® 30) in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart 70 + biphasic insulin aspart 30 with biphasic human insulin 30 in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, South America and the United States of America (USA).\\n\\nThe aim of this clinical trial is to determine whether two insulin treatments given once daily are equally effective with respect to the blood glucose lowering effect in subjects with type 2 diabetes inadequately controlled on metformin treatment with or without an additional anti-diabetic drug (OAD).|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insulin detemir twice daily injection administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight and side effects).|Diabetes Mellitus, Type 1 This study compares insulin icodec (a new insulin) to insulin degludec (an insulin already available on the market) in people with type 1 diabetes.\\n\\nThe study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin degludec taken daily.\\n\\nParticipants will either get insulin icodec that participants will have to inject once a week on the same day of the week, or insulin degludec that participants will have to inject once a day at the same time every day. Which treatment participants get is decided at random. Participants will also get a mealtime insulin.\\n\\nThe insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach.\\n\\nThe study will last for about 1 year and 2 months. Participants will have 28 clinic visits and 28 phone calls with the study doctor. At 11 clinic visits participants will have blood samples taken.\\n\\nAt 6 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.\\n\\nParticipants will be asked to wear a sensor that measures your blood sugar all the time. Participants will be asked to wear it for a total of 57 weeks (around 1 year).\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Gastric Bypass|Obesity In many studies, gastric bypass surgery led to total remission of type 2 diabetes (T2DM) as early as 1 - 2 days after surgery before any real weight loss has occurred. This suggests that the remission of the T2DM is due to the direct effect of the operation, more than the secondary effect of the weight loss. The reasons for the major effect on the glucose metabolism after gastric bypass surgery are still unaccounted for.\\n\\nThe aim of this project will be to unveil some of the mechanisms that explain the effect of gastric bypass surgery on the glucose metabolism. Further more to find a better way of testing patients that have just undergone gastric bypass surgery. It is not possible to test patients who have just undergone gastric bypass surgery with normal oral glucose tolerance test (OGTT) and a normal meal, because patients can only take in fluid and a normal OGTT will often lead to dumping. Instead we will try to modify these tests - OGTT with lower glucose level and meal-testing with a protein drink.\\n\\nThe hypothesis of the study is that the investigators can see changes in different hormones and adipokines before and after surgery, even with modified OGTT and meal testing. The project will consist of clinical trials on patients without T2DM that will undergo gastric bypass surgery. The studies will take place before and within the first week after surgery. The investigators will measure different hormones and adipokines after OGTT and a meal with a protein drink. The investigators expect to see significant changes in some of the analyses after the operation in patients undergoing gastric bypass.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to evaluate the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The purpose of the trial is to investigate the efficacy and safety of liraglutide in combination with insulin therapy compared to insulin alone in Japanese subjects with type 2 diabetes mellitus. Subjects will remain on their pre-trial insulin therapy.|Hyperglycemia|Chronic Heart Failure Type 2 diabetes (T2D) is a major risk factor of chronic heart failure (CHF). Glycemic control in patients with the combination of T2D and CHF is complicated and the currently available treatments have proven to be inadequate in clinical trials.\\n\\nObjectives To investigate the effect of Liraglutide compared to placebo on left ventricular ejection fraction (LVEF) in CHF patients with and without T2D.\\n\\nMulticenter, randomized, double blind study of 240 patients with documented systolic CHF (50% with T2DM) will be randomised. The effect of Liraglutide on left ventricular systolic and diastolic function will be evaluated by advanced echocardiography\\n\\nPrimary outcome parameter is change in LVEF from visit 1 to week 24.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe and South America. The aim of this trial is to compare the glycaemic control of insulin detemir plus insulin aspart with that of insulin NPH plus human soluble insulin in subjects with type 1 diabetes on a basal/bolus regimen.|Diabetes Mellitus, Type 2 The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.\\n\\nParticipants will be asked to complete some questionnaires about their diabetes treatment. Participants will complete these during their normally scheduled visits with the study doctor.|Obesity|Overweight This study will look at the change in the participant\\'s body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking \"dummy\" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk of type 2 diabetes. Therefore, weight loss has shown to have a beneficial impact on the blood sugar levels. The participant will either get semaglutide or \"dummy\" medicine - which treatment the participant get is decided by chance. The participant will need to take 2 injections at the same time once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 1.5 years|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Delivery Systems This trial is conducted in Europe. The aim of this trial is to compare two insulin delivery pens in the everyday life setting of patients with diabetes treated with insulin.|Diabetes|Diabetes Mellitus, Type 1 The aim of the study is to compare the pharmacokinetics (i.e. the course of the blood concentrations of the administered trial drug) of faster-acting insulin aspart (faster aspart), and the currently marketed formulation of insulin aspart (NovoRapid®) when given as a bolus using an insulin pump in people with type 1 diabetes. The pharmacodynamic response (i.e. the course of the blood sugar lowering effect of the administered trial drug) and the safety and tolerability of faster aspart and NovoRapid® will also be assessed.\\n\\nThe participants will be in the study for approx. 21 days. Each participant will have 5 visits to the clinic, with an overnight stay at both dosing visits. Participants will have a number of tests, and they will have to give blood and urine samples.|Diabetes Mellitus, Type 2 This study is looking at the way insulin icodec stays and moves over time in the blood after injections in Chinese people with type 2 diabetes.\\n\\nParticipants will get insulin icodec once a week for 6 weeks. The medicine will be injected under the skin of the thigh. There will also be a run-in period that will last between 1 week and 8 weeks with daily doses of insulin degludec before start on insulin icodec.\\n\\nThe study will last for about 15 to 22 weeks. Participants will have about 17 visits with the study doctor including phone contact during your run-in period.\\n\\nParticipants will have blood samples taken at the clinic visits. Several samples of participants blood will be taken for up to 48 hours after getting the first and the last dose of insulin icodec.\\n\\nParticipants must be a Chinese person diagnosed with type 2 diabetes for at least 6 months and be on basal insulin treatment for at least 2 months before participating in the study.\\n\\nWomen: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2 diabetes never treated with insulin followed by the extension trial investigating the long-term safety and tolerability in terms of comparing NN1250 with insulin glargine in subjects with type 2 diabetes.\\n\\nAll oral anti-diabetic drug (OAD) treatment will be discontinued when trial participant enters the main trial (NN1250-3579) with the exception of metformin and dipeptidyl peptidase-IV (DPP-IV) inhibitor treatment (only in countries where DPP-IV inhibitor treatment is approved for combination treatment together with insulin, otherwise DPP-IV inhibitor treatment is also discontinued). Subjects who consent to participate in the extension trial will continue the treatment (NN1250 or insulin glargine + oral antidiabetic drugs (OADs)) to which they were randomly allocated in the 52 week main trial.\\n\\nThe main period is registered internally at Novo Nordisk as NN1250-3579 while the extension period is registered as NN1250-3643.|Healthy Volunteers|Diabetes Mellitus, Type 2 This study looks at the way a new medicine tablet called semaglutide moves in and throughout the body over time. It will also look at if the medicine is safe and the body can accept it. The new medicine is planned to treat diabetes. The aim of the study is to see how semaglutide tablets work in healthy people who are Chinese. Participants will either get oral semaglutide tablets or placebo (dummy) tablets - which treatment is decided by chance. The tablet form of semaglutide is a new medicine that cannot be prescribed. Doctors can prescribe semaglutide as an injection only. It is for the treatment of diabetes in some countries. Participants will get 1 tablet per day for 12 weeks (84 days). Participants will get 1 tablet a day to take with up to half a glass of water (maximum 120 mL). Participants must take the tablet first thing in the morning on an empty stomach (water is allowed until 2 hours before taking the tablet). After taking the tablet, participants must not eat or drink anything for at least 30 minutes. After 30 minutes, they can have their first meal of the day and take any other medicines they may need, such as birth control tablets, routine vitamins and use of paracetamol at times.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of three different premixed insulin analogues given in combination with an oral anti-diabetic drug.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. This trial aims for a comparison of the efficacy and safety of Insulin Aspart, given in a fixed or in a flexible supplementary insulin therapy, with or without Insulin Detemir plus Metformin, if needed, in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia, Europe, Oceania and South America. The aim of this clinical trial is to generate data demonstrating how to intensify diabetes treatment using BIAsp 30 (biphasic insulin aspart 30) by adding or substituting BIAsp 30 to sitagliptin in various regimens for type 2 patients inadequately controlled on sitagliptin and metformin (with or without other oral anti-diabetic drugs (OADs)).\\n\\nThe trial is conducted as a phase 4 trial in the majority of the participating countries. However, in some countries the trial is conducted as phase 3b.|Healthy Volunteers (Diabetes Mellitus, Type 2) NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes, as it is expected to lower elevated sugar levels in the blood. The medicine may also lower the appetite. This could help reducing overweight which is often present in participants with type 2 diabetes. In this study NNC0519-0130 is given to humans for the first time. This study will be looking into how safe the new medicine NNC0519-0130 is and will measure its concentrations in the blood. Moreover, effects on blood sugar, blood fat and body weight will be tested. There are different study parts with different participants. Healthy participants (men), healthy participants (men) with high body weight and people with diabetes (men and women) take part. Single doses and multiple doses are tested and the medicine is studied as an injection or when given orally (as a tablet). The participants are invited to take part in a part of the study which will look at the effects of weekly injected doses of NNC0519-0130 taken over the course of several weeks. It is planned that participants will be given the study medicine once weekly. The dose will be increased every three weeks, if safety and tolerability allow. Participants will take up to six different dose levels. This means that the period with weekly injections of study medicine will in total last up to 18 weeks. Participants will either get the study medicine NNC0519-0130 or placebo (a \\'dummy\\' medicine that looks like the medicines but without any active medicine). Which medicine participant gets is decided by chance. The injection of study medicine will be done by trained staff into the tissue underneath the skin of belly using a syringe and needle. The total duration of the study could last up to 25 weeks.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in South America. This trial aims for a comparison of the safety and efficacy of insulin NPH and a new insulin formulation on blood glucose control.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of the trial is to investigate safety and efficacy of semaglutide once weekly in monotherapy or in combination with one OAD (oral anti-diabetic drug) in Japanese subjects with type 2 diabetes who are insufficiently controlled on diet/exercise therapy or OAD monotherapy.\\n\\nAll subjects will continue their pre-trial treatment (diet and exercise therapy or OAD monotherapy in addition to diet and exercise therapy) during the trial.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe. The aim of this trial is to compare the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe.\\n\\nThe aim of this trial is to compare the efficacy and safety of insulin detemir and insulin NPH in adults with type 1 diabetes on blood glucose control.|Diabetes|Diabetes Mellitus, Type 2 This observational study is conducted in Europe. The trial aims to observe the incidence of serious adverse drug reactions in children and adolescents with type 1 diabetes during Levemir® treatment.|Diabetes Mellitus, Type 2 Insulin icodec is a new medicine which is under development for use in humans and is not yet available at the pharmacy. It is being developed for the treatment of diabetes, a condition that causes high blood sugar levels. Insulin icodec will be investigated in participants with type 2 diabetes. Participant will get one dose of insulin icodec, which will be administered in the afternoon or evening of the day of dosing. The study will last for about 8 weeks. Insulin icodec will be injected into a skin fold with a small needle (subcutaneous application) using a pen injector prefilled with a volume of 3 milliliter (mL) (a little less than a quarter of a teaspoonful). The amount of insulin icodec participant will receive depends on participant\\'s body weight. Participant must not participate if participant meets certain conditions called exclusion criteria, such as an age of above 18 years when the informed consent is signed or has serious health conditions. Female participant cannot take part if she is pregnant, breast-feeding or planning to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted globally. The aim of this study is to describe the proportion of patients with hypoglycaemic episodes and estimate the incidence of various types of hypoglycaemia in the retrospective and prospective periods.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in South Africa. The aim of this trial is to investigate Long term safety of biphasic insulin aspart 30 in juveniles with type 1 diabetes previously treated in trial BIAsp-1240.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to investigate the effect of oral semaglutide compared with placebo on postprandial glucose and triglyceride metabolism, energy intake, appetite sensations and gastric emptying in subjects with Type 2 diabetes|Type2 Diabetes|Coronary Artery Disease Epicardial adipose tissue (EAT) is the visceral fat of the heart. EAT could locally affect the coronary arteries through local secretion of pro-inflammatory cytokines. EAT plays a role in the development of the coronary artery disease (CAD). EAT is a highly enriched with genes involved in inflammation. Given its rapid metabolism and simple measurability, as first developed by Iacobellis, EAT serves as target for medications targeting the fat. Glucagon-like peptide-1 agonists (GLP-1A) are anti-diabetic medications with recently suggested cardio-protective properties. Liraglutide, a GLP-1A, has recently shown to reduce the cardiovascular risk. Iacobellis\\'group found that EAT thickness decreased by an unprecedented 36% after 12 weeks of treatment with liraglutide. Remarkably, Iacobellis\\'group found for the first time that human EAT express GLP-1 Receptor (GLP-1R). GLP-1A effects may be therefore visceral fat specific and target EAT. Based on these preliminary data, we hypothesize that treatment with liraglutide will significantly and rapidly reduce EAT inflammation. Decreased EAT inflammation can reduce the burden of the coronary plaques. We will test our hypothesis in a 12-week randomized, double-blind, placebo-controlled, interventional study in 40 patients with type 2 diabetes mellitus (T2DM), and CAD, with an acceptable glycemic control on their current diabetes regimen who require elective coronary artery bypass graft (CABG) regardless of their participation in the study. A minimum time frame of 4-week treatment will be considered to detect significant changes in the study endpoints. Inclusion criteria for body fat markers will rule out the confounding effect of different body fast distribution at baseline. Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide or to remain on current treatment/ placebo prior to cardiac surgery. CAD subjects not allocated to liraglutide will be started on a supervised low calorie diet (LCD) to achieve approximately 5% of weight loss after from a minimum of 4 weeks up to 12 weeks to avoid the confounding effect of weight loss on the study outcomes. EAT samples will be collected during cardiac surgery and processed for analysis of mRNA and protein expression of EAT inflammatory genes such as Tumor Necrosis Factor-alpha (TNF-α) and Interleukin 6 (IL-6), and GLP-1R.|Diabetes|Diabetes Mellitus, Type 2 This trial was conducted in Europe. The aim of this clinical trial was to evaluate the blood glucose-lowering effect of NN1250 (insulin degludec/insulin 454) in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using insulin aspart in children with diabetes under normal clinical practice conditions.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this study is to assess the well-being of patients following treatment with insulin detemir (Levemir®) in subjects with type 1 or type 2 diabetes in whom either initiation of or a switch to insulin treatment with a long-acting basal insulin analogue is needed.|Diabetes Mellitus, Type 2 This study will focus on how different injection needles are perceived by patients. The needles differ in design and mechanical properties, and will be tested in people with Type 2 Diabetes. The measured parameters during and after needle insertion are: penetration force through skin (measured with force gauge), pain perception (rated on visual analog scale, VAS, on a scale from 0 to 10), and skin blood perfusion at insertion site (measured with laser speckle contrast scanner). Furthermore, any skin reactions will be recorded.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.|Diabetes Mellitus, Type 2|Healthy Participants In this study, a known investigational medicine called \\'semaglutide\\' will be tested in 2 drug concentrations of 0.68 milligram per milliliter (mg/mL) and 1.34 mg/mL. Both drug concentrations are tested for the treatment of type 2 diabetes. The U.S. Food and Drug Administration (FDA), has approved semaglutide in prefilled pen-injector form. Currently, the drug concentration of 1.34 mg/ml can be prescribed in some countries including U.S. The objective of the study is to compare the amount of investigational drug taken up in the body for the 2 drug concentrations. Participants will be divided by chance into 2 groups. Group A will receive a single dose of 0.5 mg semaglutide of the drug concentration 1.34 mg/mL in the first study period; and will receive a single dose of 0.5 mg semaglutide of the drug concentration 0.68 mg/mL in the second study period. Participants assigned to group B will receive the two drug concentrations in the reverse order. Participants will get 1 subcutaneous injection on Day 1 of each of the two study periods. The two injections are separated by 7-11 weeks. The study will last up to approximately 87 to 141 days for each participant. This includes a screening period (up to 4 weeks), study period 1 (5 weeks), washout period (2-6 weeks), and study period 2 (5 weeks). At some periods during the study, participant should not get vaccinations. Participant should agree on timing of vaccination with study doctor. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia and Japan. The aim of this trial is to compare insulin degludec (NN1250) with insulin glargine both combined with oral antidiabetic drugs (OADs) in subjects with type 2 diabetes never treated with insulin.|Diabetes Mellitus The purpose of the study is to evaluate the effect of the basal-bolus detemir-aspart insulin regimen coupled with continuous glucose monitoring (CGM) on glycemic control in hemodialyzed patients with diabetes|Diabetes Mellitus, Type 2 NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes. This study, will look into how safe the new medicine NNC0519-0130 is, and we will measure its concentrations in the blood and look at its effects. This study will last for a maximum of 19 weeks and Japanese and Non-Japanese male participants will be included.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in the United States of America (USA). This trial compares the changes in HbA1c after 26 weeks of repaglinide and metformin fixed dose combination tablet given as twice daily versus three times daily regimens or versus twice daily rosiglitazone and metformin fixed dose combination tablet in subjects with type 2 diabetes currently on monotherapy.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes failing OAD therapy.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Asia. The aim of this observational study is to compare the clinical safety profile and effectiveness of NovoMix® 30 and Levemir™ for the treatment of diabetes in the Philippines.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as mealtime insulin in subjects with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2|Delivery Systems This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.|Type 2 Diabetes This initiative supports a real-world study of practice and physician prescribing patterns and a quality improvement initiative evaluating best practices (including clinical decision support, facilitated referral to cardiometabolic team-based care model, and general educational tools/resources) to im-prove use of guideline-directed therapeutics known to lower cardiovascular risk (CV) in patients with type 2 diabetes (T2D).|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in South America. The aim of this trial is to evaluate the efficacy of metformin plus biphasic insulin aspart or insulin NPH on blood glucose control in subjects with type 2 diabetes.|Diabetes Mellitus, Type 2 The study is investigating Ryzodeg®,a medication prescribed to patients with type 2 diabetes mellitus.The study is being carried out to investigate the effect of Ryzodeg® on the change of glycated haemoglobin levels and other diabetes indicators. Participants participation will not affect their medical care. In this retrospective study, the study doctor will collect data from the participants patient files available at the study site. Participants will need to sign the informed consent form during a single visit. Participants files will be reviewed and data relevant to the study will be extracted, within 26 weeks before and after Ryzodeg® treatment initiation (total of 52 weeks). Chart review for all patients is expected to take approximately 12 weeks.|Obesity This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking \"dummy\" medicine. Participants will either get semaglutide or \"dummy\" medicine. Which treatment participants get is decided by chance.\\n\\nParticipants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. During the study, participants will have talks with study staff about how to eat healthy food and how to be more physically active. The study will last for about 1 ½ years. Participants will have 14 clinic visits with the study staff. At the first clinic visit participants will have a blood sample taken. Participants will have an X-ray of participants knee taken at the first visit. If participants have had an X-ray recently, this may not be needed.\\n\\nAt 6 of the clinic visits participants cannot take pain medications for 3 days before the visit. Participants cannot take part if participants have had a joint replacement surgery in participants knee. Participants cannot take part if participants have or have had diabetes. Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Europe.\\n\\nThe aim of this trial is to investigate the efficacy of insulin aspart compared to soluble human insulin on blood glucose control in children below 7 years of age with type 1 diabetes.|Diabetes|Diabetes Mellitus, Type 2 This trial is conducted in Asia. The aim of this trial is to compare the glycaemic control when subjects initiate a biphasic insulin aspart 30 treatment followed by an intensified treatment if treatment target of HbA1c below 7% is not reached by OAD (oral anti-diabetic drugs) alone.|Type 2 Diabetes The optimal insulin therapy in T2DM is controversial and its impact on nonalcoholic fatty liver disease (NAFLD) has not been systematically studied before, and in particular, never when using the new insulin formulations detemir (Levemir®) or aspart (Novolog®). This study is to determine the effect on hepatic steatosis and insulin secretion/action of lowering the fasting plasma glucose (FPG) to target with once daily basal insulin detemir alone or combining insulin detemir with premeal insulin aspart in patients with uncontrolled type 2 diabetes mellitus (T2DM).\\n\\nIn the first 3 months the investigators will optimize metabolic control in all patients with intensive basal (bedtime) detemir insulin aiming at a normal fasting plasma glucose. After this treatment period, patients will be randomized in the second 3 months in a 2:1 ratio to insulin detemir or detemir plus aspart. The investigators propose that insulin will improve day-long glycemic control and A1c, reduce hepatic steatosis (NAFLD) (primary endpoint) and insulin secretion/sensitivity being well tolerated while causing minimal weight gain and hypoglycemia (secondary endpoints). The study will allow to assess if there is an additional benefit of adding pre-meal rapid-acting insulin aspart to basal insulin to these endpoints.|Diabetes Mellitus, Type 2 The aim of the study is to improve clinical outcomes for patients with type 2 diabetes by limiting the burden associated with insulin treatment.\\n\\nParticipants will get insulin degludec as well as insulin icodec - Insulin icodec is a new medicine while insulin degludec is commonly used and prescribed by doctors.\\n\\nParticipants will administer subcutaneous injections of insulin degludec once daily for at least one week (7 injections) but this period may be extended up to 8 weeks. Thereafter, once weekly subcutaneous injections of insulin icodec will follow, resulting in a total of at least 8 but not more than 16 subcutaneous injections of icodec.\\n\\nThe study will last for about 17-32 weeks Participants will have at least 5 in-house visits (where participants will stay at the clinic) and 17 outpatient visits with the study doctor.\\n\\nWomen cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.|Diabetes|Diabetes Mellitus, Type 2|Delivery Systems This trial is conducted in the United States of America (USA). The aim of this trial is to compare desired (target) with actual target amounts of insulin dispensed using NovoLog® Mix 70/30 FlexPen® and vial and syringe in subjects with type 2 diabetes mellitus. No insulin is administered in this trial - insulin is dispensed into an empty vial.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of treatment in people with type 2 diabetes. The study will last approximately 9 months (37 weeks). Each participant will have 7 visits at the clinic and 3 phone calls with the study doctor. At the visits, participants will have a number of tests, for example: general health checks, blood samples, heart and eye checks etc. Participants will also fill in some forms about their health and satisfaction with their diabetes treatment.|Diabetes|Diabetes Mellitus, Type 2 This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions when initiating or switching to insulin therapy with NovoMix® 30 in subjects with type 2 diabetes under normal clinical practice conditions|Diabetes|Diabetes Mellitus, Type 1 This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.|Diabetes Mellitus, Type 1 This study is looking at the effect and safety of 3 formulations of the new rapid-acting insulin analogue NNC0471-0119, for the treatment of type 1 diabetes when given by insulin pump.\\n\\nThe study will test how 3 different formulations of insulin NNC0471-0119 are tolerated by the body, how they are transported in participants bloodstream, how long they stay there and how the blood sugar is lowered.\\n\\nThe 3 formulations of insulin NNC0471-0119 are given as one bolus on top of a constant insulin basal rate and compared to Faster Aspart (Fiasp®).\\n\\nParticipants will get 3 formulations of insulin NNC0471-0119 and Faster Aspart (Fiasp®) Insulin NNC0471-0119 is a new rapid-acting insulin designed to be used in an insulin pump. Faster Aspart (Fiasp®) is a globally used medication for the treatment of diabetes.\\n\\nParticipants will have each study medicine administered once via pump at separate study visits. This mean that participants will have a total of 4 dosing visits where participants will get a study medicine. Which study medicine participants get at what visit will be decided by chance.\\n\\nThe study will last 1-4 months. Participants will have 7 visits at the clinic, 4 of them will require an in-house stay of 3 consecutive days each.\\n\\nDuring the in-house visits 2 intravenous (into the vein) cannulas will be inserted for blood sampling and infusions.\\n\\nWomen: Women cannot take part if they are of childbearing potential.|Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2 This study is conducted in Africa, Asia, Europe, Japan and South America. The aim of this observational study is to evaluate the incidence of serious adverse reactions (SARs) while using Levemir® (insulin detemir) under normal clinical practice conditions.\\n\\nStudy conducted globally in 26 countries. Some countries participated in the study for only 3 months (Austria, Brazil, Denmark, Germany, Israel, Lebanon, Slovenia, Russia, and Turkey), while others extended their participation to 6 (Belgium/Luxembourg, Czech Republic, Greece, India, Italy, Netherlands, Saudi Arabia, South Africa, South Korea, Sweden, Tunisia, and United Kingdom/Ireland) and 12 months (Finland, France, and Japan), respectively.'"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "countdf['sentences'].tolist()[0]"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## node & edge"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "13880it [01:04, 214.47it/s]\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "      <th>next</th>\n",
       "      <th>cnt</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>432</th>\n",
       "      <td>Boehringer Ingelheim</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>62</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>336</th>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>50</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>231</th>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>46</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>213</th>\n",
       "      <td>National Institutes of Health (NIH)</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>43</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>331</th>\n",
       "      <td>Yale University</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>24</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18184</th>\n",
       "      <td>Helse i Hardanger</td>\n",
       "      <td>Haukeland University Hospital</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18183</th>\n",
       "      <td>University of Copenhagen</td>\n",
       "      <td>Juvenile Diabetes Research Foundation</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18182</th>\n",
       "      <td>Filip Krag Knop</td>\n",
       "      <td>Juvenile Diabetes Research Foundation</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18181</th>\n",
       "      <td>Wuhan Union Hospital, China</td>\n",
       "      <td>Peking University First Hospital</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19300</th>\n",
       "      <td>Swiss Federal Institute of Technology</td>\n",
       "      <td>University of St.Gallen</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>19301 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                       index  \\\n",
       "432                     Boehringer Ingelheim   \n",
       "336                              AstraZeneca   \n",
       "231                              AstraZeneca   \n",
       "213      National Institutes of Health (NIH)   \n",
       "331                          Yale University   \n",
       "...                                      ...   \n",
       "18184                      Helse i Hardanger   \n",
       "18183               University of Copenhagen   \n",
       "18182                        Filip Krag Knop   \n",
       "18181            Wuhan Union Hospital, China   \n",
       "19300  Swiss Federal Institute of Technology   \n",
       "\n",
       "                                                    next cnt  \n",
       "432                                Eli Lilly and Company  62  \n",
       "336                                 Bristol-Myers Squibb  50  \n",
       "231                                Eli Lilly and Company  46  \n",
       "213    National Institute of Diabetes and Digestive a...  43  \n",
       "331    National Institute of Diabetes and Digestive a...  24  \n",
       "...                                                  ...  ..  \n",
       "18184                      Haukeland University Hospital   1  \n",
       "18183              Juvenile Diabetes Research Foundation   1  \n",
       "18182              Juvenile Diabetes Research Foundation   1  \n",
       "18181                   Peking University First Hospital   1  \n",
       "19300                            University of St.Gallen   1  \n",
       "\n",
       "[19301 rows x 3 columns]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import tqdm\n",
    "# check sponsor network\n",
    "df_spon = pd.DataFrame(columns=['index','next','cnt'])\n",
    "dict_spon = {}\n",
    "one_spon = {}\n",
    "\n",
    "for idx,row in tqdm.tqdm(df.iterrows()):\n",
    "    # affiliations\n",
    "    spon = row['affiliations']\n",
    "    if spon is not np.nan:\n",
    "        spon = spon.split('|')\n",
    "        # times of research (only me)\n",
    "        if len(spon) == 1:\n",
    "            if spon[0] not in one_spon.keys(): one_spon[spon[0]]=1\n",
    "            else: one_spon[spon[0]]+=1\n",
    "        # times of research (each)\n",
    "        temp = list(set(spon))\n",
    "        for t in temp:\n",
    "            if t is not np.nan:\n",
    "                if t not in dict_spon.keys():\n",
    "                    dict_spon[t]=1\n",
    "                else:\n",
    "                    dict_spon[t]+=1\n",
    "\n",
    "        for idx,a in enumerate(spon):\n",
    "            # times of research (co)\n",
    "            for i in range(idx+1,len(spon)):                \n",
    "                if a != spon[i] and a is not np.nan:\n",
    "                    dup = df_spon.loc[(df_spon['index']==a)&(df_spon['next']==spon[i])]\n",
    "                    if dup.size != 0:\n",
    "                        df_spon.loc[(df_spon['index']==a) & (df_spon['next']==spon[i]),'cnt'] = dup['cnt'].iloc[0] + 1\n",
    "                    else:\n",
    "                        df_spon = df_spon.append({'index':a,'next':spon[i],'cnt':1}, ignore_index=True)\n",
    "\n",
    "df_spon = df_spon.sort_values('cnt',ascending=False)\n",
    "display(df_spon.sort_values('cnt',ascending=False))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('Novo Nordisk A/S', 709),\n",
       " ('National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)',\n",
       "  688),\n",
       " ('Eli Lilly and Company', 386),\n",
       " ('AstraZeneca', 314),\n",
       " ('Sanofi', 272),\n",
       " ('Merck Sharp & Dohme LLC', 198),\n",
       " ('Juvenile Diabetes Research Foundation', 155),\n",
       " ('National Heart, Lung, and Blood Institute (NHLBI)', 151),\n",
       " ('Boehringer Ingelheim', 145),\n",
       " ('University of Colorado, Denver', 138),\n",
       " ('National Institutes of Health (NIH)', 132),\n",
       " ('GlaxoSmithKline', 125),\n",
       " ('Pfizer', 117),\n",
       " ('Takeda', 108),\n",
       " ('University of Aarhus', 104),\n",
       " ('American Diabetes Association', 96),\n",
       " ('University of Copenhagen', 95),\n",
       " ('VA Office of Research and Development', 90),\n",
       " ('University of Michigan', 90),\n",
       " ('DexCom, Inc.', 87),\n",
       " ('Bristol-Myers Squibb', 87),\n",
       " ('Yale University', 86),\n",
       " ('Washington University School of Medicine', 85),\n",
       " ('Massachusetts General Hospital', 85),\n",
       " ('Mayo Clinic', 82),\n",
       " ('Steno Diabetes Center Copenhagen', 81),\n",
       " ('Emory University', 80),\n",
       " ('Canadian Institutes of Health Research (CIHR)', 79),\n",
       " ('University of Pittsburgh', 73),\n",
       " ('Novartis', 73),\n",
       " ('University of Virginia', 73),\n",
       " ('Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)',\n",
       "  71),\n",
       " ('Stanford University', 70),\n",
       " ('University of California, San Francisco', 70),\n",
       " ('Hoffmann-La Roche', 68),\n",
       " (\"Brigham and Women's Hospital\", 67),\n",
       " ('Jaeb Center for Health Research', 65),\n",
       " ('Bayer', 64),\n",
       " ('Assistance Publique - Hôpitaux de Paris', 64),\n",
       " ('Novartis Pharmaceuticals', 63),\n",
       " ('Johns Hopkins University', 63),\n",
       " ('University of Pennsylvania', 61),\n",
       " ('University of Alabama at Birmingham', 59),\n",
       " ('Joslin Diabetes Center', 59),\n",
       " ('Karolinska Institutet', 59),\n",
       " ('University of Minnesota', 58),\n",
       " ('Imperial College London', 58),\n",
       " ('US Department of Veterans Affairs', 57),\n",
       " ('Duke University', 56),\n",
       " ('National Institute on Aging (NIA)', 56),\n",
       " ('University of Alberta', 55),\n",
       " ('Maastricht University Medical Center', 54),\n",
       " ('NYU Langone Health', 53),\n",
       " ('Chinese University of Hong Kong', 53),\n",
       " ('University Hospital, Gentofte, Copenhagen', 52),\n",
       " ('Aarhus University Hospital', 49),\n",
       " ('Northwestern University', 49),\n",
       " ('Rigshospitalet, Denmark', 48),\n",
       " ('Institut de Recherches Cliniques de Montreal', 47),\n",
       " ('University of Southern California', 47),\n",
       " ('University of Texas Southwestern Medical Center', 47),\n",
       " ('Cairo University', 46),\n",
       " ('Odense University Hospital', 46),\n",
       " ('Baylor College of Medicine', 45),\n",
       " ('Kaiser Permanente', 45),\n",
       " ('University of California, San Diego', 44),\n",
       " ('University of British Columbia', 44),\n",
       " ('University of Cambridge', 44),\n",
       " ('Assiut University', 44),\n",
       " ('Vanderbilt University Medical Center', 43),\n",
       " ('University of North Carolina, Chapel Hill', 43),\n",
       " ('The University of Texas Health Science Center at San Antonio', 43),\n",
       " ('Ohio State University', 43),\n",
       " ('National Institute of Allergy and Infectious Diseases (NIAID)', 42),\n",
       " ('National Cancer Institute (NCI)', 42),\n",
       " ('University of Florida', 42),\n",
       " ('National Institute on Minority Health and Health Disparities (NIMHD)', 41),\n",
       " ('Vanderbilt University', 40),\n",
       " ('Medical University of Graz', 40),\n",
       " ('University of Chicago', 39),\n",
       " ('National Center for Research Resources (NCRR)', 38),\n",
       " ('University Hospital, Basel, Switzerland', 38),\n",
       " ('University of Washington', 38),\n",
       " ('Indiana University', 38),\n",
       " ('Abbott Diabetes Care', 38),\n",
       " ('Medtronic', 37),\n",
       " ('Oregon Health and Science University', 37),\n",
       " ('Medical University of Vienna', 37),\n",
       " (\"King's College London\", 37),\n",
       " ('University of Oxford', 36),\n",
       " ('University of Leicester', 36),\n",
       " ('University of California, Los Angeles', 36),\n",
       " ('Hvidovre University Hospital', 36),\n",
       " ('HealthPartners Institute', 36),\n",
       " ('Cambridge University Hospitals NHS Foundation Trust', 36),\n",
       " ('University of Toronto', 36),\n",
       " ('Icahn School of Medicine at Mount Sinai', 36),\n",
       " ('The University of Hong Kong', 36),\n",
       " ('Medtronic Diabetes', 35),\n",
       " ('Hospices Civils de Lyon', 35),\n",
       " ('Astellas Pharma Inc', 34),\n",
       " ('Albert Einstein College of Medicine', 34),\n",
       " ('Radboud University Medical Center', 33),\n",
       " ('National Eye Institute (NEI)', 33),\n",
       " ('Janssen Research & Development, LLC', 33),\n",
       " ('University of Manitoba', 32),\n",
       " ('Patient-Centered Outcomes Research Institute', 32),\n",
       " ('University Hospital Tuebingen', 32),\n",
       " ('University of Southern Denmark', 32),\n",
       " ('Insel Gruppe AG, University Hospital Bern', 32),\n",
       " ('Seoul National University Bundang Hospital', 32),\n",
       " ('Medical College of Wisconsin', 32),\n",
       " ('The University of Texas Health Science Center, Houston', 31),\n",
       " ('Centre Hospitalier Universitaire Dijon', 30),\n",
       " ('Ain Shams University', 30),\n",
       " ('National Taiwan University Hospital', 30),\n",
       " ('Université de Sherbrooke', 30),\n",
       " ('Agency for Healthcare Research and Quality (AHRQ)', 30),\n",
       " ('Hospital de Clinicas de Porto Alegre', 30),\n",
       " ('McMaster University', 29),\n",
       " ('Columbia University', 29),\n",
       " ('University Hospital, Lille', 29),\n",
       " ('Medical University of South Carolina', 29),\n",
       " ('Lund University', 29),\n",
       " ('McGill University Health Centre/Research Institute of the McGill University Health Centre',\n",
       "  29),\n",
       " ('Rabin Medical Center', 29),\n",
       " ('University of Illinois at Chicago', 29),\n",
       " ('Yonsei University', 29),\n",
       " ('University of Massachusetts, Worcester', 29),\n",
       " ('Weill Medical College of Cornell University', 28),\n",
       " ('Sansum Diabetes Research Institute', 28),\n",
       " ('University of California, Davis', 28),\n",
       " ('University of Exeter', 27),\n",
       " ('University Hospital, Montpellier', 27),\n",
       " ('Oslo University Hospital', 27),\n",
       " ('Pennington Biomedical Research Center', 27),\n",
       " ('The Leona M. and Harry B. Helmsley Charitable Trust', 26),\n",
       " ('Mannkind Corporation', 26),\n",
       " ('University of Arkansas', 26),\n",
       " ('McGill University', 26),\n",
       " (\"Nemours Children's Clinic\", 26),\n",
       " ('Laval University', 26),\n",
       " ('University of Campania \"Luigi Vanvitelli\"', 26),\n",
       " ('Universitaire Ziekenhuizen KU Leuven', 25),\n",
       " ('University of Nottingham', 25),\n",
       " ('University of Wisconsin, Madison', 25),\n",
       " ('Shanghai Jiao Tong University School of Medicine', 25),\n",
       " ('University of Missouri-Columbia', 25),\n",
       " ('Daiichi Sankyo, Inc.', 25),\n",
       " ('Unity Health Toronto', 24),\n",
       " ('University of Padova', 24),\n",
       " ('Wake Forest University Health Sciences', 24),\n",
       " ('University Health Network, Toronto', 24),\n",
       " ('Ascensia Diabetes Care', 24),\n",
       " ('Abbott Nutrition', 24),\n",
       " ('University of Calgary', 24),\n",
       " ('Beth Israel Deaconess Medical Center', 23),\n",
       " ('Norwegian University of Science and Technology', 23),\n",
       " ('Sohag University', 23),\n",
       " ('University of Maryland, Baltimore', 23),\n",
       " ('University of Guadalajara', 22),\n",
       " ('University of Leeds', 22),\n",
       " ('Tandem Diabetes Care, Inc.', 22),\n",
       " ('Royal Devon and Exeter NHS Foundation Trust', 22),\n",
       " ('Mitsubishi Tanabe Pharma Corporation', 22),\n",
       " ('Riphah International University', 22),\n",
       " ('Canadian Diabetes Association', 22),\n",
       " ('National University of Singapore', 22),\n",
       " ('Vastra Gotaland Region', 21),\n",
       " ('Bispebjerg Hospital', 21),\n",
       " ('Institut National de la Santé Et de la Recherche Médicale, France', 21),\n",
       " ('National Institute for Health Research, United Kingdom', 21),\n",
       " ('Manchester University NHS Foundation Trust', 21),\n",
       " ('National Institute of Mental Health (NIMH)', 21),\n",
       " ('Postgraduate Institute of Medical Education and Research', 21),\n",
       " ('Adocia', 21),\n",
       " ('National Center for Complementary and Integrative Health (NCCIH)', 21),\n",
       " ('Amylin Pharmaceuticals, LLC.', 21),\n",
       " ('Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)', 21),\n",
       " ('German Diabetes Center', 21),\n",
       " ('University Hospital, Grenoble', 20),\n",
       " (\"Children's Hospital of Philadelphia\", 20),\n",
       " ('Aalborg University Hospital', 20),\n",
       " (\"Boston Children's Hospital\", 20),\n",
       " ('National Institute of Nursing Research (NINR)', 20),\n",
       " ('University of Miami', 20),\n",
       " ('University Medical Center Groningen', 20),\n",
       " ('Société des Produits Nestlé (SPN)', 20),\n",
       " ('Lexicon Pharmaceuticals', 19),\n",
       " ('University of New Mexico', 19),\n",
       " ('University of Dundee', 19),\n",
       " ('LifeScan', 19),\n",
       " ('University of Glasgow', 19),\n",
       " ('Johnson & Johnson Pharmaceutical Research & Development, L.L.C.', 19),\n",
       " ('European Foundation for the Study of Diabetes', 19),\n",
       " ('University of Helsinki', 19),\n",
       " ('University Hospitals, Leicester', 19),\n",
       " ('Boston University', 19),\n",
       " ('University of Sao Paulo', 19),\n",
       " ('The Cleveland Clinic', 18),\n",
       " ('Amsterdam UMC, location VUmc', 18),\n",
       " ('Seoul National University Hospital', 18),\n",
       " ('University of Sao Paulo General Hospital', 18),\n",
       " ('Centers for Disease Control and Prevention', 18),\n",
       " ('Aristotle University Of Thessaloniki', 18),\n",
       " ('University College, London', 17),\n",
       " ('Tehran University of Medical Sciences', 17),\n",
       " ('Federico II University', 17),\n",
       " ('University Hospital, Toulouse', 17),\n",
       " ('Conselho Nacional de Desenvolvimento Científico e Tecnológico', 17),\n",
       " ('Mario Negri Institute for Pharmacological Research', 17),\n",
       " ('Diabetes UK', 17),\n",
       " ('AdventHealth Translational Research Institute', 17),\n",
       " ('Abbott', 17),\n",
       " ('American Heart Association', 17),\n",
       " ('Istanbul University', 17),\n",
       " ('Sheba Medical Center', 17),\n",
       " ('Charite University, Berlin, Germany', 17),\n",
       " ('Hacettepe University', 17),\n",
       " ('Harvard University', 17),\n",
       " ('The Hospital for Sick Children', 17),\n",
       " ('Arizona State University', 17),\n",
       " ('Nanjing First Hospital, Nanjing Medical University', 17),\n",
       " ('Peking Union Medical College Hospital', 16),\n",
       " ('University of California, Irvine', 16),\n",
       " ('Fondation Hôpital Saint-Joseph', 16),\n",
       " ('International Diabetes Center at Park Nicollet', 16),\n",
       " ('Turku University Hospital', 16),\n",
       " ('Sahlgrenska University Hospital, Sweden', 16),\n",
       " ('Göteborg University', 16),\n",
       " ('University of Roma La Sapienza', 16),\n",
       " ('University of Utah', 16),\n",
       " ('Karolinska University Hospital', 15),\n",
       " ('University Hospital, Antwerp', 15),\n",
       " ('University of Edinburgh', 15),\n",
       " ('Sun Yat-sen University', 15),\n",
       " ('University of Arizona', 15),\n",
       " ('Jiangsu HengRui Medicine Co., Ltd.', 15),\n",
       " ('Hadassah Medical Organization', 15),\n",
       " ('Virginia Commonwealth University', 15),\n",
       " ('University of Mississippi Medical Center', 15),\n",
       " ('Profil Institut für Stoffwechselforschung GmbH', 15),\n",
       " ('University of Oslo', 15),\n",
       " ('Singapore General Hospital', 15),\n",
       " ('Leiden University Medical Center', 15),\n",
       " ('Case Western Reserve University', 15),\n",
       " ('Chang Gung Memorial Hospital', 15),\n",
       " ('University of Oklahoma', 14),\n",
       " ('University Ghent', 14),\n",
       " (\"Children's National Research Institute\", 14),\n",
       " ('University of Rochester', 14),\n",
       " ('University of Campinas, Brazil', 14),\n",
       " ('University of Lausanne Hospitals', 14),\n",
       " ('University of Birmingham', 14),\n",
       " ('Kinderkrankenhaus auf der Bult', 14),\n",
       " ('Hillerod Hospital, Denmark', 14),\n",
       " ('University of Cincinnati', 14),\n",
       " ('National Nutrition and Food Technology Institute', 14),\n",
       " ('Scripps Whittier Diabetes Institute', 14),\n",
       " ('University of Eastern Finland', 14),\n",
       " ('Robert Wood Johnson Foundation', 14),\n",
       " ('Tanta University', 14),\n",
       " ('The Catholic University of Korea', 14),\n",
       " ('Universiti Putra Malaysia', 14),\n",
       " ('University of Bath', 14),\n",
       " ('Region Skane', 13),\n",
       " ('Forschungsinstitut der Diabetes Akademie Mergentheim', 13),\n",
       " ('University of Milan', 13),\n",
       " ('Mount Sinai Hospital, Canada', 13),\n",
       " ('University of Nebraska', 13),\n",
       " ('Uppsala University', 13),\n",
       " ('Herlev Hospital', 13),\n",
       " ('Temple University', 13),\n",
       " ('Second Xiangya Hospital of Central South University', 13),\n",
       " ('Johns Hopkins Bloomberg School of Public Health', 13),\n",
       " ('George Washington University', 13),\n",
       " ('Maastricht University', 13),\n",
       " ('CHU de Quebec-Universite Laval', 13),\n",
       " ('Catholic University of the Sacred Heart', 13),\n",
       " (\"Children's Hospital Medical Center, Cincinnati\", 13),\n",
       " ('Diabetes Foundation, India', 13),\n",
       " ('National Center for Advancing Translational Sciences (NCATS)', 13),\n",
       " ('Liverpool John Moores University', 13),\n",
       " ('University at Buffalo', 13),\n",
       " ('Takeda Pharmaceuticals North America, Inc.', 12),\n",
       " ('University of Adelaide', 12),\n",
       " ('Virginia Polytechnic Institute and State University', 12),\n",
       " ('Samsung Medical Center', 12),\n",
       " ('University Hospital, Ghent', 12),\n",
       " ('University Hospital, Strasbourg, France', 12),\n",
       " ('University of Kansas Medical Center', 12),\n",
       " ('Oxford University Hospitals NHS Trust', 12),\n",
       " ('University of Oulu', 12),\n",
       " ('Monash University', 12),\n",
       " ('University Hospital, Geneva', 12),\n",
       " ('Insulet Corporation', 12),\n",
       " ('University of Ljubljana, Faculty of Medicine', 12),\n",
       " ('The Leeds Teaching Hospitals NHS Trust', 12),\n",
       " ('Texas A&M University', 12),\n",
       " ('Western University, Canada', 12),\n",
       " ('Harvard School of Public Health (HSPH)', 12),\n",
       " ('Fundação de Amparo à Pesquisa do Estado de São Paulo', 12),\n",
       " ('Sunnybrook Health Sciences Centre', 12),\n",
       " ('Lawson Health Research Institute', 12),\n",
       " ('Penn State University', 12),\n",
       " ('Becton, Dickinson and Company', 12),\n",
       " ('MedImmune LLC', 12),\n",
       " ('UMC Utrecht', 12),\n",
       " ('Peking University Third Hospital', 12),\n",
       " ('City of Hope Medical Center', 12),\n",
       " ('Medical University of Warsaw', 12),\n",
       " ('LMC Diabetes & Endocrinology Ltd.', 12),\n",
       " ('Helmholtz Zentrum München', 12),\n",
       " ('Amgen', 12),\n",
       " ('M.D. Anderson Cancer Center', 12),\n",
       " ('University of Manchester', 11),\n",
       " ('Helsinki University Central Hospital', 11),\n",
       " ('Centre Hospitalier Universitaire de Nīmes', 11),\n",
       " ('University of Zurich', 11),\n",
       " ('Biodel', 11),\n",
       " ('National and Kapodistrian University of Athens', 11),\n",
       " ('Harokopio University', 11),\n",
       " ('Assistance Publique Hopitaux De Marseille', 11),\n",
       " ('University of Aberdeen', 11),\n",
       " ('St. Olavs Hospital', 11),\n",
       " ('NHS Greater Glasgow and Clyde', 11),\n",
       " ('Jessa Hospital', 11),\n",
       " ('Coordinación de Investigación en Salud, Mexico', 11),\n",
       " ('Nantes University Hospital', 11),\n",
       " ('Indonesia University', 11),\n",
       " ('Alkermes, Inc.', 11),\n",
       " ('Milton S. Hershey Medical Center', 11),\n",
       " ('Skane University Hospital', 11),\n",
       " ('European Commission', 11),\n",
       " ('University Hospital, Caen', 11),\n",
       " ('Duke-NUS Graduate Medical School', 11),\n",
       " ('Xeris Pharmaceuticals', 11),\n",
       " ('Centre Hospitalier Sud Francilien', 11),\n",
       " ('University College Dublin', 11),\n",
       " ('Shanghai Zhongshan Hospital', 11),\n",
       " ('Daewoong Pharmaceutical Co. LTD.', 11),\n",
       " ('National Health and Medical Research Council, Australia', 11),\n",
       " ('Ludwig-Maximilians - University of Munich', 11),\n",
       " ('Yaounde Central Hospital', 11),\n",
       " ('The University of Texas Medical Branch, Galveston', 11),\n",
       " ('University of Texas at Austin', 11),\n",
       " ('Wayne State University', 11),\n",
       " ('University Hospital, Bordeaux', 11),\n",
       " ('Zealand Pharma', 11),\n",
       " ('Tufts Medical Center', 11),\n",
       " ('State University of New York at Buffalo', 11),\n",
       " ('Dutch Diabetes Research Foundation', 11),\n",
       " ('ZonMw: The Netherlands Organisation for Health Research and Development',\n",
       "  11),\n",
       " ('The Lawson Foundation', 10),\n",
       " ('Medstar Health Research Institute', 10),\n",
       " ('University of Erlangen-Nürnberg Medical School', 10),\n",
       " ('University of Bern', 10),\n",
       " ('Korea University', 10),\n",
       " ('Ohio University', 10),\n",
       " ('Medical Research Council', 10),\n",
       " ('Institute for Clinical and Experimental Medicine', 10),\n",
       " ('Technische Universität Dresden', 10),\n",
       " ('Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran', 10),\n",
       " ('University of Hull', 10),\n",
       " ('TNO', 10),\n",
       " (\"Women's Hospital School Of Medicine Zhejiang University\", 10),\n",
       " ('Theracos', 10),\n",
       " ('Boston Medical Center', 10),\n",
       " ('Cook County Health', 10),\n",
       " ('Fondazione Policlinico Universitario Agostino Gemelli IRCCS', 10),\n",
       " (\"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina\", 10),\n",
       " ('KU Leuven', 10),\n",
       " ('University of Bergen', 10),\n",
       " ('Roche Pharma AG', 10),\n",
       " ('VeraLight, Inc.', 10),\n",
       " ('Augusta University', 10),\n",
       " (\"Children's Mercy Hospital Kansas City\", 10),\n",
       " ('University of Giessen', 10),\n",
       " ('Medical Research Foundation, The Netherlands', 10),\n",
       " ('Instituto Mexicano del Seguro Social', 10),\n",
       " ('Clinical Nutrition Research Centre, Singapore', 10),\n",
       " ('Assaf-Harofeh Medical Center', 10),\n",
       " ('Genentech, Inc.', 10),\n",
       " ('San Diego State University', 10),\n",
       " (\"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals\",\n",
       "  10),\n",
       " ('Zealand University Hospital', 10),\n",
       " ('London School of Hygiene and Tropical Medicine', 10),\n",
       " ('Montefiore Medical Center', 10),\n",
       " ('University of Iowa', 10),\n",
       " ('University of South Carolina', 10),\n",
       " (\"Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète\",\n",
       "  10),\n",
       " ('Gilead Sciences', 10),\n",
       " ('The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School',\n",
       "  10),\n",
       " ('Heart and Stroke Foundation of Canada', 10),\n",
       " ('Wageningen University', 9),\n",
       " ('Montana State University', 9),\n",
       " ('Hamad Medical Corporation', 9),\n",
       " ('Handok Inc.', 9),\n",
       " ('University of Reading', 9),\n",
       " ('United States Department of Defense', 9),\n",
       " ('Colorado State University', 9),\n",
       " ('University of California, Santa Barbara', 9),\n",
       " ('Diamyd Medical AB', 9),\n",
       " ('Griffin Hospital', 9),\n",
       " ('Xijing Hospital', 9),\n",
       " ('National Human Genome Research Institute (NHGRI)', 9),\n",
       " ('Wellcome Trust', 9),\n",
       " ('Universitair Ziekenhuis Brussel', 9),\n",
       " ('Glostrup University Hospital, Copenhagen', 9),\n",
       " ('Tampere University Hospital', 9),\n",
       " ('Florida State University', 9),\n",
       " ('The George Institute', 9),\n",
       " ('University of Sydney', 9),\n",
       " ('Nordsjaellands Hospital', 9),\n",
       " ('Hospital of South West Jutland', 9),\n",
       " ('University Hospital, Clermont-Ferrand', 9),\n",
       " ('Hull University Teaching Hospitals NHS Trust', 9),\n",
       " ('University of Tromso', 9),\n",
       " (\"First Affiliated Hospital Xi'an Jiaotong University\", 9),\n",
       " ('The Danish Diabetes Association', 9),\n",
       " ('University of Pisa', 9),\n",
       " ('Rennes University Hospital', 9),\n",
       " ('The Research Council of Norway', 9),\n",
       " ('Montreal Heart Institute', 9),\n",
       " ('University of Lausanne', 9),\n",
       " ('Centre Hospitalier Universitaire de Nice', 9),\n",
       " ('Region Stockholm', 9),\n",
       " ('Association for Innovation and Biomedical Research on Light and Image', 9),\n",
       " ('Halozyme Therapeutics', 9),\n",
       " ('Denver Health and Hospital Authority', 9),\n",
       " ('Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm',\n",
       "  9),\n",
       " ('University of South Florida', 9),\n",
       " ('Ministry of Health, Malaysia', 9),\n",
       " ('University Hospitals Cleveland Medical Center', 9),\n",
       " ('Ionis Pharmaceuticals, Inc.', 9),\n",
       " ('LG Life Sciences', 9),\n",
       " ('Dartmouth-Hitchcock Medical Center', 9),\n",
       " ('Integrium', 9),\n",
       " ('Oramed, Ltd.', 9),\n",
       " ('Dasman Diabetes Institute', 9),\n",
       " ('Ottawa Hospital Research Institute', 9),\n",
       " ('German Institute of Human Nutrition', 9),\n",
       " ('Ruijin Hospital', 9),\n",
       " ('Universiti Sains Malaysia', 9),\n",
       " ('Federal University of Rio Grande do Sul', 9),\n",
       " ('West German Center of Diabetes and Health', 9),\n",
       " (\"King's College Hospital NHS Trust\", 9),\n",
       " ('National Institute of Environmental Health Sciences (NIEHS)', 9),\n",
       " ('Baskent University', 9),\n",
       " ('University Medical Centre Ljubljana', 9),\n",
       " ('Erasmus Medical Center', 8),\n",
       " ('Hamilton Health Sciences Corporation', 8),\n",
       " ('Laboratorios Silanes S.A. de C.V.', 8),\n",
       " (\"Queen's University, Belfast\", 8),\n",
       " ('Cornell University', 8),\n",
       " (\"Centre hospitalier de l'Université de Montréal (CHUM)\", 8),\n",
       " ('Newcastle University', 8),\n",
       " ('Centre Hospitalier Universitaire de la Réunion', 8),\n",
       " ('British Heart Foundation', 8),\n",
       " ('Linkoeping University', 8),\n",
       " ('IRCCS San Raffaele', 8),\n",
       " ('Brown University', 8),\n",
       " ('Ruhr University of Bochum', 8),\n",
       " ('EMS', 8),\n",
       " ('Steno Diabetes Center Sjaelland', 8),\n",
       " ('Uppsala University Hospital', 8),\n",
       " ('Yuhan Corporation', 8),\n",
       " ('National Cheng-Kung University Hospital', 8),\n",
       " ('Tufts University', 8),\n",
       " ('Oulu University Hospital', 8),\n",
       " ('Northwell Health', 8),\n",
       " ('Thrasher Research Fund', 8),\n",
       " ('Rush University Medical Center', 8),\n",
       " ('Instituto de Salud Carlos III', 8),\n",
       " ('University of Portsmouth', 8),\n",
       " ('Getz Pharma', 8),\n",
       " ('Castilla-La Mancha Health Service', 8),\n",
       " ('Solvay Pharmaceuticals', 8),\n",
       " ('Purdue University', 8),\n",
       " ('Nanfang Hospital, Southern Medical University', 8),\n",
       " ('Steno Diabetes Center Odense', 8),\n",
       " ('Asia Diabetes Foundation', 8),\n",
       " ('Organon and Co', 8),\n",
       " ('University of Guelph', 8),\n",
       " ('Universita di Verona', 8),\n",
       " ('Centro Universitario de Ciencias de la Salud, Mexico', 8),\n",
       " (\"Woman's\", 8),\n",
       " ('University Hospital, Rouen', 8),\n",
       " ('Rockefeller University', 8),\n",
       " ('German Center for Diabetes Research', 8),\n",
       " ('Barts & The London NHS Trust', 8),\n",
       " (\"Children's Hospital Los Angeles\", 8),\n",
       " ('Finnish Institute for Health and Welfare', 8),\n",
       " ('Roche Diagnostics', 8),\n",
       " (\"Guy's and St Thomas' NHS Foundation Trust\", 8),\n",
       " ('Danish Heart Foundation', 8),\n",
       " ('Merck KGaA, Darmstadt, Germany', 8),\n",
       " ('Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud',\n",
       "  8),\n",
       " ('Mackay Memorial Hospital', 8),\n",
       " ('Wake Forest University', 8),\n",
       " ('Technical University of Denmark', 8),\n",
       " ('GI Dynamics', 8),\n",
       " ('National University of Malaysia', 8),\n",
       " ('Loma Linda University', 8),\n",
       " ('Ministry of Health, France', 8),\n",
       " ('Haukeland University Hospital', 8),\n",
       " ('National Institute of General Medical Sciences (NIGMS)', 8),\n",
       " ('Second Affiliated Hospital, School of Medicine, Zhejiang University', 8),\n",
       " ('Clinica Universidad de Navarra, Universidad de Navarra', 8),\n",
       " ('Ege University', 8),\n",
       " ('University Hospital, Limoges', 8),\n",
       " (\"Children's Hospital of Eastern Ontario\", 8),\n",
       " ('National University Hospital, Singapore', 8),\n",
       " ('Fred Hutchinson Cancer Center', 8),\n",
       " ('Icadom', 7),\n",
       " (\"Shanghai 10th People's Hospital\", 7),\n",
       " ('State University of New York - Upstate Medical University', 7),\n",
       " ('Swansea University', 7),\n",
       " ('Kyowa Kirin Co., Ltd.', 7),\n",
       " ('University of Hawaii', 7),\n",
       " ('CHU de Reims', 7),\n",
       " ('NHS Tayside', 7),\n",
       " ('National Institute of Neurological Disorders and Stroke (NINDS)', 7),\n",
       " ('William Beaumont Hospitals', 7),\n",
       " ('Aalborg University', 7),\n",
       " ('Indiana University School of Medicine', 7),\n",
       " ('Portsmouth Hospitals NHS Trust', 7),\n",
       " ('Sanwa Kagaku Kenkyusho Co., Ltd.', 7),\n",
       " ('Rodolfo Alejandro', 7),\n",
       " ('Poznan University of Medical Sciences', 7),\n",
       " ('Medical University Innsbruck', 7),\n",
       " ('The Miriam Hospital', 7),\n",
       " ('Dong-A ST Co., Ltd.', 7),\n",
       " ('Palo Alto Medical Foundation', 7),\n",
       " (\"Shanghai 6th People's Hospital\", 7),\n",
       " ('SingHealth Polyclinics', 7),\n",
       " ('JW Pharmaceutical', 7),\n",
       " ('Universidad de Guanajuato', 7),\n",
       " ('Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey', 7),\n",
       " ('Washington State University', 7),\n",
       " ('Baystate Medical Center', 7),\n",
       " ('Allergan', 7),\n",
       " ('Sheffield Teaching Hospitals NHS Foundation Trust', 7),\n",
       " ('Geisinger Clinic', 7),\n",
       " ('Swiss National Science Foundation', 7),\n",
       " ('Georgetown University', 7),\n",
       " ('Garvan Institute of Medical Research', 7),\n",
       " ('Tel-Aviv Sourasky Medical Center', 7),\n",
       " (\"Guangdong Provincial People's Hospital\", 7),\n",
       " ('University of Bristol', 7),\n",
       " ('HaEmek Medical Center, Israel', 7),\n",
       " (\"St. Jude Children's Research Hospital\", 7),\n",
       " ('National Council of Science and Technology, Mexico', 7),\n",
       " ('Oxford Brookes University', 7),\n",
       " ('Universitat de Girona', 7),\n",
       " ('Cliniques universitaires Saint-Luc- Université Catholique de Louvain', 7),\n",
       " ('Population Health Research Institute', 7),\n",
       " ('Physicians Committee for Responsible Medicine', 7),\n",
       " ('Dairy Farmers of Canada', 7),\n",
       " ('RWTH Aachen University', 7),\n",
       " ('Charles University, Czech Republic', 7),\n",
       " ('Peking University', 7),\n",
       " ('Azienda Ospedaliero-Universitaria di Parma', 7),\n",
       " ('Huazhong University of Science and Technology', 7),\n",
       " (\"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.\", 7),\n",
       " ('The Royal Bournemouth Hospital', 7),\n",
       " ('Department of Health and Human Services', 7),\n",
       " ('Chongqing Medical University', 7),\n",
       " ('Pamukkale University', 7),\n",
       " ('Immune Tolerance Network (ITN)', 7),\n",
       " ('Oregon Research Institute', 7),\n",
       " ('Korea University Anam Hospital', 7),\n",
       " ('University of Liverpool', 7),\n",
       " ('East Carolina University', 7),\n",
       " ('University of Vermont', 7),\n",
       " ('Beijing Friendship Hospital', 7),\n",
       " ('Heidelberg University', 7),\n",
       " ('Rambam Health Care Campus', 7),\n",
       " ('Thomas Jefferson University', 7),\n",
       " ('Technical University of Munich', 7),\n",
       " ('Cystic Fibrosis Foundation', 7),\n",
       " ('University of Pavia', 7),\n",
       " ('Charles Drew University of Medicine and Science', 7),\n",
       " ('National Institutes of Health Clinical Center (CC)', 7),\n",
       " ('University of Maryland', 7),\n",
       " ('University of Turku', 7),\n",
       " ('Tampere University', 7),\n",
       " ('German Federal Ministry of Education and Research', 7),\n",
       " ('Jagiellonian University', 7),\n",
       " ('University of Connecticut', 7),\n",
       " ('Hospital Clinic of Barcelona', 7),\n",
       " ('Tan Tock Seng Hospital', 7),\n",
       " ('National Institute of Dental and Craniofacial Research (NIDCR)', 7),\n",
       " ('Regeneron Pharmaceuticals', 7),\n",
       " ('Wolfson Medical Center', 7),\n",
       " ('Stony Brook University', 7),\n",
       " ('Daiichi Sankyo Co., Ltd.', 7),\n",
       " ('Salk Institute for Biological Studies', 7),\n",
       " ('Dompé Farmaceutici S.p.A', 6),\n",
       " ('Fogarty International Center of the National Institute of Health', 6),\n",
       " ('Northumbria University', 6),\n",
       " ('NHS Lothian', 6),\n",
       " ('Memorial Sloan Kettering Cancer Center', 6),\n",
       " ('Taipei Medical University', 6),\n",
       " ('Medpace, Inc.', 6),\n",
       " ('Universidad de Antioquia', 6),\n",
       " ('King Saud University', 6),\n",
       " ('Hasselt University', 6),\n",
       " ('Chromaderm, Inc.', 6),\n",
       " ('Azienda Ospedaliero Universitaria Maggiore della Carita', 6),\n",
       " ('The Novo Nordisk Foundation Center for Basic Metabolic Research', 6),\n",
       " ('Poitiers University Hospital', 6),\n",
       " ('University of Ottawa', 6),\n",
       " ('UNEEG Medical A/S', 6),\n",
       " ('The Swedish Research Council', 6),\n",
       " ('Istanbul University - Cerrahpasa (IUC)', 6),\n",
       " ('Clalit Health Services', 6),\n",
       " ('Heinrich-Heine University, Duesseldorf', 6),\n",
       " ('St. Louis University', 6),\n",
       " ('University of Leipzig', 6),\n",
       " ('Mansoura University', 6),\n",
       " ('Ottawa Heart Institute Research Corporation', 6),\n",
       " ('Intarcia Therapeutics', 6),\n",
       " ('Universidad Peruana Cayetano Heredia', 6),\n",
       " ('Taichung Veterans General Hospital', 6),\n",
       " ('Centre Hospitalier Universitaire de Besancon', 6),\n",
       " ('Universidade do Porto', 6),\n",
       " ('National Science Council, Taiwan', 6),\n",
       " ('Universidade Federal do Rio de Janeiro', 6),\n",
       " ('Animas Corporation', 6),\n",
       " ('Chulalongkorn University', 6),\n",
       " ('Region of Southern Denmark', 6),\n",
       " ('Harvard Medical School (HMS and HSDM)', 6),\n",
       " ('REMD Biotherapeutics, Inc.', 6),\n",
       " ('Centre for Addiction and Mental Health', 6),\n",
       " ('Evidation Health', 6),\n",
       " (\"Peking University People's Hospital\", 6),\n",
       " ('Peking University First Hospital', 6),\n",
       " ('University of Surrey', 6),\n",
       " ('XOMA (US) LLC', 6),\n",
       " ('Loughborough University', 6),\n",
       " ('Central Hospital, Nancy, France', 6),\n",
       " ('University of Rome Tor Vergata', 6),\n",
       " ('Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.', 6),\n",
       " ('Ataturk University', 6),\n",
       " ('Nottingham University Hospitals NHS Trust', 6),\n",
       " ('Newcastle-upon-Tyne Hospitals NHS Trust', 6),\n",
       " ('Michigan State University', 6),\n",
       " ('Regionshospitalet Silkeborg', 6),\n",
       " (\"Guang'anmen Hospital of China Academy of Chinese Medical Sciences\", 6),\n",
       " ('Loyola University', 6),\n",
       " ('University of Tennessee', 6),\n",
       " ('Texas Tech University Health Sciences Center', 6),\n",
       " ('Alberta Health services', 6),\n",
       " ('Unilever R&D', 6),\n",
       " ('Biotechnology and Biological Sciences Research Council', 6),\n",
       " ('Bogomolets National Medical University', 6),\n",
       " ('University of Castilla-La Mancha', 6),\n",
       " ('Fundação para a Ciência e a Tecnologia', 6),\n",
       " ('University of California, Berkeley', 6),\n",
       " ('University of Sheffield', 6),\n",
       " ('Academy of Finland', 6),\n",
       " ('Medanta, The Medicity, India', 6),\n",
       " ('Gazi University', 6),\n",
       " ('Ono Pharmaceutical Co. Ltd', 6),\n",
       " ('Danish Diabetes Academy', 6),\n",
       " ('DSM Nutritional Products, Inc.', 6),\n",
       " ('Norwegian Diabetes Association', 6),\n",
       " (\"UCSF Benioff Children's Hospital Oakland\", 6),\n",
       " ('OPKO Health, Inc.', 6),\n",
       " ('Istanbul Medeniyet University', 6),\n",
       " ('Intermountain Health Care, Inc.', 6),\n",
       " ('Rashid Centre for Diabetes and Research', 6),\n",
       " ('Abant Izzet Baysal University', 6),\n",
       " ('Midwest Center for Metabolic and Cardiovascular Research', 6),\n",
       " ('Harvard Pilgrim Health Care', 6),\n",
       " ('Maccabi Healthcare Services, Israel', 6),\n",
       " ('Top Institute Food and Nutrition', 6),\n",
       " ('Diabetes Research Institute Foundation', 6),\n",
       " ('National Health Service, United Kingdom', 6),\n",
       " ('Groupe Hospitalier Pitie-Salpetriere', 6),\n",
       " ('Canadian Network for Observational Drug Effect Studies, CNODES', 6),\n",
       " ('Drug Safety and Effectiveness Network, Canada', 6),\n",
       " ('University of Thessaly', 6),\n",
       " ('Creighton University', 6),\n",
       " ('Baylor Research Institute', 6),\n",
       " ('Liverpool University Hospitals NHS Foundation Trust', 6),\n",
       " ('University of Malaya', 6),\n",
       " ('Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal',\n",
       "  5),\n",
       " ('Azienda Ospedaliero-Universitaria Careggi', 5),\n",
       " (\"Children's Hospital Colorado\", 5),\n",
       " ('Diabeloop', 5),\n",
       " ('AGIR à Dom', 5),\n",
       " ('GWT-TUD GmbH', 5),\n",
       " ('Kasr El Aini Hospital', 5),\n",
       " ('Onze Lieve Vrouw Hospital', 5),\n",
       " ('Weizmann Institute of Science', 5),\n",
       " ('DCB Research AG', 5),\n",
       " ('University of Bari', 5),\n",
       " ('Gulhane School of Medicine', 5),\n",
       " ('University of St.Gallen', 5),\n",
       " ('ETH Zurich', 5),\n",
       " ('Peter Rossing', 5),\n",
       " ('Kuopio University Hospital', 5),\n",
       " (\"St. Joseph's Healthcare Hamilton\", 5),\n",
       " ('Université Montpellier', 5),\n",
       " ('Second Hospital of Shanxi Medical University', 5),\n",
       " ('Inreda Diabetic B.V.', 5),\n",
       " ('Sidra Medical and Research Center', 5),\n",
       " ('The Hong Kong Polytechnic University', 5),\n",
       " ('Zhongda Hospital', 5),\n",
       " ('University Hospital Birmingham NHS Foundation Trust', 5),\n",
       " ('University of Geneva, Switzerland', 5),\n",
       " ('Alexandria University', 5),\n",
       " ('PPD', 5),\n",
       " ('Holbaek Sygehus', 5),\n",
       " ('Meir Medical Center', 5),\n",
       " ('PhaseBio Pharmaceuticals Inc.', 5),\n",
       " ('The University of Queensland', 5),\n",
       " ('Parexel', 5),\n",
       " ('AdventHealth', 5),\n",
       " (\"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico\", 5),\n",
       " ('Imperial College Healthcare NHS Trust', 5),\n",
       " ('Alberta Innovates Health Solutions', 5),\n",
       " ('Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders',\n",
       "  5),\n",
       " ('Pusan National University Hospital', 5),\n",
       " ('Cardiff University', 5),\n",
       " ('All India Institute of Medical Sciences, New Delhi', 5),\n",
       " ('Umeå University', 5),\n",
       " ('University of Ljubljana', 5),\n",
       " ('Centre Hospitalier Universitaire Vaudois', 5),\n",
       " ('United States Department of Agriculture (USDA)', 5),\n",
       " ('Hannover Medical School', 5),\n",
       " ('University Hospital of North Norway', 5),\n",
       " ('Eastern Virginia Medical School', 5),\n",
       " ('Mahidol University', 5),\n",
       " ('Campus Bio-Medico University', 5),\n",
       " ('Hennepin Healthcare Research Institute', 5),\n",
       " ('University of Massachusetts, Amherst', 5),\n",
       " ('United Arab Emirates University', 5),\n",
       " ('University of Auckland, New Zealand', 5),\n",
       " ('Beijing Chao Yang Hospital', 5),\n",
       " (\"Montreal Children's Hospital of the MUHC\", 5),\n",
       " (\"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement\",\n",
       "  5),\n",
       " (\"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta\", 5),\n",
       " ('Vrije Universiteit Brussel', 5),\n",
       " ('Diabetes Canada', 5),\n",
       " ('University of Yaounde 1', 5),\n",
       " ('University of Athens', 5),\n",
       " ('Hanmi Pharmaceutical Company Limited', 5),\n",
       " ('University of Southampton', 5),\n",
       " ('Arla Foods', 5),\n",
       " ('Geropharm', 5),\n",
       " ('University of Turin, Italy', 5),\n",
       " ('Rijnstate Hospital', 5),\n",
       " ('York University', 5),\n",
       " ('Fondation Ophtalmologique Adolphe de Rothschild', 5),\n",
       " ('Royal College of Surgeons, Ireland', 5),\n",
       " ('Akdeniz University', 5),\n",
       " ('Endocrine Research Society', 5),\n",
       " ('Ministry of Health, Singapore', 5),\n",
       " ('Changi General Hospital', 5),\n",
       " ('National Medical Research Council (NMRC), Singapore', 5),\n",
       " ('University of Kansas', 5),\n",
       " ('Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes', 5),\n",
       " ('Fractyl Laboratories, Inc.', 5),\n",
       " ('Kangbuk Samsung Hospital', 5),\n",
       " ('University of Illinois at Urbana-Champaign', 5),\n",
       " ('Instituto Nacional de Salud Publica, Mexico', 5),\n",
       " ('Chinese Academy of Sciences', 5),\n",
       " ('Istanbul Medipol University Hospital', 5),\n",
       " ('University Hospital Carl Gustav Carus', 5),\n",
       " ('Singapore Institute for Clinical Sciences', 5),\n",
       " ('Dexa Medica Group', 5),\n",
       " ('University of Messina', 5),\n",
       " ('The Danish Medical Research Council', 5),\n",
       " ('Université de Montréal', 5),\n",
       " ('Astra Zeneca, Bristol-Myers Squibb', 5),\n",
       " ('Third Military Medical University', 5),\n",
       " ('Liegang Liu', 5),\n",
       " ('Tulane University', 5),\n",
       " ('Beijing Tongren Hospital', 5),\n",
       " ('RTI International', 5),\n",
       " ('Kaohsiung Medical University Chung-Ho Memorial Hospital', 5),\n",
       " ('Legacy Health System', 5),\n",
       " ('Philip Kern', 5),\n",
       " ('TrygFonden, Denmark', 5),\n",
       " ('Hangzhou Sciwind Biosciences Co., Ltd.', 5),\n",
       " ('University of Groningen', 5),\n",
       " ('Hospital Regional de Alta Especialidad del Bajio', 5),\n",
       " ('Filip Krag Knop', 5),\n",
       " ('China Medical University Hospital', 5),\n",
       " ('Helse Stavanger HF', 5),\n",
       " (\"Office of Research on Women's Health (ORWH)\", 5),\n",
       " ('Universiti Teknologi Mara', 5),\n",
       " ('National Diabetes Obesity and Cholesterol Foundation', 5),\n",
       " ('Université de Reims Champagne-Ardenne', 5),\n",
       " ('Benaroya Research Institute', 5),\n",
       " ('AbbVie', 5),\n",
       " ('University of Western Ontario, Canada', 5),\n",
       " ('China National Center for Cardiovascular Diseases', 5),\n",
       " ('Ankara Yildirim Beyazıt University', 5),\n",
       " ('Rutgers University', 5),\n",
       " ('Ningbo No. 1 Hospital', 5),\n",
       " ('University Hospital Heidelberg', 5),\n",
       " ('Taipei Medical University WanFang Hospital', 5),\n",
       " ('American Egg Board', 5),\n",
       " (\"Hospital Universitari Vall d'Hebron Research Institute\", 5),\n",
       " ('Taipei Veterans General Hospital, Taiwan', 5),\n",
       " ('University of Stellenbosch', 5),\n",
       " ('Janssen Scientific Affairs, LLC', 5),\n",
       " ('CSPC ZhongQi Pharmaceutical Technology Co., Ltd.', 5),\n",
       " ('Ontario Ministry of Health and Long Term Care', 5),\n",
       " ('The First Affiliated Hospital with Nanjing Medical University', 5),\n",
       " ('Chong Kun Dang Pharmaceutical', 5),\n",
       " ('Chinese PLA General Hospital', 5),\n",
       " ('RenJi Hospital', 5),\n",
       " ('Samuel Lunenfeld Research Institute, Mount Sinai Hospital', 5),\n",
       " ('PegBio Co., Ltd.', 5),\n",
       " ('Cedars-Sinai Medical Center', 5),\n",
       " ('Khoo Teck Puat Hospital', 5),\n",
       " (\"Nationwide Children's Hospital\", 5),\n",
       " ('Academy of Nutrition and Dietetics', 5),\n",
       " ('University of Zagreb', 5),\n",
       " ('Zhongshan Ophthalmic Center, Sun Yat-sen University', 4),\n",
       " ('Aventis Pharmaceuticals', 4),\n",
       " ('vTv Therapeutics', 4),\n",
       " ('SomaLogic, Inc.', 4),\n",
       " ('Akros Pharma Inc.', 4),\n",
       " ('Universidad de Sonora', 4),\n",
       " ('ICON plc', 4),\n",
       " (\"Mike O'Callaghan Military Hospital\", 4),\n",
       " ('Weill Cornell Medical College in Qatar', 4),\n",
       " ('Centers for Medicare and Medicaid Services', 4),\n",
       " ('University Hospital, Zürich', 4),\n",
       " ('Marc Breton', 4),\n",
       " ('Sciema UG', 4),\n",
       " ('Tianjin Medical University Eye Hospital', 4),\n",
       " ('Antaros Medical', 4),\n",
       " ('Sunnybrook Research Institute', 4),\n",
       " ('Suzhou Yabao Pharmaceutical R&D Co., Ltd.', 4),\n",
       " ('Marjukka Kolehmainen', 4),\n",
       " ('Universitätsklinikum Hamburg-Eppendorf', 4),\n",
       " ('Madras Diabetes Research Foundation', 4),\n",
       " ('Swedish Child Diabetes Foundation', 4),\n",
       " ('Ecole Polytechnique Fédérale de Lausanne', 4),\n",
       " ('University of Freiburg', 4),\n",
       " ('Glooko', 4),\n",
       " ('Ethicon Endo-Surgery', 4),\n",
       " ('China-Japan Friendship Hospital', 4),\n",
       " ('European Union', 4),\n",
       " ('Université Catholique de Louvain', 4),\n",
       " ('Norfolk and Norwich University Hospitals NHS Foundation Trust', 4),\n",
       " ('Nanjing Medical University', 4),\n",
       " ('Institut Pasteur de Lille', 4),\n",
       " ('West China Hospital', 4),\n",
       " ('Chungbuk National University Hospital', 4),\n",
       " ('Innovent Biologics (Suzhou) Co. Ltd.', 4),\n",
       " ('National Taiwan University', 4),\n",
       " ('Bezmialem Vakif University', 4),\n",
       " ('Lund University Hospital', 4),\n",
       " ('Fayoum University', 4),\n",
       " ('Centre Hospitalier Universitaire de Saint Etienne', 4),\n",
       " ('UnitedHealth Group', 4),\n",
       " ('University of Plymouth', 4),\n",
       " ('Heart and Diabetes Center North-Rhine Westfalia', 4),\n",
       " ('Ankara City Hospital Bilkent', 4),\n",
       " ('Ministerio de Economía y Competitividad, Spain', 4),\n",
       " ('Westlake University', 4),\n",
       " ('University Hospitals Bristol and Weston NHS Foundation Trust', 4),\n",
       " ('Beni-Suef University', 4),\n",
       " ('Public Health Foundation of India', 4),\n",
       " ('Carmot Therapeutics, Inc.', 4),\n",
       " ('Catalysis SL', 4),\n",
       " ('Kansas State University', 4),\n",
       " ('Nanyang Technological University', 4),\n",
       " ('University Hospital, Angers', 4),\n",
       " ('Shahid Beheshti University of Medical Sciences', 4),\n",
       " ('Huashan Hospital', 4),\n",
       " ('University College London Hospitals', 4),\n",
       " ('University of Bologna', 4),\n",
       " ('Wuhan General Hospital of Guangzhou Military Command', 4),\n",
       " ('Umm Al-Qura University', 4),\n",
       " ('Office of Dietary Supplements (ODS)', 4),\n",
       " ('Ospedale San Raffaele', 4),\n",
       " ('Ziekenhuisgroep Twente', 4),\n",
       " ('University of Twente', 4),\n",
       " ('Mỹ Đức Hospital', 4),\n",
       " ('University Magna Graecia', 4),\n",
       " ('Zhejiang University', 4),\n",
       " (\"Women's College Hospital\", 4),\n",
       " ('AbbVie (prior sponsor, Abbott)', 4),\n",
       " ('Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado',\n",
       "  4),\n",
       " ('University of Nevada, Las Vegas', 4),\n",
       " ('Al-Azhar University', 4),\n",
       " ('Norbert Hermanns', 4),\n",
       " ('James J. Peters Veterans Affairs Medical Center', 4),\n",
       " ('University Hospital, Akershus', 4),\n",
       " ('Mondelēz International, Inc.', 4),\n",
       " ('Chonbuk National University Hospital', 4),\n",
       " ('Tel Aviv University', 4),\n",
       " ('Universidad de Valparaiso', 4),\n",
       " ('Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center',\n",
       "  4),\n",
       " ('Women and Infants Hospital of Rhode Island', 4),\n",
       " ('Institute of Liver and Biliary Sciences, India', 4),\n",
       " ('Manitoba Institute of Child Health', 4),\n",
       " ('Per-Ola Carlsson', 4),\n",
       " ('Cargill', 4),\n",
       " ('Agriculture and Agri-Food Canada', 4),\n",
       " ('Carnegie Mellon University', 4),\n",
       " ('BioKier Inc.', 4),\n",
       " ('Wroclaw Medical University', 4),\n",
       " ('King Abdullah International Medical Research Center', 4),\n",
       " ('Colorado Clinical & Translational Sciences Institute', 4),\n",
       " ('Ramathibodi Hospital', 4),\n",
       " ('Genzyme, a Sanofi Company', 4),\n",
       " ('Albert Einstein Healthcare Network', 4),\n",
       " ('Medical University of Bialystok', 4),\n",
       " ('Medical University of Gdansk', 4),\n",
       " ('Universidade Nova de Lisboa', 4),\n",
       " ('Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis',\n",
       "  4),\n",
       " ('Herlev and Gentofte Hospital', 4),\n",
       " ('Universidad de Zaragoza', 4),\n",
       " ('Baker Heart and Diabetes Institute', 4),\n",
       " ('IKFE Institute for Clinical Research and Development', 4),\n",
       " ('University of Saskatchewan', 4),\n",
       " ('Diabetes Research Foundation, Finland', 4),\n",
       " ('Scripps Translational Science Institute', 4),\n",
       " (\"Fourth People's Hospital of Shenyang\", 4),\n",
       " ('Medipol University', 4),\n",
       " ('Microclinic International', 4),\n",
       " ('Royal Brompton & Harefield NHS Foundation Trust', 4),\n",
       " (\"KK Women's and Children's Hospital\", 4),\n",
       " ('National University Health System, Singapore', 4),\n",
       " (\"The Physicians' Services Incorporated Foundation\", 4),\n",
       " ('National Research Council, Spain', 4),\n",
       " ('Istituto Auxologico Italiano', 4),\n",
       " ('Region Örebro County', 4),\n",
       " ('The Danish Council for Strategic Research', 4),\n",
       " ('Sanford Health', 4),\n",
       " ('University Hospital, Brest', 4),\n",
       " ('USDA, Western Human Nutrition Research Center', 4),\n",
       " ('Colgate Palmolive', 4),\n",
       " ('Queen Mary University of London', 4),\n",
       " ('Adrian Vella', 4),\n",
       " ('Société Francophone du Diabète', 4),\n",
       " (\"Children's Hospital of Fudan University\", 4),\n",
       " ('Saglik Bilimleri Universitesi', 4),\n",
       " ('Almond Board of California', 4),\n",
       " ('University Hospital Ostrava', 4),\n",
       " ('Changhua Christian Hospital', 4),\n",
       " ('Astellas Pharma Korea, Inc.', 4),\n",
       " ('UConn Health', 4),\n",
       " ('Medical University of Silesia', 4),\n",
       " ('Diasome Pharmaceuticals', 4),\n",
       " ('Örebro University, Sweden', 4),\n",
       " ('National Taipei University of Nursing and Health Sciences', 4),\n",
       " ('University of Roehampton', 4),\n",
       " ('Integrated Medical Development', 4),\n",
       " ('Mylan Inc.', 4),\n",
       " ('Mylan GmbH', 4),\n",
       " ('Slagelse Hospital', 4),\n",
       " ('University of East Anglia', 4),\n",
       " ('University of Dublin, Trinity College', 4),\n",
       " ('University College Hospital Galway', 4),\n",
       " ('Institute for Clinical Evaluative Sciences', 4),\n",
       " ('Chemical Resources', 4),\n",
       " ('Universitat Politècnica de València', 4),\n",
       " ('Bo Feldt-Rasmussen', 4),\n",
       " ('Tulane University School of Medicine', 4),\n",
       " ('Lundbeck Foundation', 4),\n",
       " ('Institut Investigacio Sanitaria Pere Virgili', 4),\n",
       " ('Elcelyx Therapeutics, Inc.', 4),\n",
       " ('Fuzhou General Hospital', 4),\n",
       " ('Imperial College London Diabetes Centre', 4),\n",
       " ('Medtronic - MITG', 4),\n",
       " ('Mexican National Institute of Public Health', 4),\n",
       " ('Diabetes Québec', 4),\n",
       " ('The Emmes Company, LLC', 4),\n",
       " ('Foundation for the National Institutes of Health', 4),\n",
       " (\"Queen's University\", 4),\n",
       " ('Department of Health, United Kingdom', 4),\n",
       " ('First Affiliated Hospital, Sun Yat-Sen University', 4),\n",
       " ('Beta Bionics, Inc.', 4),\n",
       " ('Public Health Agency of Canada (PHAC)', 4),\n",
       " ('Integra LifeSciences Corporation', 4),\n",
       " ('Northwestern University Feinberg School of Medicine', 4),\n",
       " ('Soroka University Medical Center', 4),\n",
       " ('Locemia Solutions ULC', 4),\n",
       " ('Christiana Care Health Services', 4),\n",
       " ('Azienda Ospedaliera Universitaria Integrata Verona', 4),\n",
       " ('Okan University', 4),\n",
       " ('French Cardiology Society', 4),\n",
       " ('ResMed', 4),\n",
       " (\"Centre de Recherche du Centre Hospitalier de l'Université de Montréal\", 4),\n",
       " ('Beijing Hospital', 4),\n",
       " ('Institut Català de la Salut', 4),\n",
       " ('Canadian Foundation for Dietetic Research (CFDR)', 4),\n",
       " ('Groupe Hospitalier de la Region de Mulhouse et Sud Alsace', 4),\n",
       " ('Henry Ford Health System', 4),\n",
       " ...]"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sortedspon = sorted(dict_spon.items(), key=lambda x:x[1],reverse=True)\n",
    "sortedspon"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(19301,)"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_spon = pd.read_csv('../Diabetes/Diabetes_index_next_cnt_total.csv')\n",
    "df_spon['index'].shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "      <th>next</th>\n",
       "      <th>cnt</th>\n",
       "      <th>condition</th>\n",
       "      <th>condition_len</th>\n",
       "      <th>idxcnt</th>\n",
       "      <th>onecnt</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Boehringer Ingelheim</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>62</td>\n",
       "      <td>diabetes mellitus, type 2|diabetes mellitus, t...</td>\n",
       "      <td>171</td>\n",
       "      <td>145</td>\n",
       "      <td>62</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>50</td>\n",
       "      <td>type 2 diabetes mellitus|type 2 diabetes melli...</td>\n",
       "      <td>401</td>\n",
       "      <td>314</td>\n",
       "      <td>138</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>National Institutes of Health (NIH)</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>43</td>\n",
       "      <td>obesity|insulin resistance|type2 diabetes|diab...</td>\n",
       "      <td>245</td>\n",
       "      <td>132</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Yale University</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>24</td>\n",
       "      <td>hypo-unawareness|type 1 diabetes mellitus|type...</td>\n",
       "      <td>143</td>\n",
       "      <td>86</td>\n",
       "      <td>18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>University of Virginia</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>23</td>\n",
       "      <td>diabetes mellitus, type 1|pregnancy|type 1 dia...</td>\n",
       "      <td>91</td>\n",
       "      <td>73</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19277</th>\n",
       "      <td>University of North Texas Health Science Center</td>\n",
       "      <td>University of California, San Francisco</td>\n",
       "      <td>1</td>\n",
       "      <td>hiv/aids|diabetes mellitus, type 2|hypertensio...</td>\n",
       "      <td>5</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19285</th>\n",
       "      <td>Ospedale dell'Angelo, Venezia-Mestre</td>\n",
       "      <td>University of Pavia</td>\n",
       "      <td>1</td>\n",
       "      <td>covid19</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19291</th>\n",
       "      <td>Papa Giovanni XXIII Hospital</td>\n",
       "      <td>IRCCS Policlinico S. Matteo</td>\n",
       "      <td>1</td>\n",
       "      <td>covid19|chronic heart failure|diabetes mellitus</td>\n",
       "      <td>3</td>\n",
       "      <td>2</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19295</th>\n",
       "      <td>IRCCS Policlinico S. Matteo</td>\n",
       "      <td>Humanitas Hospital, Italy</td>\n",
       "      <td>1</td>\n",
       "      <td>covid19|sexual dysfunction|neuropathy|diabetes...</td>\n",
       "      <td>5</td>\n",
       "      <td>3</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19298</th>\n",
       "      <td>Humanitas Hospital, Italy</td>\n",
       "      <td>Ospedale dell'Angelo, Venezia-Mestre</td>\n",
       "      <td>1</td>\n",
       "      <td>covid19</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3613 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                 index  \\\n",
       "0                                 Boehringer Ingelheim   \n",
       "1                                          AstraZeneca   \n",
       "3                  National Institutes of Health (NIH)   \n",
       "4                                      Yale University   \n",
       "5                               University of Virginia   \n",
       "...                                                ...   \n",
       "19277  University of North Texas Health Science Center   \n",
       "19285             Ospedale dell'Angelo, Venezia-Mestre   \n",
       "19291                     Papa Giovanni XXIII Hospital   \n",
       "19295                      IRCCS Policlinico S. Matteo   \n",
       "19298                        Humanitas Hospital, Italy   \n",
       "\n",
       "                                                    next  cnt  \\\n",
       "0                                  Eli Lilly and Company   62   \n",
       "1                                   Bristol-Myers Squibb   50   \n",
       "3      National Institute of Diabetes and Digestive a...   43   \n",
       "4      National Institute of Diabetes and Digestive a...   24   \n",
       "5      National Institute of Diabetes and Digestive a...   23   \n",
       "...                                                  ...  ...   \n",
       "19277            University of California, San Francisco    1   \n",
       "19285                                University of Pavia    1   \n",
       "19291                        IRCCS Policlinico S. Matteo    1   \n",
       "19295                          Humanitas Hospital, Italy    1   \n",
       "19298               Ospedale dell'Angelo, Venezia-Mestre    1   \n",
       "\n",
       "                                               condition  condition_len  \\\n",
       "0      diabetes mellitus, type 2|diabetes mellitus, t...            171   \n",
       "1      type 2 diabetes mellitus|type 2 diabetes melli...            401   \n",
       "3      obesity|insulin resistance|type2 diabetes|diab...            245   \n",
       "4      hypo-unawareness|type 1 diabetes mellitus|type...            143   \n",
       "5      diabetes mellitus, type 1|pregnancy|type 1 dia...             91   \n",
       "...                                                  ...            ...   \n",
       "19277  hiv/aids|diabetes mellitus, type 2|hypertensio...              5   \n",
       "19285                                            covid19              1   \n",
       "19291    covid19|chronic heart failure|diabetes mellitus              3   \n",
       "19295  covid19|sexual dysfunction|neuropathy|diabetes...              5   \n",
       "19298                                            covid19              1   \n",
       "\n",
       "       idxcnt  onecnt  \n",
       "0         145      62  \n",
       "1         314     138  \n",
       "3         132       0  \n",
       "4          86      18  \n",
       "5          73      11  \n",
       "...       ...     ...  \n",
       "19277       2       0  \n",
       "19285       1       0  \n",
       "19291       2       0  \n",
       "19295       3       0  \n",
       "19298       1       0  \n",
       "\n",
       "[3613 rows x 7 columns]"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_spon.drop_duplicates('index') #3613노드 #19301엣지"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "      <th>next</th>\n",
       "      <th>cnt</th>\n",
       "      <th>sentences</th>\n",
       "      <th>idxcnt</th>\n",
       "      <th>onecnt</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Boehringer Ingelheim</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>62</td>\n",
       "      <td>Diabetes Mellitus, Type 2 Primary objective: s...</td>\n",
       "      <td>145</td>\n",
       "      <td>62</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>50</td>\n",
       "      <td>Type 2 Diabetes Mellitus This study will exami...</td>\n",
       "      <td>314</td>\n",
       "      <td>138</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>46</td>\n",
       "      <td>Type 2 Diabetes Mellitus This study will exami...</td>\n",
       "      <td>314</td>\n",
       "      <td>138</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>National Institutes of Health (NIH)</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>43</td>\n",
       "      <td>Obesity|Insulin Resistance|Type2 Diabetes The ...</td>\n",
       "      <td>132</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Yale University</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>24</td>\n",
       "      <td>Hypo-unawareness|Type 1 Diabetes Mellitus Insu...</td>\n",
       "      <td>86</td>\n",
       "      <td>18</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                 index  \\\n",
       "0                 Boehringer Ingelheim   \n",
       "1                          AstraZeneca   \n",
       "2                          AstraZeneca   \n",
       "3  National Institutes of Health (NIH)   \n",
       "4                      Yale University   \n",
       "\n",
       "                                                next cnt  \\\n",
       "0                              Eli Lilly and Company  62   \n",
       "1                               Bristol-Myers Squibb  50   \n",
       "2                              Eli Lilly and Company  46   \n",
       "3  National Institute of Diabetes and Digestive a...  43   \n",
       "4  National Institute of Diabetes and Digestive a...  24   \n",
       "\n",
       "                                           sentences  idxcnt  onecnt  \n",
       "0  Diabetes Mellitus, Type 2 Primary objective: s...     145      62  \n",
       "1  Type 2 Diabetes Mellitus This study will exami...     314     138  \n",
       "2  Type 2 Diabetes Mellitus This study will exami...     314     138  \n",
       "3  Obesity|Insulin Resistance|Type2 Diabetes The ...     132       0  \n",
       "4  Hypo-unawareness|Type 1 Diabetes Mellitus Insu...      86      18  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "def checkcond(x):\n",
    "    return str(countdf[countdf['aff']==x]['sentences'].iloc[0])\n",
    "\n",
    "filepath = '../Diabetes/Diabetes_index_next_cnt_total.csv'\n",
    "# if os.path.isfile(filepath):\n",
    "#     df_spon = pd.read_csv(filepath)\n",
    "#     df_spon = df_spon.sort_values('idxcnt')\n",
    "\n",
    "# else:        \n",
    "df_spon['sentences'] = df_spon['index'].apply(lambda x:checkcond(x))\n",
    "# df_spon['sentences_len'] = df_spon['sentences'].apply(lambda x:len(x.split('|')))\n",
    "df_spon['idxcnt'] = df_spon.apply(lambda x:dict_spon[x['index']],axis=1)\n",
    "df_spon['onecnt'] = df_spon.apply(lambda x:one_spon[x['index']] if x['index'] in one_spon.keys() else 0,axis=1)\n",
    "df_spon.reset_index(drop=True,inplace=True)\n",
    "df_spon.to_csv('../Diabetes/Diabetes_index_next_cnt_total.csv',index=False) # affiliation + sponsor\n",
    "display(df_spon.head(5))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>index</th>\n",
       "      <th>next</th>\n",
       "      <th>cnt</th>\n",
       "      <th>condition</th>\n",
       "      <th>condition_len</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>432</th>\n",
       "      <td>Boehringer Ingelheim</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>62</td>\n",
       "      <td>diabetes mellitus, type 2|diabetes mellitus, t...</td>\n",
       "      <td>171</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>336</th>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>50</td>\n",
       "      <td>type 2 diabetes mellitus|type 2 diabetes melli...</td>\n",
       "      <td>401</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>231</th>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>46</td>\n",
       "      <td>type 2 diabetes mellitus|type 2 diabetes melli...</td>\n",
       "      <td>401</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>213</th>\n",
       "      <td>National Institutes of Health (NIH)</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>43</td>\n",
       "      <td>obesity|insulin resistance|type2 diabetes|diab...</td>\n",
       "      <td>245</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>331</th>\n",
       "      <td>Yale University</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>24</td>\n",
       "      <td>hypo-unawareness|type 1 diabetes mellitus|type...</td>\n",
       "      <td>143</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7188</th>\n",
       "      <td>IRCCS Policlinico S. Matteo</td>\n",
       "      <td>Ospedale dell'Angelo, Venezia-Mestre</td>\n",
       "      <td>1</td>\n",
       "      <td>covid19|sexual dysfunction|neuropathy|diabetes...</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7189</th>\n",
       "      <td>IRCCS Policlinico S. Matteo</td>\n",
       "      <td>University of Pavia</td>\n",
       "      <td>1</td>\n",
       "      <td>covid19|sexual dysfunction|neuropathy|diabetes...</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7190</th>\n",
       "      <td>Humanitas Hospital, Italy</td>\n",
       "      <td>Ospedale dell'Angelo, Venezia-Mestre</td>\n",
       "      <td>1</td>\n",
       "      <td>covid19</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7191</th>\n",
       "      <td>Humanitas Hospital, Italy</td>\n",
       "      <td>University of Pavia</td>\n",
       "      <td>1</td>\n",
       "      <td>covid19</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19300</th>\n",
       "      <td>Swiss Federal Institute of Technology</td>\n",
       "      <td>University of St.Gallen</td>\n",
       "      <td>1</td>\n",
       "      <td>diabetes type 2|obesity|diabetes|diabetes mell...</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>19301 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                       index  \\\n",
       "432                     Boehringer Ingelheim   \n",
       "336                              AstraZeneca   \n",
       "231                              AstraZeneca   \n",
       "213      National Institutes of Health (NIH)   \n",
       "331                          Yale University   \n",
       "...                                      ...   \n",
       "7188             IRCCS Policlinico S. Matteo   \n",
       "7189             IRCCS Policlinico S. Matteo   \n",
       "7190               Humanitas Hospital, Italy   \n",
       "7191               Humanitas Hospital, Italy   \n",
       "19300  Swiss Federal Institute of Technology   \n",
       "\n",
       "                                                    next cnt  \\\n",
       "432                                Eli Lilly and Company  62   \n",
       "336                                 Bristol-Myers Squibb  50   \n",
       "231                                Eli Lilly and Company  46   \n",
       "213    National Institute of Diabetes and Digestive a...  43   \n",
       "331    National Institute of Diabetes and Digestive a...  24   \n",
       "...                                                  ...  ..   \n",
       "7188                Ospedale dell'Angelo, Venezia-Mestre   1   \n",
       "7189                                 University of Pavia   1   \n",
       "7190                Ospedale dell'Angelo, Venezia-Mestre   1   \n",
       "7191                                 University of Pavia   1   \n",
       "19300                            University of St.Gallen   1   \n",
       "\n",
       "                                               condition  condition_len  \n",
       "432    diabetes mellitus, type 2|diabetes mellitus, t...            171  \n",
       "336    type 2 diabetes mellitus|type 2 diabetes melli...            401  \n",
       "231    type 2 diabetes mellitus|type 2 diabetes melli...            401  \n",
       "213    obesity|insulin resistance|type2 diabetes|diab...            245  \n",
       "331    hypo-unawareness|type 1 diabetes mellitus|type...            143  \n",
       "...                                                  ...            ...  \n",
       "7188   covid19|sexual dysfunction|neuropathy|diabetes...              5  \n",
       "7189   covid19|sexual dysfunction|neuropathy|diabetes...              5  \n",
       "7190                                             covid19              1  \n",
       "7191                                             covid19              1  \n",
       "19300  diabetes type 2|obesity|diabetes|diabetes mell...              4  \n",
       "\n",
       "[19301 rows x 5 columns]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# def checkcond(x):\n",
    "#     return str(countdf[countdf['aff']==x]['normalized_conditions'].iloc[0])\n",
    "\n",
    "# filepath = '../Diabetes/Diabetes_index_next_cnt_total.csv'\n",
    "# if os.path.isfile(filepath):\n",
    "#     df_spon = pd.read_csv(filepath)\n",
    "#     df_spon = df_spon.sort_values('idxcnt')\n",
    "\n",
    "# else:        \n",
    "#     df_spon['condition'] = df_spon['index'].apply(lambda x:checkcond(x))\n",
    "#     df_spon['condition_len'] = df_spon['condition'].apply(lambda x:len(x.split('|')))\n",
    "#     df_spon['idxcnt'] = df_spon.apply(lambda x:dict_spon[x['index']],axis=1)\n",
    "#     df_spon['onecnt'] = df_spon.apply(lambda x:one_spon[x['index']] if x['index'] in one_spon.keys() else 0,axis=1)\n",
    "#     df_spon.reset_index(drop=True,inplace=True)\n",
    "#     df_spon.to_csv('../Diabetes/Diabetes_index_next_cnt_total.csv',index=False) # affiliation + sponsor\n",
    "# display(df_spon.head(5))"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### graph"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Select top N collaborations based on 'cnt'\n",
    "import networkx as nx\n",
    "import matplotlib.pyplot as plt\n",
    "\n",
    "N = 50\n",
    "top_data = data.nlargest(N, 'cnt')\n",
    "\n",
    "# Create a new graph from the top_data\n",
    "G_top = nx.from_pandas_edgelist(top_data, 'index', 'next', ['cnt'])\n",
    "\n",
    "# Set node sizes for the top data\n",
    "node_sizes_top = {}\n",
    "for index, row in top_data.iterrows():\n",
    "    node_sizes_top[row['index']] = row['idxcnt']\n",
    "\n",
    "# Get unique sizes (to prevent overwriting in the loop)\n",
    "unique_sizes_top = list(set(node_sizes_top.values()))\n",
    "\n",
    "# Update node sizes dictionary to include 'next' nodes as well\n",
    "for index, row in top_data.iterrows():\n",
    "    node_sizes_top[row['next']] = row['idxcnt']\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1008x1008 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Adjust node sizes for better visualization (reduce size)\n",
    "adjusted_sizes_top_reduced = [node_sizes_top[node] * 10 for node in G_top.nodes()]\n",
    "\n",
    "# Draw the graph with adjusted layout (increased space)\n",
    "plt.figure(figsize=(14, 14))\n",
    "pos_top_adjusted = nx.spring_layout(G_top, iterations=50, k=0.5)\n",
    "nx.draw_networkx_nodes(G_top, pos_top_adjusted, nodelist=G_top.nodes(), node_size=adjusted_sizes_top_reduced, alpha=0.6)\n",
    "nx.draw_networkx_edges(G_top, pos_top_adjusted, width=[edata['cnt']*0.1 for _, _, edata in G_top.edges(data=True)], alpha=0.6)\n",
    "nx.draw_networkx_labels(G_top, pos_top_adjusted, font_size=9)\n",
    "plt.title(\"Top 30 Collaborations Network (Adjusted)\")\n",
    "plt.savefig('../graph/graph30.png')\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1008x1008 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import ast\n",
    "\n",
    "exploded_data = df.explode('affiliations').explode('Conditions')\n",
    "\n",
    "# Convert list items in Affiliations to comma separated strings\n",
    "exploded_data['affiliations'] = exploded_data['affiliations'].apply(lambda x: ', '.join(x) if isinstance(x, list) else x)\n",
    "\n",
    "# Group by affiliations and get unique Conditions\n",
    "affiliation_conditions = exploded_data.groupby('affiliations')['Conditions'].unique()\n",
    "\n",
    "affiliation_conditions.head()\n",
    "affiliation_condition_counts = affiliation_conditions.apply(len)\n",
    "\n",
    "# Create a colormap based on the number of conditions for each affiliation\n",
    "condition_colors = {affiliation: plt.cm.viridis(count/max(affiliation_condition_counts)) \n",
    "                    for affiliation, count in affiliation_condition_counts.items()}\n",
    "\n",
    "# Extract colors for the top graph nodes based on condition counts\n",
    "node_colors_top = [condition_colors.get(node, (1, 1, 1, 1)) for node in G_top.nodes()]\n",
    "\n",
    "# Draw the graph with adjusted layout and node colors\n",
    "plt.figure(figsize=(14, 14))\n",
    "nx.draw_networkx_nodes(G_top, pos_top_adjusted, nodelist=G_top.nodes(), node_size=adjusted_sizes_top_reduced, \n",
    "                       node_color=node_colors_top, alpha=0.6, cmap=plt.cm.viridis)\n",
    "nx.draw_networkx_edges(G_top, pos_top_adjusted, width=[edata['cnt']*0.1 for _, _, edata in G_top.edges(data=True)], alpha=0.6)\n",
    "nx.draw_networkx_labels(G_top, pos_top_adjusted, font_size=9)\n",
    "plt.title(\"Top 30 Collaborations Network with Condition Information\")\n",
    "plt.colorbar(plt.cm.ScalarMappable(cmap=plt.cm.viridis), label='Number of Conditions', orientation='horizontal')\n",
    "plt.savefig('../graph/graph30_wcolors.png')\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1008x1008 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Recalculate the number of unique conditions for each affiliation\n",
    "affiliation_condition_counts_corrected = exploded_data.groupby('affiliations')['Conditions'].nunique()\n",
    "\n",
    "# Create a colormap based on the corrected number of conditions for each affiliation\n",
    "condition_colors_corrected = {affiliation: plt.cm.viridis(count/max(affiliation_condition_counts_corrected)) \n",
    "                             for affiliation, count in affiliation_condition_counts_corrected.items()}\n",
    "\n",
    "# Extract corrected colors for the top graph nodes based on condition counts\n",
    "node_colors_top_corrected = [condition_colors_corrected.get(node, (1, 1, 1, 1)) for node in G_top.nodes()]\n",
    "\n",
    "# Draw the graph with adjusted layout and corrected node colors\n",
    "plt.figure(figsize=(14, 14))\n",
    "nx.draw_networkx_nodes(G_top, pos_top_adjusted, nodelist=G_top.nodes(), node_size=adjusted_sizes_top_reduced, \n",
    "                       node_color=node_colors_top_corrected, alpha=0.6, cmap=plt.cm.viridis)\n",
    "nx.draw_networkx_edges(G_top, pos_top_adjusted, width=[edata['cnt']*0.1 for _, _, edata in G_top.edges(data=True)], alpha=0.6)\n",
    "nx.draw_networkx_labels(G_top, pos_top_adjusted, font_size=9)\n",
    "plt.title(\"Top 30 Collaborations Network with Condition Information (Corrected)\")\n",
    "plt.colorbar(plt.cm.ScalarMappable(cmap=plt.cm.viridis), label='Number of Conditions', orientation='horizontal')\n",
    "plt.savefig('../graph/graph30_wcolors.png')\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "## networkx -> DGL\n",
    "## torch-geometric (torchtensor)"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 임베딩"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Study URL</th>\n",
       "      <th>Study Status</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Collaborators</th>\n",
       "      <th>Phases</th>\n",
       "      <th>Study Design</th>\n",
       "      <th>Locations</th>\n",
       "      <th>country</th>\n",
       "      <th>affiliations</th>\n",
       "      <th>normalized_conditions</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05284071</td>\n",
       "      <td>Actiste® Diabetes Management as a Service (ADM...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05284071</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>The overall aim of the clinical investigation ...</td>\n",
       "      <td>Diabetes type1|Diabetes type2</td>\n",
       "      <td>DEVICE: Device: Actiste 1.0 and the Companion ...</td>\n",
       "      <td>Northern Care Alliance NHS Foundation Trust</td>\n",
       "      <td>Brighter AB</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>Salford Royal Hospital Northern Care Alliance ...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>Northern Care Alliance NHS Foundation Trust|Br...</td>\n",
       "      <td>Diabetes type1|Diabetes type2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05029271</td>\n",
       "      <td>InPen User Experience</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05029271</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of this study is to evaluate the u...</td>\n",
       "      <td>Diabetes Type 1</td>\n",
       "      <td>DEVICE: InPen with Guardian 4 System</td>\n",
       "      <td>Medtronic Diabetes</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>NU-Hospital Group, Uddevalla, Sweden|Frolunda ...</td>\n",
       "      <td>Sweden</td>\n",
       "      <td>Medtronic Diabetes</td>\n",
       "      <td>Diabetes Type 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03976271</td>\n",
       "      <td>Consequences of Hypoglycaemia on Cardiovascula...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT03976271</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>People with Type 1 diabetes (T1DM), type 2 dia...</td>\n",
       "      <td>Hypoglycemia|Inflammatory Response|Diabetes Me...</td>\n",
       "      <td>PROCEDURE: hyperinsulinemic normoglycaemic-hyp...</td>\n",
       "      <td>Radboud University Medical Center</td>\n",
       "      <td>Rigshospitalet, Denmark</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NON_RANDOMIZED|Intervention Model:...</td>\n",
       "      <td>Nordsjællands University Hospital, Hillerød, N...</td>\n",
       "      <td>['Netherlands', 'Denmark']</td>\n",
       "      <td>Radboud University Medical Center|Rigshospital...</td>\n",
       "      <td>Hypoglycemia|Inflammatory Response|Diabetes Me...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05560971</td>\n",
       "      <td>Monounsaturated Fatty Acid Supplementation for...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05560971</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of this study is to understand and...</td>\n",
       "      <td>PreDiabetes|Insulin Resistance|Overweight|Obesity</td>\n",
       "      <td>DIETARY_SUPPLEMENT: Palmitoleic acid|OTHER: Pl...</td>\n",
       "      <td>Brigham and Women's Hospital</td>\n",
       "      <td>Tersus Life Sciences LLC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>Brigham and Women's Hospital, Boston, Massachu...</td>\n",
       "      <td>United States</td>\n",
       "      <td>Brigham and Women's Hospital|Tersus Life Scien...</td>\n",
       "      <td>PreDiabetes|Insulin Resistance|Overweight|Obesity</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00462371</td>\n",
       "      <td>Comparison Between Insulin Pump Treatment and ...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT00462371</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>Comparison between insulin pump treatment and ...</td>\n",
       "      <td>Diabetes Mellitus, Type 1|Child</td>\n",
       "      <td>DEVICE: Insulin pump (CSII)</td>\n",
       "      <td>Erasmus Medical Center</td>\n",
       "      <td>Ministry of Health</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: CRO...</td>\n",
       "      <td>ErasmusMC/Sophia´s children´s Hospital, Rotter...</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Erasmus Medical Center|Ministry of Health</td>\n",
       "      <td>Diabetes Mellitus, Type 1|Child</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    NCT Number                                        Study Title  \\\n",
       "0  NCT05284071  Actiste® Diabetes Management as a Service (ADM...   \n",
       "1  NCT05029271                              InPen User Experience   \n",
       "2  NCT03976271  Consequences of Hypoglycaemia on Cardiovascula...   \n",
       "3  NCT05560971  Monounsaturated Fatty Acid Supplementation for...   \n",
       "4  NCT00462371  Comparison Between Insulin Pump Treatment and ...   \n",
       "\n",
       "                                      Study URL Study Status  \\\n",
       "0  https://clinicaltrials.gov/study/NCT05284071    COMPLETED   \n",
       "1  https://clinicaltrials.gov/study/NCT05029271   RECRUITING   \n",
       "2  https://clinicaltrials.gov/study/NCT03976271    COMPLETED   \n",
       "3  https://clinicaltrials.gov/study/NCT05560971   RECRUITING   \n",
       "4  https://clinicaltrials.gov/study/NCT00462371    COMPLETED   \n",
       "\n",
       "                                       Brief Summary  \\\n",
       "0  The overall aim of the clinical investigation ...   \n",
       "1  The purpose of this study is to evaluate the u...   \n",
       "2  People with Type 1 diabetes (T1DM), type 2 dia...   \n",
       "3  The purpose of this study is to understand and...   \n",
       "4  Comparison between insulin pump treatment and ...   \n",
       "\n",
       "                                          Conditions  \\\n",
       "0                      Diabetes type1|Diabetes type2   \n",
       "1                                    Diabetes Type 1   \n",
       "2  Hypoglycemia|Inflammatory Response|Diabetes Me...   \n",
       "3  PreDiabetes|Insulin Resistance|Overweight|Obesity   \n",
       "4                    Diabetes Mellitus, Type 1|Child   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0  DEVICE: Device: Actiste 1.0 and the Companion ...   \n",
       "1               DEVICE: InPen with Guardian 4 System   \n",
       "2  PROCEDURE: hyperinsulinemic normoglycaemic-hyp...   \n",
       "3  DIETARY_SUPPLEMENT: Palmitoleic acid|OTHER: Pl...   \n",
       "4                        DEVICE: Insulin pump (CSII)   \n",
       "\n",
       "                                       Sponsor             Collaborators  \\\n",
       "0  Northern Care Alliance NHS Foundation Trust               Brighter AB   \n",
       "1                           Medtronic Diabetes                       NaN   \n",
       "2            Radboud University Medical Center   Rigshospitalet, Denmark   \n",
       "3                 Brigham and Women's Hospital  Tersus Life Sciences LLC   \n",
       "4                       Erasmus Medical Center        Ministry of Health   \n",
       "\n",
       "   Phases                                       Study Design  \\\n",
       "0     NaN  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "1     NaN  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "2     NaN  Allocation: NON_RANDOMIZED|Intervention Model:...   \n",
       "3     NaN  Allocation: RANDOMIZED|Intervention Model: PAR...   \n",
       "4  PHASE4  Allocation: RANDOMIZED|Intervention Model: CRO...   \n",
       "\n",
       "                                           Locations  \\\n",
       "0  Salford Royal Hospital Northern Care Alliance ...   \n",
       "1  NU-Hospital Group, Uddevalla, Sweden|Frolunda ...   \n",
       "2  Nordsjællands University Hospital, Hillerød, N...   \n",
       "3  Brigham and Women's Hospital, Boston, Massachu...   \n",
       "4  ErasmusMC/Sophia´s children´s Hospital, Rotter...   \n",
       "\n",
       "                      country  \\\n",
       "0              United Kingdom   \n",
       "1                      Sweden   \n",
       "2  ['Netherlands', 'Denmark']   \n",
       "3               United States   \n",
       "4                 Netherlands   \n",
       "\n",
       "                                        affiliations  \\\n",
       "0  Northern Care Alliance NHS Foundation Trust|Br...   \n",
       "1                                 Medtronic Diabetes   \n",
       "2  Radboud University Medical Center|Rigshospital...   \n",
       "3  Brigham and Women's Hospital|Tersus Life Scien...   \n",
       "4          Erasmus Medical Center|Ministry of Health   \n",
       "\n",
       "                               normalized_conditions  \n",
       "0                      Diabetes type1|Diabetes type2  \n",
       "1                                    Diabetes Type 1  \n",
       "2  Hypoglycemia|Inflammatory Response|Diabetes Me...  \n",
       "3  PreDiabetes|Insulin Resistance|Overweight|Obesity  \n",
       "4                    Diabetes Mellitus, Type 1|Child  "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        [-0.6533576, 0.2899124, 0.3582823, -0.02207345...\n",
       "1        [-1.5576812, -1.0615007, 0.9219568, 0.8384592,...\n",
       "2        [0.7630125, 0.023779418, 1.7297945, 1.0684724,...\n",
       "3        [-1.2706982, 3.5712657, 0.72434443, -0.3983059...\n",
       "4        [-1.2361405, -0.076714456, 1.7889788, 1.062637...\n",
       "                               ...                        \n",
       "13875    [-0.47521353, 0.45017236, 1.2653893, 0.7703568...\n",
       "13876    [2.2284987, 2.828872, 4.283614, 1.2687007, 1.4...\n",
       "13877    [0.4154884, 0.5133937, 1.0775734, 0.51025105, ...\n",
       "13878    [0.64259994, 0.14503738, 0.55169725, 1.1456509...\n",
       "13879    [-0.34579745, 0.6177559, 1.1981419, 1.275478, ...\n",
       "Name: embeddings_doc2vec, Length: 13880, dtype: object"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "'''1. Embedding - Doc2vec'''\n",
    "from gensim.models.doc2vec import Doc2Vec, TaggedDocument\n",
    "from nltk.tokenize import word_tokenize\n",
    "\n",
    "# 데이터 전처리 (토크나이징)\n",
    "df['sentences'] = df['normalized_conditions'] + df['Brief Summary']\n",
    "tagged_data = [TaggedDocument(words=word_tokenize(_d.lower()), tags=[str(i)]) for i, _d in enumerate(df['sentences'])]\n",
    "\n",
    "# Doc2Vec 모델 학습\n",
    "model = Doc2Vec(vector_size=100, window=5, min_count=1, workers=4, epochs=100)\n",
    "model.build_vocab(tagged_data)\n",
    "model.train(tagged_data, total_examples=model.corpus_count, epochs=model.epochs)\n",
    "\n",
    "# 각 summary의 임베딩 생성\n",
    "df['embeddings_doc2vec'] = df['sentences'].apply(lambda x: model.infer_vector(word_tokenize(x.lower())))\n",
    "df['embeddings_doc2vec']\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-09-16 19:49:54.831143: I tensorflow/core/platform/cpu_feature_guard.cc:193] This TensorFlow binary is optimized with oneAPI Deep Neural Network Library (oneDNN) to use the following CPU instructions in performance-critical operations:  AVX2 AVX512F AVX512_VNNI FMA\n",
      "To enable them in other operations, rebuild TensorFlow with the appropriate compiler flags.\n",
      "2023-09-16 19:49:54.951909: I tensorflow/core/util/port.cc:104] oneDNN custom operations are on. You may see slightly different numerical results due to floating-point round-off errors from different computation orders. To turn them off, set the environment variable `TF_ENABLE_ONEDNN_OPTS=0`.\n",
      "2023-09-16 19:49:54.954894: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libcudart.so.11.0'; dlerror: libcudart.so.11.0: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:54.954909: I tensorflow/compiler/xla/stream_executor/cuda/cudart_stub.cc:29] Ignore above cudart dlerror if you do not have a GPU set up on your machine.\n",
      "2023-09-16 19:49:55.476462: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libnvinfer.so.7'; dlerror: libnvinfer.so.7: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:55.476528: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libnvinfer_plugin.so.7'; dlerror: libnvinfer_plugin.so.7: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:55.476533: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Cannot dlopen some TensorRT libraries. If you would like to use Nvidia GPU with TensorRT, please make sure the missing libraries mentioned above are installed properly.\n",
      "2023-09-16 19:49:56.143742: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libcudart.so.11.0'; dlerror: libcudart.so.11.0: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:56.143810: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libcublas.so.11'; dlerror: libcublas.so.11: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:56.143844: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libcublasLt.so.11'; dlerror: libcublasLt.so.11: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:56.143877: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libcufft.so.10'; dlerror: libcufft.so.10: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:56.143909: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libcurand.so.10'; dlerror: libcurand.so.10: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:56.143943: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libcusolver.so.11'; dlerror: libcusolver.so.11: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:56.143974: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libcusparse.so.11'; dlerror: libcusparse.so.11: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:56.144007: W tensorflow/compiler/xla/stream_executor/platform/default/dso_loader.cc:64] Could not load dynamic library 'libcudnn.so.8'; dlerror: libcudnn.so.8: cannot open shared object file: No such file or directory; LD_LIBRARY_PATH: /usr/local/cuda/lib64:/usr/local/cuda/extras/CUPTI/lib64\n",
      "2023-09-16 19:49:56.144015: W tensorflow/core/common_runtime/gpu/gpu_device.cc:1934] Cannot dlopen some GPU libraries. Please make sure the missing libraries mentioned above are installed properly if you would like to use GPU. Follow the guide at https://www.tensorflow.org/install/gpu for how to download and setup the required libraries for your platform.\n",
      "Skipping registering GPU devices...\n",
      "2023-09-16 19:49:56.144219: I tensorflow/core/platform/cpu_feature_guard.cc:193] This TensorFlow binary is optimized with oneAPI Deep Neural Network Library (oneDNN) to use the following CPU instructions in performance-critical operations:  AVX2 AVX512F AVX512_VNNI FMA\n",
      "To enable them in other operations, rebuild TensorFlow with the appropriate compiler flags.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Study URL</th>\n",
       "      <th>Study Status</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Collaborators</th>\n",
       "      <th>Phases</th>\n",
       "      <th>Study Design</th>\n",
       "      <th>Locations</th>\n",
       "      <th>country</th>\n",
       "      <th>affiliations</th>\n",
       "      <th>normalized_conditions</th>\n",
       "      <th>sentences</th>\n",
       "      <th>embeddings_doc2vec</th>\n",
       "      <th>embeddings_use</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05284071</td>\n",
       "      <td>Actiste® Diabetes Management as a Service (ADM...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05284071</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>The overall aim of the clinical investigation ...</td>\n",
       "      <td>Diabetes type1|Diabetes type2</td>\n",
       "      <td>DEVICE: Device: Actiste 1.0 and the Companion ...</td>\n",
       "      <td>Northern Care Alliance NHS Foundation Trust</td>\n",
       "      <td>Brighter AB</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>Salford Royal Hospital Northern Care Alliance ...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>Northern Care Alliance NHS Foundation Trust|Br...</td>\n",
       "      <td>Diabetes type1|Diabetes type2</td>\n",
       "      <td>Diabetes type1|Diabetes type2The overall aim o...</td>\n",
       "      <td>[-0.6533576, 0.2899124, 0.3582823, -0.02207345...</td>\n",
       "      <td>[-0.05177863, -0.053549428, -0.05081451, 0.057...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05029271</td>\n",
       "      <td>InPen User Experience</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05029271</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of this study is to evaluate the u...</td>\n",
       "      <td>Diabetes Type 1</td>\n",
       "      <td>DEVICE: InPen with Guardian 4 System</td>\n",
       "      <td>Medtronic Diabetes</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>NU-Hospital Group, Uddevalla, Sweden|Frolunda ...</td>\n",
       "      <td>Sweden</td>\n",
       "      <td>Medtronic Diabetes</td>\n",
       "      <td>Diabetes Type 1</td>\n",
       "      <td>Diabetes Type 1The purpose of this study is to...</td>\n",
       "      <td>[-1.5576812, -1.0615007, 0.9219568, 0.8384592,...</td>\n",
       "      <td>[0.010143899, 0.009666905, -0.046026397, 0.052...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03976271</td>\n",
       "      <td>Consequences of Hypoglycaemia on Cardiovascula...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT03976271</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>People with Type 1 diabetes (T1DM), type 2 dia...</td>\n",
       "      <td>Hypoglycemia|Inflammatory Response|Diabetes Me...</td>\n",
       "      <td>PROCEDURE: hyperinsulinemic normoglycaemic-hyp...</td>\n",
       "      <td>Radboud University Medical Center</td>\n",
       "      <td>Rigshospitalet, Denmark</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NON_RANDOMIZED|Intervention Model:...</td>\n",
       "      <td>Nordsjællands University Hospital, Hillerød, N...</td>\n",
       "      <td>['Netherlands', 'Denmark']</td>\n",
       "      <td>Radboud University Medical Center|Rigshospital...</td>\n",
       "      <td>Hypoglycemia|Inflammatory Response|Diabetes Me...</td>\n",
       "      <td>Hypoglycemia|Inflammatory Response|Diabetes Me...</td>\n",
       "      <td>[0.7630125, 0.023779418, 1.7297945, 1.0684724,...</td>\n",
       "      <td>[-0.0008871535, -0.012041841, -0.029269502, 0....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05560971</td>\n",
       "      <td>Monounsaturated Fatty Acid Supplementation for...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05560971</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of this study is to understand and...</td>\n",
       "      <td>PreDiabetes|Insulin Resistance|Overweight|Obesity</td>\n",
       "      <td>DIETARY_SUPPLEMENT: Palmitoleic acid|OTHER: Pl...</td>\n",
       "      <td>Brigham and Women's Hospital</td>\n",
       "      <td>Tersus Life Sciences LLC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>Brigham and Women's Hospital, Boston, Massachu...</td>\n",
       "      <td>United States</td>\n",
       "      <td>Brigham and Women's Hospital|Tersus Life Scien...</td>\n",
       "      <td>PreDiabetes|Insulin Resistance|Overweight|Obesity</td>\n",
       "      <td>PreDiabetes|Insulin Resistance|Overweight|Obes...</td>\n",
       "      <td>[-1.2706982, 3.5712657, 0.72434443, -0.3983059...</td>\n",
       "      <td>[0.023469983, 0.04538531, -0.025541266, -0.026...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00462371</td>\n",
       "      <td>Comparison Between Insulin Pump Treatment and ...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT00462371</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>Comparison between insulin pump treatment and ...</td>\n",
       "      <td>Diabetes Mellitus, Type 1|Child</td>\n",
       "      <td>DEVICE: Insulin pump (CSII)</td>\n",
       "      <td>Erasmus Medical Center</td>\n",
       "      <td>Ministry of Health</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: CRO...</td>\n",
       "      <td>ErasmusMC/Sophia´s children´s Hospital, Rotter...</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Erasmus Medical Center|Ministry of Health</td>\n",
       "      <td>Diabetes Mellitus, Type 1|Child</td>\n",
       "      <td>Diabetes Mellitus, Type 1|ChildComparison betw...</td>\n",
       "      <td>[-1.2361405, -0.076714456, 1.7889788, 1.062637...</td>\n",
       "      <td>[-0.009891663, -0.054471746, -0.004345603, 0.0...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    NCT Number                                        Study Title  \\\n",
       "0  NCT05284071  Actiste® Diabetes Management as a Service (ADM...   \n",
       "1  NCT05029271                              InPen User Experience   \n",
       "2  NCT03976271  Consequences of Hypoglycaemia on Cardiovascula...   \n",
       "3  NCT05560971  Monounsaturated Fatty Acid Supplementation for...   \n",
       "4  NCT00462371  Comparison Between Insulin Pump Treatment and ...   \n",
       "\n",
       "                                      Study URL Study Status  \\\n",
       "0  https://clinicaltrials.gov/study/NCT05284071    COMPLETED   \n",
       "1  https://clinicaltrials.gov/study/NCT05029271   RECRUITING   \n",
       "2  https://clinicaltrials.gov/study/NCT03976271    COMPLETED   \n",
       "3  https://clinicaltrials.gov/study/NCT05560971   RECRUITING   \n",
       "4  https://clinicaltrials.gov/study/NCT00462371    COMPLETED   \n",
       "\n",
       "                                       Brief Summary  \\\n",
       "0  The overall aim of the clinical investigation ...   \n",
       "1  The purpose of this study is to evaluate the u...   \n",
       "2  People with Type 1 diabetes (T1DM), type 2 dia...   \n",
       "3  The purpose of this study is to understand and...   \n",
       "4  Comparison between insulin pump treatment and ...   \n",
       "\n",
       "                                          Conditions  \\\n",
       "0                      Diabetes type1|Diabetes type2   \n",
       "1                                    Diabetes Type 1   \n",
       "2  Hypoglycemia|Inflammatory Response|Diabetes Me...   \n",
       "3  PreDiabetes|Insulin Resistance|Overweight|Obesity   \n",
       "4                    Diabetes Mellitus, Type 1|Child   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0  DEVICE: Device: Actiste 1.0 and the Companion ...   \n",
       "1               DEVICE: InPen with Guardian 4 System   \n",
       "2  PROCEDURE: hyperinsulinemic normoglycaemic-hyp...   \n",
       "3  DIETARY_SUPPLEMENT: Palmitoleic acid|OTHER: Pl...   \n",
       "4                        DEVICE: Insulin pump (CSII)   \n",
       "\n",
       "                                       Sponsor             Collaborators  \\\n",
       "0  Northern Care Alliance NHS Foundation Trust               Brighter AB   \n",
       "1                           Medtronic Diabetes                       NaN   \n",
       "2            Radboud University Medical Center   Rigshospitalet, Denmark   \n",
       "3                 Brigham and Women's Hospital  Tersus Life Sciences LLC   \n",
       "4                       Erasmus Medical Center        Ministry of Health   \n",
       "\n",
       "   Phases                                       Study Design  \\\n",
       "0     NaN  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "1     NaN  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "2     NaN  Allocation: NON_RANDOMIZED|Intervention Model:...   \n",
       "3     NaN  Allocation: RANDOMIZED|Intervention Model: PAR...   \n",
       "4  PHASE4  Allocation: RANDOMIZED|Intervention Model: CRO...   \n",
       "\n",
       "                                           Locations  \\\n",
       "0  Salford Royal Hospital Northern Care Alliance ...   \n",
       "1  NU-Hospital Group, Uddevalla, Sweden|Frolunda ...   \n",
       "2  Nordsjællands University Hospital, Hillerød, N...   \n",
       "3  Brigham and Women's Hospital, Boston, Massachu...   \n",
       "4  ErasmusMC/Sophia´s children´s Hospital, Rotter...   \n",
       "\n",
       "                      country  \\\n",
       "0              United Kingdom   \n",
       "1                      Sweden   \n",
       "2  ['Netherlands', 'Denmark']   \n",
       "3               United States   \n",
       "4                 Netherlands   \n",
       "\n",
       "                                        affiliations  \\\n",
       "0  Northern Care Alliance NHS Foundation Trust|Br...   \n",
       "1                                 Medtronic Diabetes   \n",
       "2  Radboud University Medical Center|Rigshospital...   \n",
       "3  Brigham and Women's Hospital|Tersus Life Scien...   \n",
       "4          Erasmus Medical Center|Ministry of Health   \n",
       "\n",
       "                               normalized_conditions  \\\n",
       "0                      Diabetes type1|Diabetes type2   \n",
       "1                                    Diabetes Type 1   \n",
       "2  Hypoglycemia|Inflammatory Response|Diabetes Me...   \n",
       "3  PreDiabetes|Insulin Resistance|Overweight|Obesity   \n",
       "4                    Diabetes Mellitus, Type 1|Child   \n",
       "\n",
       "                                           sentences  \\\n",
       "0  Diabetes type1|Diabetes type2The overall aim o...   \n",
       "1  Diabetes Type 1The purpose of this study is to...   \n",
       "2  Hypoglycemia|Inflammatory Response|Diabetes Me...   \n",
       "3  PreDiabetes|Insulin Resistance|Overweight|Obes...   \n",
       "4  Diabetes Mellitus, Type 1|ChildComparison betw...   \n",
       "\n",
       "                                  embeddings_doc2vec  \\\n",
       "0  [-0.6533576, 0.2899124, 0.3582823, -0.02207345...   \n",
       "1  [-1.5576812, -1.0615007, 0.9219568, 0.8384592,...   \n",
       "2  [0.7630125, 0.023779418, 1.7297945, 1.0684724,...   \n",
       "3  [-1.2706982, 3.5712657, 0.72434443, -0.3983059...   \n",
       "4  [-1.2361405, -0.076714456, 1.7889788, 1.062637...   \n",
       "\n",
       "                                      embeddings_use  \n",
       "0  [-0.05177863, -0.053549428, -0.05081451, 0.057...  \n",
       "1  [0.010143899, 0.009666905, -0.046026397, 0.052...  \n",
       "2  [-0.0008871535, -0.012041841, -0.029269502, 0....  \n",
       "3  [0.023469983, 0.04538531, -0.025541266, -0.026...  \n",
       "4  [-0.009891663, -0.054471746, -0.004345603, 0.0...  "
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import tensorflow_hub as hub\n",
    "\n",
    "embed = hub.load(\"https://tfhub.dev/google/universal-sentence-encoder/4\")\n",
    "embeddings_use = embed(df['sentences']).numpy()\n",
    "\n",
    "# 임베딩을 Python 리스트로 변환\n",
    "embeddings_list = [list(row) for row in embeddings_use]\n",
    "\n",
    "# 데이터프레임에 새로운 열로 추가\n",
    "df['embeddings_use'] = embeddings_list\n",
    "df.head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# conda install pytorch==1.12.1 torchvision==0.13.1 torchaudio==0.12.1 cudatoolkit==11.4 -c pytorch -c nvidia -c conda-forge\n",
    "# conda install pytorch==1.9.0 torchvision==0.10.0 torchaudio==0.9.0 cudatoolkit=11.4 -c pytorch\n",
    "# conda install pytorch==1.11.0 torchvision==0.12.0 torchaudio==0.11.0 cudatoolkit=11.3 -c pytorch #이걸로돌림"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sentence_transformers import SentenceTransformer\n",
    "\n",
    "model = SentenceTransformer(\"sentence-transformers/all-MiniLM-L12-v2\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load model directly\n",
    "from transformers import AutoModel\n",
    "model = AutoModel.from_pretrained(\"microsoft/MiniLM-L12-H384-uncased\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "'''1. Embedding - miniLM2'''\n",
    "from transformers import AutoTokenizer, AutoModel\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained(\"microsoft/MiniLM-L6-H384-uncased\")\n",
    "model = AutoModel.from_pretrained(\"microsoft/MiniLM-L6-H384-uncased\")\n",
    "\n",
    "def embed_sentence_minilm(sentence):\n",
    "    tokens = tokenizer(sentence, return_tensors='pt', truncation=True, padding=True)\n",
    "    with torch.no_grad():\n",
    "        return model(**tokens).last_hidden_state.mean(dim=1).numpy()\n",
    "\n",
    "embeddings_minilm = [embed_sentence_minilm(sentence) for sentence in df['sentences']]\n",
    "df['embeddings_minilm'] = embeddings_minilm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of the model checkpoint at distilbert-base-uncased were not used when initializing DistilBertModel: ['vocab_transform.weight', 'vocab_projector.weight', 'vocab_projector.bias', 'vocab_transform.bias', 'vocab_layer_norm.bias', 'vocab_layer_norm.weight']\n",
      "- This IS expected if you are initializing DistilBertModel from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing DistilBertModel from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n"
     ]
    }
   ],
   "source": [
    "'''1. Embedding - DistilBERT'''\n",
    "from transformers import DistilBertTokenizer, DistilBertModel\n",
    "import torch\n",
    "\n",
    "tokenizer = DistilBertTokenizer.from_pretrained('distilbert-base-uncased')\n",
    "model = DistilBertModel.from_pretrained('distilbert-base-uncased')\n",
    "\n",
    "def embed_sentence(sentence):\n",
    "    tokens = tokenizer(sentence, return_tensors='pt', truncation=True, padding=True)\n",
    "    with torch.no_grad():\n",
    "        return model(**tokens).last_hidden_state.mean(dim=1).numpy()\n",
    "\n",
    "embeddings_distilbert = [embed_sentence(sentence) for sentence in df['sentences']]\n",
    "df['embeddings_distilbert'] = embeddings_distilbert"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "df.to_csv('../Diabetes/Diabetes_embedding.csv',index=False)"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Embedding\n",
    "- doc2vec\n",
    "- USE (Universal sentence encoder)\n",
    "- DistilBERT\n",
    "- miniLM (아직X)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "df = pd.read_csv('../Diabetes/Diabetes_embedding.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValueError",
     "evalue": "could not convert string to float: '-0.05177863,'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValueError\u001b[0m                                Traceback (most recent call last)",
      "\u001b[0;32m/tmp/ipykernel_26096/784617430.py\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     13\u001b[0m \u001b[0;31m# 각 임베딩 변수 저장\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     14\u001b[0m \u001b[0mdoc2vec_embeddings\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'embeddings_doc2vec'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mremake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 15\u001b[0;31m \u001b[0muse_embeddings\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'embeddings_use'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mremake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     16\u001b[0m \u001b[0mdistilbert_embeddings\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'embeddings_distilbert'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mremake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     17\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/stg_py37/lib/python3.7/site-packages/pandas/core/series.py\u001b[0m in \u001b[0;36mapply\u001b[0;34m(self, func, convert_dtype, args, **kwargs)\u001b[0m\n\u001b[1;32m   4355\u001b[0m         \u001b[0mdtype\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mfloat64\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   4356\u001b[0m         \"\"\"\n\u001b[0;32m-> 4357\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mSeriesApply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mfunc\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mconvert_dtype\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   4358\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   4359\u001b[0m     def _reduce(\n",
      "\u001b[0;32m~/anaconda3/envs/stg_py37/lib/python3.7/site-packages/pandas/core/apply.py\u001b[0m in \u001b[0;36mapply\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1041\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply_str\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1042\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1043\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply_standard\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1044\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1045\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0magg\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/stg_py37/lib/python3.7/site-packages/pandas/core/apply.py\u001b[0m in \u001b[0;36mapply_standard\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1099\u001b[0m                     \u001b[0mvalues\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1100\u001b[0m                     \u001b[0mf\u001b[0m\u001b[0;34m,\u001b[0m  \u001b[0;31m# type: ignore[arg-type]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1101\u001b[0;31m                     \u001b[0mconvert\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mconvert_dtype\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1102\u001b[0m                 )\n\u001b[1;32m   1103\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/anaconda3/envs/stg_py37/lib/python3.7/site-packages/pandas/_libs/lib.pyx\u001b[0m in \u001b[0;36mpandas._libs.lib.map_infer\u001b[0;34m()\u001b[0m\n",
      "\u001b[0;32m/tmp/ipykernel_26096/784617430.py\u001b[0m in \u001b[0;36m<lambda>\u001b[0;34m(x)\u001b[0m\n\u001b[1;32m     13\u001b[0m \u001b[0;31m# 각 임베딩 변수 저장\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     14\u001b[0m \u001b[0mdoc2vec_embeddings\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'embeddings_doc2vec'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mremake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 15\u001b[0;31m \u001b[0muse_embeddings\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'embeddings_use'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mremake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     16\u001b[0m \u001b[0mdistilbert_embeddings\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mdf\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'embeddings_distilbert'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mapply\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;32mlambda\u001b[0m \u001b[0mx\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0mremake\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mx\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     17\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/tmp/ipykernel_26096/1833711878.py\u001b[0m in \u001b[0;36mremake\u001b[0;34m(raw_string)\u001b[0m\n\u001b[1;32m      4\u001b[0m     \u001b[0mnumber_strings\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mraw_string\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstrip\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'[]'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msplit\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      5\u001b[0m     \u001b[0;31m# 문자열을 부동소수점(float)으로 변환\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 6\u001b[0;31m     \u001b[0mnumbers\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mfloat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnumber_str\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfor\u001b[0m \u001b[0mnumber_str\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mnumber_strings\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      7\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      8\u001b[0m     \u001b[0;31m# numbers 리스트에는 부동소수점 숫자 값들이 포함됩니다.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/tmp/ipykernel_26096/1833711878.py\u001b[0m in \u001b[0;36m<listcomp>\u001b[0;34m(.0)\u001b[0m\n\u001b[1;32m      4\u001b[0m     \u001b[0mnumber_strings\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mraw_string\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstrip\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'[]'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msplit\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      5\u001b[0m     \u001b[0;31m# 문자열을 부동소수점(float)으로 변환\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 6\u001b[0;31m     \u001b[0mnumbers\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0mfloat\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnumber_str\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mfor\u001b[0m \u001b[0mnumber_str\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mnumber_strings\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      7\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      8\u001b[0m     \u001b[0;31m# numbers 리스트에는 부동소수점 숫자 값들이 포함됩니다.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mValueError\u001b[0m: could not convert string to float: '-0.05177863,'"
     ]
    }
   ],
   "source": [
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "import numpy as np\n",
    "\n",
    "def top_k_similar_ids(embeddings, k=20):\n",
    "    \"\"\"Compute top k similar sentences for each sentence based on embeddings.\"\"\"\n",
    "    cosine_sim_matrix = cosine_similarity(embeddings)\n",
    "    top_k_ids = []\n",
    "    for i in range(cosine_sim_matrix.shape[0]):\n",
    "        similar_ids = cosine_sim_matrix[i].argsort()[::-1][1:k+1]\n",
    "        top_k_ids.append(similar_ids)\n",
    "    return top_k_ids\n",
    "\n",
    "# 각 임베딩 변수 저장\n",
    "doc2vec_embeddings = df['embeddings_doc2vec'].apply(lambda x: remake(x))\n",
    "use_embeddings = df['embeddings_use'].apply(lambda x: remake(x))\n",
    "distilbert_embeddings = df['embeddings_distilbert'].apply(lambda x: remake(x))\n",
    "\n",
    "# 각 임베딩에 대해 유사도 계산\n",
    "doc2vec_top_k_ids = top_k_similar_ids(doc2vec_embeddings)\n",
    "use_top_k_ids = top_k_similar_ids(use_embeddings)\n",
    "distilbert_top_k_ids = top_k_similar_ids(distilbert_embeddings)\n",
    "\n",
    "# 결과 저장\n",
    "df['doc2vec_top_k_ids'] = doc2vec_top_k_ids\n",
    "df['use_top_k_ids'] = use_top_k_ids\n",
    "df['distilbert_top_k_ids'] = distilbert_top_k_ids\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/dxlab/.local/lib/python3.7/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n",
      "Downloading (…)7f4ef/.gitattributes: 100%|██████████| 391/391 [00:00<00:00, 44.7kB/s]\n",
      "Downloading (…)_Pooling/config.json: 100%|██████████| 190/190 [00:00<00:00, 29.9kB/s]\n",
      "Downloading (…)f279f7f4ef/README.md: 100%|██████████| 3.74k/3.74k [00:00<00:00, 2.25MB/s]\n",
      "Downloading (…)79f7f4ef/config.json: 100%|██████████| 718/718 [00:00<00:00, 349kB/s]\n",
      "Downloading (…)ce_transformers.json: 100%|██████████| 122/122 [00:00<00:00, 62.3kB/s]\n",
      "Downloading (…)279f7f4ef/merges.txt: 100%|██████████| 456k/456k [00:00<00:00, 1.29MB/s]\n",
      "Downloading pytorch_model.bin: 100%|██████████| 329M/329M [00:17<00:00, 18.5MB/s] \n",
      "Downloading (…)nce_bert_config.json: 100%|██████████| 53.0/53.0 [00:00<00:00, 8.62kB/s]\n",
      "Downloading (…)cial_tokens_map.json: 100%|██████████| 239/239 [00:00<00:00, 123kB/s]\n",
      "Downloading (…)7f4ef/tokenizer.json: 100%|██████████| 1.36M/1.36M [00:00<00:00, 3.90MB/s]\n",
      "Downloading (…)okenizer_config.json: 100%|██████████| 1.35k/1.35k [00:00<00:00, 624kB/s]\n",
      "Downloading (…)279f7f4ef/vocab.json: 100%|██████████| 798k/798k [00:00<00:00, 2.23MB/s]\n",
      "Downloading (…)9f7f4ef/modules.json: 100%|██████████| 229/229 [00:00<00:00, 109kB/s]\n"
     ]
    }
   ],
   "source": [
    "from sentence_transformers import SentenceTransformer, util\n",
    "model = SentenceTransformer('paraphrase-distilroberta-base-v1')\n",
    "\n",
    "embeddings = model.encode(df['sentences'], convert_to_tensor=True)\n",
    "cosine_scores = util.pytorch_cos_sim(embeddings, embeddings)\n",
    "cosine_scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        Diabetes type1|Diabetes type2The overall aim o...\n",
       "1        Diabetes Type 1The purpose of this study is to...\n",
       "2        Hypoglycemia|Inflammatory Response|Diabetes Me...\n",
       "3        PreDiabetes|Insulin Resistance|Overweight|Obes...\n",
       "4        Diabetes Mellitus, Type 1|ChildComparison betw...\n",
       "                               ...                        \n",
       "13875    Diabetes Mellitus, Type 1|Diabetes Mellitus, T...\n",
       "13876    Endometrial CancerThe endometrial cancers are ...\n",
       "13877    Enterovirus Infection|Type 1 Diabetes|Prediabe...\n",
       "13878    Diabetes|Diabetes Mellitus, Type 1To analyse d...\n",
       "13879    Diabetes Mellitus, Type 2|Diabetes Mellitus, T...\n",
       "Name: sentences, Length: 13880, dtype: object"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['sentences']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "False"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import torch\n",
    "torch.cuda.is_available()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Study Title</th>\n",
       "      <th>Study URL</th>\n",
       "      <th>Study Status</th>\n",
       "      <th>Brief Summary</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Sponsor</th>\n",
       "      <th>Collaborators</th>\n",
       "      <th>Phases</th>\n",
       "      <th>Study Design</th>\n",
       "      <th>Locations</th>\n",
       "      <th>country</th>\n",
       "      <th>affiliations</th>\n",
       "      <th>normalized_conditions</th>\n",
       "      <th>sentences</th>\n",
       "      <th>embeddings_doc2vec</th>\n",
       "      <th>embeddings_use</th>\n",
       "      <th>embeddings_distilbert</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05284071</td>\n",
       "      <td>Actiste® Diabetes Management as a Service (ADM...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05284071</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>The overall aim of the clinical investigation ...</td>\n",
       "      <td>Diabetes type1|Diabetes type2</td>\n",
       "      <td>DEVICE: Device: Actiste 1.0 and the Companion ...</td>\n",
       "      <td>Northern Care Alliance NHS Foundation Trust</td>\n",
       "      <td>Brighter AB</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>Salford Royal Hospital Northern Care Alliance ...</td>\n",
       "      <td>United Kingdom</td>\n",
       "      <td>Northern Care Alliance NHS Foundation Trust|Br...</td>\n",
       "      <td>Diabetes type1|Diabetes type2</td>\n",
       "      <td>Diabetes type1|Diabetes type2The overall aim o...</td>\n",
       "      <td>[-0.6533576   0.2899124   0.3582823  -0.022073...</td>\n",
       "      <td>[-0.05177863, -0.053549428, -0.05081451, 0.057...</td>\n",
       "      <td>[[-4.79432911e-01  1.63338944e-01  2.08725184e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05029271</td>\n",
       "      <td>InPen User Experience</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05029271</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of this study is to evaluate the u...</td>\n",
       "      <td>Diabetes Type 1</td>\n",
       "      <td>DEVICE: InPen with Guardian 4 System</td>\n",
       "      <td>Medtronic Diabetes</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>NU-Hospital Group, Uddevalla, Sweden|Frolunda ...</td>\n",
       "      <td>Sweden</td>\n",
       "      <td>Medtronic Diabetes</td>\n",
       "      <td>Diabetes Type 1</td>\n",
       "      <td>Diabetes Type 1The purpose of this study is to...</td>\n",
       "      <td>[-1.55768120e+00 -1.06150067e+00  9.21956778e-...</td>\n",
       "      <td>[0.010143899, 0.009666905, -0.046026397, 0.052...</td>\n",
       "      <td>[[-3.43266100e-01  1.77812949e-02  3.18139613e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03976271</td>\n",
       "      <td>Consequences of Hypoglycaemia on Cardiovascula...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT03976271</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>People with Type 1 diabetes (T1DM), type 2 dia...</td>\n",
       "      <td>Hypoglycemia|Inflammatory Response|Diabetes Me...</td>\n",
       "      <td>PROCEDURE: hyperinsulinemic normoglycaemic-hyp...</td>\n",
       "      <td>Radboud University Medical Center</td>\n",
       "      <td>Rigshospitalet, Denmark</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NON_RANDOMIZED|Intervention Model:...</td>\n",
       "      <td>Nordsjællands University Hospital, Hillerød, N...</td>\n",
       "      <td>['Netherlands', 'Denmark']</td>\n",
       "      <td>Radboud University Medical Center|Rigshospital...</td>\n",
       "      <td>Hypoglycemia|Inflammatory Response|Diabetes Me...</td>\n",
       "      <td>Hypoglycemia|Inflammatory Response|Diabetes Me...</td>\n",
       "      <td>[ 0.7630125   0.02377942  1.7297945   1.068472...</td>\n",
       "      <td>[-0.0008871535, -0.012041841, -0.029269502, 0....</td>\n",
       "      <td>[[-1.48577675e-01  1.06256127e-01  3.06467533e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05560971</td>\n",
       "      <td>Monounsaturated Fatty Acid Supplementation for...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05560971</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>The purpose of this study is to understand and...</td>\n",
       "      <td>PreDiabetes|Insulin Resistance|Overweight|Obesity</td>\n",
       "      <td>DIETARY_SUPPLEMENT: Palmitoleic acid|OTHER: Pl...</td>\n",
       "      <td>Brigham and Women's Hospital</td>\n",
       "      <td>Tersus Life Sciences LLC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: PAR...</td>\n",
       "      <td>Brigham and Women's Hospital, Boston, Massachu...</td>\n",
       "      <td>United States</td>\n",
       "      <td>Brigham and Women's Hospital|Tersus Life Scien...</td>\n",
       "      <td>PreDiabetes|Insulin Resistance|Overweight|Obesity</td>\n",
       "      <td>PreDiabetes|Insulin Resistance|Overweight|Obes...</td>\n",
       "      <td>[-1.2706982   3.5712657   0.72434443 -0.398305...</td>\n",
       "      <td>[0.023469983, 0.04538531, -0.025541266, -0.026...</td>\n",
       "      <td>[[-3.94146502e-01  1.26904011e-01  1.25811309e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00462371</td>\n",
       "      <td>Comparison Between Insulin Pump Treatment and ...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT00462371</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>Comparison between insulin pump treatment and ...</td>\n",
       "      <td>Diabetes Mellitus, Type 1|Child</td>\n",
       "      <td>DEVICE: Insulin pump (CSII)</td>\n",
       "      <td>Erasmus Medical Center</td>\n",
       "      <td>Ministry of Health</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: CRO...</td>\n",
       "      <td>ErasmusMC/Sophia´s children´s Hospital, Rotter...</td>\n",
       "      <td>Netherlands</td>\n",
       "      <td>Erasmus Medical Center|Ministry of Health</td>\n",
       "      <td>Diabetes Mellitus, Type 1|Child</td>\n",
       "      <td>Diabetes Mellitus, Type 1|ChildComparison betw...</td>\n",
       "      <td>[-1.2361405  -0.07671446  1.7889788   1.062637...</td>\n",
       "      <td>[-0.009891663, -0.054471746, -0.004345603, 0.0...</td>\n",
       "      <td>[[-2.76512563e-01  9.37814936e-02  1.31954432e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13875</th>\n",
       "      <td>NCT00420095</td>\n",
       "      <td>A Study for Patients With Diabetes Mellitus (I...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT00420095</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>The purpose of this study is to compare glycem...</td>\n",
       "      <td>Diabetes Mellitus, Type 1|Diabetes Mellitus, T...</td>\n",
       "      <td>DRUG: Human insulin 30/70|DRUG: Insulin lispro...</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>Allocation: RANDOMIZED|Intervention Model: CRO...</td>\n",
       "      <td>For additional information regarding investiga...</td>\n",
       "      <td>China</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>Diabetes Mellitus, Type 1|Diabetes Mellitus, T...</td>\n",
       "      <td>Diabetes Mellitus, Type 1|Diabetes Mellitus, T...</td>\n",
       "      <td>[-0.47521353  0.45017236  1.2653893   0.770356...</td>\n",
       "      <td>[-0.021227177, -0.021159, -0.050032027, 0.0546...</td>\n",
       "      <td>[[-2.53489524e-01 -5.60141318e-02  1.71069443e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13876</th>\n",
       "      <td>NCT02774395</td>\n",
       "      <td>Endometrial Cancer and Fractalkine-receptor Ax...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT02774395</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>The endometrial cancers are among the most com...</td>\n",
       "      <td>Endometrial Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Centre Hospitalier Universitaire de Nice</td>\n",
       "      <td>Centre National de la Recherche Scientifique, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Observational Model: |Time Perspective: p</td>\n",
       "      <td>CHU de Nice, Nice, 06200, France</td>\n",
       "      <td>France</td>\n",
       "      <td>Centre Hospitalier Universitaire de Nice|Centr...</td>\n",
       "      <td>Endometrial Cancer</td>\n",
       "      <td>Endometrial CancerThe endometrial cancers are ...</td>\n",
       "      <td>[ 2.2284987   2.828872    4.283614    1.268700...</td>\n",
       "      <td>[0.0019343764, 0.053198166, 0.019161837, -0.04...</td>\n",
       "      <td>[[-4.29979533e-01  1.30693614e-01  1.50078505e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13877</th>\n",
       "      <td>NCT02961595</td>\n",
       "      <td>Live Enterovirus Vaccine and Type 1 Diabetes</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT02961595</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>Enterovirus infections may either increase or ...</td>\n",
       "      <td>Enterovirus Infection|Type 1 Diabetes|Prediabe...</td>\n",
       "      <td>BIOLOGICAL: Oral Polio Vaccine (OPV)</td>\n",
       "      <td>Tampere University</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>Allocation: NON_RANDOMIZED|Intervention Model:...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tampere University</td>\n",
       "      <td>Enterovirus Infection|Type 1 Diabetes|Prediabe...</td>\n",
       "      <td>Enterovirus Infection|Type 1 Diabetes|Prediabe...</td>\n",
       "      <td>[ 0.4154884   0.5133937   1.0775734   0.510251...</td>\n",
       "      <td>[0.015862832, 0.009528512, -0.05748338, -0.031...</td>\n",
       "      <td>[[-1.71425164e-01  1.32257894e-01 -7.86674246e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13878</th>\n",
       "      <td>NCT05308095</td>\n",
       "      <td>The HEADWIND Study - Part 4</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT05308095</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>To analyse driving behavior of individuals wit...</td>\n",
       "      <td>Diabetes|Diabetes Mellitus, Type 1</td>\n",
       "      <td>OTHER: Controlled hypoglycaemic state while dr...</td>\n",
       "      <td>Insel Gruppe AG, University Hospital Bern</td>\n",
       "      <td>Swiss Federal Institute of Technology|Universi...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Allocation: NA|Intervention Model: SINGLE_GROU...</td>\n",
       "      <td>University Department of Endocrinology, Diabet...</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>Insel Gruppe AG, University Hospital Bern|Swis...</td>\n",
       "      <td>Diabetes|Diabetes Mellitus, Type 1</td>\n",
       "      <td>Diabetes|Diabetes Mellitus, Type 1To analyse d...</td>\n",
       "      <td>[ 0.64259994  0.14503738  0.55169725  1.145650...</td>\n",
       "      <td>[0.018295739, -0.002316081, -0.061687373, 0.00...</td>\n",
       "      <td>[[-2.77128577e-01  2.62729619e-02  2.19001591e...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13879</th>\n",
       "      <td>NCT02574195</td>\n",
       "      <td>Evolution of Effectiveness of Diabetes Medical...</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT02574195</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>The main aim of the present study is to evalua...</td>\n",
       "      <td>Diabetes Mellitus, Type 2|Diabetes Mellitus, T...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Endocrinology Research Centre, Moscow</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Observational Model: |Time Perspective: p</td>\n",
       "      <td>Endocrinology Scientific Center, Moscow, Russi...</td>\n",
       "      <td>Russian Federation</td>\n",
       "      <td>Endocrinology Research Centre, Moscow</td>\n",
       "      <td>Diabetes Mellitus, Type 2|Diabetes Mellitus, T...</td>\n",
       "      <td>Diabetes Mellitus, Type 2|Diabetes Mellitus, T...</td>\n",
       "      <td>[-0.34579745  0.6177559   1.1981419   1.275478...</td>\n",
       "      <td>[-0.0006648288, -0.022689626, -0.059732363, 0....</td>\n",
       "      <td>[[-2.09361374e-01 -1.85245983e-04  2.51275569e...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>13880 rows × 19 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        NCT Number                                        Study Title  \\\n",
       "0      NCT05284071  Actiste® Diabetes Management as a Service (ADM...   \n",
       "1      NCT05029271                              InPen User Experience   \n",
       "2      NCT03976271  Consequences of Hypoglycaemia on Cardiovascula...   \n",
       "3      NCT05560971  Monounsaturated Fatty Acid Supplementation for...   \n",
       "4      NCT00462371  Comparison Between Insulin Pump Treatment and ...   \n",
       "...            ...                                                ...   \n",
       "13875  NCT00420095  A Study for Patients With Diabetes Mellitus (I...   \n",
       "13876  NCT02774395  Endometrial Cancer and Fractalkine-receptor Ax...   \n",
       "13877  NCT02961595       Live Enterovirus Vaccine and Type 1 Diabetes   \n",
       "13878  NCT05308095                        The HEADWIND Study - Part 4   \n",
       "13879  NCT02574195  Evolution of Effectiveness of Diabetes Medical...   \n",
       "\n",
       "                                          Study URL Study Status  \\\n",
       "0      https://clinicaltrials.gov/study/NCT05284071    COMPLETED   \n",
       "1      https://clinicaltrials.gov/study/NCT05029271   RECRUITING   \n",
       "2      https://clinicaltrials.gov/study/NCT03976271    COMPLETED   \n",
       "3      https://clinicaltrials.gov/study/NCT05560971   RECRUITING   \n",
       "4      https://clinicaltrials.gov/study/NCT00462371    COMPLETED   \n",
       "...                                             ...          ...   \n",
       "13875  https://clinicaltrials.gov/study/NCT00420095    COMPLETED   \n",
       "13876  https://clinicaltrials.gov/study/NCT02774395    COMPLETED   \n",
       "13877  https://clinicaltrials.gov/study/NCT02961595    COMPLETED   \n",
       "13878  https://clinicaltrials.gov/study/NCT05308095    COMPLETED   \n",
       "13879  https://clinicaltrials.gov/study/NCT02574195    COMPLETED   \n",
       "\n",
       "                                           Brief Summary  \\\n",
       "0      The overall aim of the clinical investigation ...   \n",
       "1      The purpose of this study is to evaluate the u...   \n",
       "2      People with Type 1 diabetes (T1DM), type 2 dia...   \n",
       "3      The purpose of this study is to understand and...   \n",
       "4      Comparison between insulin pump treatment and ...   \n",
       "...                                                  ...   \n",
       "13875  The purpose of this study is to compare glycem...   \n",
       "13876  The endometrial cancers are among the most com...   \n",
       "13877  Enterovirus infections may either increase or ...   \n",
       "13878  To analyse driving behavior of individuals wit...   \n",
       "13879  The main aim of the present study is to evalua...   \n",
       "\n",
       "                                              Conditions  \\\n",
       "0                          Diabetes type1|Diabetes type2   \n",
       "1                                        Diabetes Type 1   \n",
       "2      Hypoglycemia|Inflammatory Response|Diabetes Me...   \n",
       "3      PreDiabetes|Insulin Resistance|Overweight|Obesity   \n",
       "4                        Diabetes Mellitus, Type 1|Child   \n",
       "...                                                  ...   \n",
       "13875  Diabetes Mellitus, Type 1|Diabetes Mellitus, T...   \n",
       "13876                                 Endometrial Cancer   \n",
       "13877  Enterovirus Infection|Type 1 Diabetes|Prediabe...   \n",
       "13878                 Diabetes|Diabetes Mellitus, Type 1   \n",
       "13879  Diabetes Mellitus, Type 2|Diabetes Mellitus, T...   \n",
       "\n",
       "                                           Interventions  \\\n",
       "0      DEVICE: Device: Actiste 1.0 and the Companion ...   \n",
       "1                   DEVICE: InPen with Guardian 4 System   \n",
       "2      PROCEDURE: hyperinsulinemic normoglycaemic-hyp...   \n",
       "3      DIETARY_SUPPLEMENT: Palmitoleic acid|OTHER: Pl...   \n",
       "4                            DEVICE: Insulin pump (CSII)   \n",
       "...                                                  ...   \n",
       "13875  DRUG: Human insulin 30/70|DRUG: Insulin lispro...   \n",
       "13876                                                NaN   \n",
       "13877               BIOLOGICAL: Oral Polio Vaccine (OPV)   \n",
       "13878  OTHER: Controlled hypoglycaemic state while dr...   \n",
       "13879                                                NaN   \n",
       "\n",
       "                                           Sponsor  \\\n",
       "0      Northern Care Alliance NHS Foundation Trust   \n",
       "1                               Medtronic Diabetes   \n",
       "2                Radboud University Medical Center   \n",
       "3                     Brigham and Women's Hospital   \n",
       "4                           Erasmus Medical Center   \n",
       "...                                            ...   \n",
       "13875                        Eli Lilly and Company   \n",
       "13876     Centre Hospitalier Universitaire de Nice   \n",
       "13877                           Tampere University   \n",
       "13878    Insel Gruppe AG, University Hospital Bern   \n",
       "13879        Endocrinology Research Centre, Moscow   \n",
       "\n",
       "                                           Collaborators  Phases  \\\n",
       "0                                            Brighter AB     NaN   \n",
       "1                                                    NaN     NaN   \n",
       "2                                Rigshospitalet, Denmark     NaN   \n",
       "3                               Tersus Life Sciences LLC     NaN   \n",
       "4                                     Ministry of Health  PHASE4   \n",
       "...                                                  ...     ...   \n",
       "13875                                                NaN  PHASE4   \n",
       "13876  Centre National de la Recherche Scientifique, ...     NaN   \n",
       "13877                                                NaN  PHASE1   \n",
       "13878  Swiss Federal Institute of Technology|Universi...     NaN   \n",
       "13879                                                NaN     NaN   \n",
       "\n",
       "                                            Study Design  \\\n",
       "0      Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "1      Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "2      Allocation: NON_RANDOMIZED|Intervention Model:...   \n",
       "3      Allocation: RANDOMIZED|Intervention Model: PAR...   \n",
       "4      Allocation: RANDOMIZED|Intervention Model: CRO...   \n",
       "...                                                  ...   \n",
       "13875  Allocation: RANDOMIZED|Intervention Model: CRO...   \n",
       "13876          Observational Model: |Time Perspective: p   \n",
       "13877  Allocation: NON_RANDOMIZED|Intervention Model:...   \n",
       "13878  Allocation: NA|Intervention Model: SINGLE_GROU...   \n",
       "13879          Observational Model: |Time Perspective: p   \n",
       "\n",
       "                                               Locations  \\\n",
       "0      Salford Royal Hospital Northern Care Alliance ...   \n",
       "1      NU-Hospital Group, Uddevalla, Sweden|Frolunda ...   \n",
       "2      Nordsjællands University Hospital, Hillerød, N...   \n",
       "3      Brigham and Women's Hospital, Boston, Massachu...   \n",
       "4      ErasmusMC/Sophia´s children´s Hospital, Rotter...   \n",
       "...                                                  ...   \n",
       "13875  For additional information regarding investiga...   \n",
       "13876                   CHU de Nice, Nice, 06200, France   \n",
       "13877                                                NaN   \n",
       "13878  University Department of Endocrinology, Diabet...   \n",
       "13879  Endocrinology Scientific Center, Moscow, Russi...   \n",
       "\n",
       "                          country  \\\n",
       "0                  United Kingdom   \n",
       "1                          Sweden   \n",
       "2      ['Netherlands', 'Denmark']   \n",
       "3                   United States   \n",
       "4                     Netherlands   \n",
       "...                           ...   \n",
       "13875                       China   \n",
       "13876                      France   \n",
       "13877                         NaN   \n",
       "13878                 Switzerland   \n",
       "13879          Russian Federation   \n",
       "\n",
       "                                            affiliations  \\\n",
       "0      Northern Care Alliance NHS Foundation Trust|Br...   \n",
       "1                                     Medtronic Diabetes   \n",
       "2      Radboud University Medical Center|Rigshospital...   \n",
       "3      Brigham and Women's Hospital|Tersus Life Scien...   \n",
       "4              Erasmus Medical Center|Ministry of Health   \n",
       "...                                                  ...   \n",
       "13875                              Eli Lilly and Company   \n",
       "13876  Centre Hospitalier Universitaire de Nice|Centr...   \n",
       "13877                                 Tampere University   \n",
       "13878  Insel Gruppe AG, University Hospital Bern|Swis...   \n",
       "13879              Endocrinology Research Centre, Moscow   \n",
       "\n",
       "                                   normalized_conditions  \\\n",
       "0                          Diabetes type1|Diabetes type2   \n",
       "1                                        Diabetes Type 1   \n",
       "2      Hypoglycemia|Inflammatory Response|Diabetes Me...   \n",
       "3      PreDiabetes|Insulin Resistance|Overweight|Obesity   \n",
       "4                        Diabetes Mellitus, Type 1|Child   \n",
       "...                                                  ...   \n",
       "13875  Diabetes Mellitus, Type 1|Diabetes Mellitus, T...   \n",
       "13876                                 Endometrial Cancer   \n",
       "13877  Enterovirus Infection|Type 1 Diabetes|Prediabe...   \n",
       "13878                 Diabetes|Diabetes Mellitus, Type 1   \n",
       "13879  Diabetes Mellitus, Type 2|Diabetes Mellitus, T...   \n",
       "\n",
       "                                               sentences  \\\n",
       "0      Diabetes type1|Diabetes type2The overall aim o...   \n",
       "1      Diabetes Type 1The purpose of this study is to...   \n",
       "2      Hypoglycemia|Inflammatory Response|Diabetes Me...   \n",
       "3      PreDiabetes|Insulin Resistance|Overweight|Obes...   \n",
       "4      Diabetes Mellitus, Type 1|ChildComparison betw...   \n",
       "...                                                  ...   \n",
       "13875  Diabetes Mellitus, Type 1|Diabetes Mellitus, T...   \n",
       "13876  Endometrial CancerThe endometrial cancers are ...   \n",
       "13877  Enterovirus Infection|Type 1 Diabetes|Prediabe...   \n",
       "13878  Diabetes|Diabetes Mellitus, Type 1To analyse d...   \n",
       "13879  Diabetes Mellitus, Type 2|Diabetes Mellitus, T...   \n",
       "\n",
       "                                      embeddings_doc2vec  \\\n",
       "0      [-0.6533576   0.2899124   0.3582823  -0.022073...   \n",
       "1      [-1.55768120e+00 -1.06150067e+00  9.21956778e-...   \n",
       "2      [ 0.7630125   0.02377942  1.7297945   1.068472...   \n",
       "3      [-1.2706982   3.5712657   0.72434443 -0.398305...   \n",
       "4      [-1.2361405  -0.07671446  1.7889788   1.062637...   \n",
       "...                                                  ...   \n",
       "13875  [-0.47521353  0.45017236  1.2653893   0.770356...   \n",
       "13876  [ 2.2284987   2.828872    4.283614    1.268700...   \n",
       "13877  [ 0.4154884   0.5133937   1.0775734   0.510251...   \n",
       "13878  [ 0.64259994  0.14503738  0.55169725  1.145650...   \n",
       "13879  [-0.34579745  0.6177559   1.1981419   1.275478...   \n",
       "\n",
       "                                          embeddings_use  \\\n",
       "0      [-0.05177863, -0.053549428, -0.05081451, 0.057...   \n",
       "1      [0.010143899, 0.009666905, -0.046026397, 0.052...   \n",
       "2      [-0.0008871535, -0.012041841, -0.029269502, 0....   \n",
       "3      [0.023469983, 0.04538531, -0.025541266, -0.026...   \n",
       "4      [-0.009891663, -0.054471746, -0.004345603, 0.0...   \n",
       "...                                                  ...   \n",
       "13875  [-0.021227177, -0.021159, -0.050032027, 0.0546...   \n",
       "13876  [0.0019343764, 0.053198166, 0.019161837, -0.04...   \n",
       "13877  [0.015862832, 0.009528512, -0.05748338, -0.031...   \n",
       "13878  [0.018295739, -0.002316081, -0.061687373, 0.00...   \n",
       "13879  [-0.0006648288, -0.022689626, -0.059732363, 0....   \n",
       "\n",
       "                                   embeddings_distilbert  \n",
       "0      [[-4.79432911e-01  1.63338944e-01  2.08725184e...  \n",
       "1      [[-3.43266100e-01  1.77812949e-02  3.18139613e...  \n",
       "2      [[-1.48577675e-01  1.06256127e-01  3.06467533e...  \n",
       "3      [[-3.94146502e-01  1.26904011e-01  1.25811309e...  \n",
       "4      [[-2.76512563e-01  9.37814936e-02  1.31954432e...  \n",
       "...                                                  ...  \n",
       "13875  [[-2.53489524e-01 -5.60141318e-02  1.71069443e...  \n",
       "13876  [[-4.29979533e-01  1.30693614e-01  1.50078505e...  \n",
       "13877  [[-1.71425164e-01  1.32257894e-01 -7.86674246e...  \n",
       "13878  [[-2.77128577e-01  2.62729619e-02  2.19001591e...  \n",
       "13879  [[-2.09361374e-01 -1.85245983e-04  2.51275569e...  \n",
       "\n",
       "[13880 rows x 19 columns]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.13"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
